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Current and reoccurring viral epidemic outbreaks such as those caused by Zika
virus illustrate the need for rapid development of antivirals. Such development
would be facilitated by computational approaches that can provide experimentally
testable predictions for possible antiviral strategies. To this end, here the focus
is on the fact that viruses are directly dependent on their host metabolism for
reproduction. This thesis develops a set of stoichiometric, genome-scale metabolic
models that integrates human macrophage cell metabolism with the biochemi-
cal demands arising from virus production and use it to virus impact on host
metabolism and vice versa. While this approach applies to any host-virus pair,
this project focuses on first applying it to currently epidemic viruses: Chikungunya,
Dengue and Zika.
Overall, it is found that each of these viruses causes specific alterations in the
host metabolic flux towards fulfilling their biochemical demands as predicted by
their genome and capsid structure. It is predicted that all three viruses utilise
the host metabolic network in a di erent manner than that of the host, upregu-
lating the areas of the network that are associated with the biosynthesis of their
biomass components whilst downregulating areas that are not. Subsequent anal-
ysis of this integrated model allows the prediction a set of host reactions, which
when constrained inhibit virus production. These prediction recovers most of the
known targets of existing metabolism-orientated antiviral drugs while highlighting
a set of hitherto unexplored reactions with either broad or virus-specific antiviral
potential.
To further probe how these reactions can be perturbed to inhibit virus produc-
tion, the methodology created in this thesis is expanded from single-reactions to
combinations of pairs of reactions, known as the double-reaction analysis. These
predictions expand the novel repertoire of antiviral targets against Chikungunya,
Dengue and Zika virus, and are combined with candidate drug compounds (identi-
fied from online databases) for experimental validation and implementation.
This project demonstrates that, with a combination of the application of flux bal-
ance analysis and development of a novel, integrated computational platform, the
viral infection process can be better understood and potential antiviral targets
predicted. The insights gained are of significant relevance, not only to the under-
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Viruses are intracellular parasites that are ubiquitous around the globe and can
infect a variety of organisms, from humans to plants and insects. They are re-
sponsible for some of the deadliest disease outbreaks in human history, such as
the Spanish Influenza, Ebola or Severe acute respiratory syndrome (SARS) coro-
navirus outbreaks. The geographical distribution of viruses coupled with their
disease-causing potential increase the globally recognised threat of the introduc-
tion of new ”novel” or adapted viruses into the human population, otherwise known
as emergent viruses.
Several international organisations, such as the Centre for Disease Control (CDC),
European Centre for Disease Control (ECDC) and World Health Organisation
(WHO) have highlighted the threat of emergent and novel viruses to global biose-
curity. While there has been significant progress concerning vaccine and antiviral
development for some endemic human viruses, such as HIV and Measles, there
remains a significant lack of possible antiviral strategies and therapeutics that are
useful against these viral outbreaks.
As has been seen with the recent Ebola and Zika virus outbreaks, globally we
currently lack antivirals that can be used during such an event. While vaccines
confer long-term protection, antiviral therapeutics would provide a first-line de-
fence in combatting the biosecurity risks of an outbreak in combination with other
healthcare initiatives (i.e. vaccination programs, quarantine).
A significant issue in the development of such antivirals, in response to emergent
1
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and novel viruses, is the time required for identification, experimentation and clin-
ical verification. This is further compounded by the potential lack of information
regarding the virus, its cell and tissue tropism, and the ideal conditions required
to cultivate the virus in vitro successfully. To be able to combat the ever-growing
threat of emerging and novel virus outbreaks, a rapid, easily deployable response
is required before, during and after an outbreak.
In an attempt to provide this, this study attempts to fully realise a systems biology
framework that utilises computational modelling of viral-mediated e ects on their
host’s metabolic system to predict antiviral targets. This approach requires rela-
tively few data sources, such as genomic and proteomic sequences and information
regarding the virus structure and symmetry. The predicted outcomes of such an
approach can then be used in experimental studies, increasing the speed of which
a response against current or existing outbreaks can be generated.
1.2 VIRUS INFECTIONS
Virus infections represent not only a risk to individual human health, but also
to global health and biosecurity (Cecchine & Moore 2006, Smith et al. 2014).
Over the past several decades, incidences of infectious diseases of humans have
increased (Smith et al. 2014), with a significant proportion of those attributed to
virus infections (Fig. 1.1). In particular, there has been an observed increase in
the number of RNA virus infections cases and virus of a zoonotic origin (Wolfe
et al. 2007, Dunn et al. 2010, Smith et al. 2014).
The spread of these viruses are not just limited to isolated geographical regions;
with increased globalisation (Smith & Guégan 2010) and a changing climate (Guernier
et al. 2004, Bonds et al. 2012), virus infections are a global health issue. The un-
derstanding of what a virus ”is” and how it interacts with humans in both health
and otherwise, is required to protect global biosecurity and health.
1.2.1 Defining a Virus
A virus is an intracellular obligate parasite, an infectious agent that is able to
enter, replicate and escape from a host cell that it infects. Viruses are composed
of amino acids, nucleotides and lipids (if they are enveloped viruses). The virus
structure, known as the capsid, contains the virus genetic information in the form
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Figure 1.1: Incidences of recorded global (a) diseases and (b) outbreaks, grouped
by taxonomic groups. The virus taxonomic group is highlighted in orange. Data
obtained from (Smith et al. 2014).
of a DNA or RNA genome, which may be single-stranded, double-stranded or
segmented.
Viruses do not have their own metabolic machinery or resources, although some
viruses do carry their own genome replication enzymes, and so are entirely depen-
dent on the host that they infect. Infected hosts are utilised by the viral agent
purely for the purposes of replication and subsequent escape, to spread and infect
more of the host’s cells. This parasitic relationship between host and virus, and the
specific circumstances that occur during the process of viral infection, may cause
damage to the host cell and wider organism through diversion of crucial metabolites
and compounds to the viral replication agenda (Maynard et al. 2010, Ritter et al.
2010). Virus and host are considered entangled due to this relationship, which
ultimately links the virus to its host’s metabolic network. This is repeatedly seen
in experimental studies, where viral manipulation of the host metabolic system
results in observable metabolite resource rearrangements (Goodwin et al. 2015).
Furthermore, this is highlighted by observed variations in virus production levels
correlating with cell-to-cell variance in growth rate and phase (Zhu et al. 2009),
as well as virus infection leading to changes in host metabolism (Yu et al. 2011a).
In particular, virus infection leads to significant metabolic alterations in the host,
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in some cases resulting in up to 3-fold increase in glycolysis rates (El-Bacha et al.
2004, Jain & Srivastava 2009, Yu et al. 2011a) and changes in ATP production
rates (Zhu et al. 2009). These observations can be seen as an emergent property
of the combined host-virus metabolic system and could be related to changes in
host cellular demands arising from viral production (Molenaar et al. 2009, Weiße
et al. 2015). More specifically, alterations in host metabolism upon infection can
be understood as viruses actively manipulating the host system to their advantage
(Maynard et al. 2010), or the additional draw of metabolic components for viral
production simply resulting in a re-arrangement of host metabolic fluxes.
Understanding virus infections in this manner, where alterations in metabolism are
driven by the viral disease, opens up the possibility of controlling viral infection
through alterations of the host metabolism (Kotzamanis et al. 2015, Maynard et al.
2010, Jain & Srivastava 2009, Ikeda & Kato 2007). Whilst this may be possible for
any virus and any host organism, this study primarily focuses on the applications
to viruses that represent significant risks to global biosecurity, with a focus on
mosquito-borne diseases due to their global emergence and resurgence in recent
decades (Gubler 2002).
1.2.2 Classification of Viruses
Viruses are classified using two main systems: the International Code for Virus
Classification and Nomenclature (Adams et al. 2013) and the Baltimore classifica-
tion groupings (Yu et al. 2013, Hulo et al. 2011). In the case of the latter, infor-
mation regarding the viral genome composition (i.e. DNA, RNA, single-stranded
or double-stranded) is used in conjunction with information on the replication in-
termediates to determine a broad, group-based classification system. A summary
of the Baltimore classification system is shown in Fig. 1.2.
This classification system aids both in deciding the direction of viral research, for
instance RNA vs DNA antiviral targets, but also in the system biology modelling
e orts; virus in silico modelling requires the knowledge of multiple parameters,














Figure 1.2: Baltimore classification of viruses. Viruses are classified based upon
the method of messenger RNA (mRNA) synthesis, and their genome, into one of
seven groups (I-VII): group I, double-stranded DNA (dsDNA); group II, positive-
sense single-stranded DNA (+ ssDNA); group III, double-stranded RNA (dsRNA);
group VI, positive-sense single-stranded RNA (+ ssRNA); group V, negative
single-stranded RNA (- ssRNA); group VI, positive-sense single-stranded RNA
reverse-transcriptase (+ ssRNA-RT); group VII, double-stranded DNA reverse-
transcriptase (dsDNA-RT). Viruses that replicate using reverse transcriptase are
indicated with RT.
1.3 EMERGING AND NOVEL VIRUS INFECTIONS
As discussed, viral diseases pose a credible risk to global human health and biose-
curity (Howard & Fletcher 2012) and in particular it is viruses that are considered
emerging [novel] or exotic that represent the most significant burden (Geisbert
& Jahrling 2004). However, for many of these emerging viral infections antiviral
discovery remains a significant challenge to overcome (Littler & Oberg 2005), and
coupled with an already small set of viable antiviral drugs, further compounds
the human health threat (Fauci et al. 2005). Viruses can emerge and re-emerge
from many di erent sources, although animals and insects still remain a significant
resevior for virus outbreaks, and are typically distributed over a wide geographical
Sean Aller 5
1 | Introduction
area (Bonds et al. 2012, Guernier et al. 2004, Wolfe et al. 2007).
1.3.1 Alphaviruses and Flaviviruses
As discussed, the incidences of both vector-borne and viral disease outbreaks have
increased between 1980 and 2010 (Smith et al. 2014). Of these viral vectors, the
mosquito is responsible for the transmission of many di erent pathogens including
many viruses. As mosquitos are arthropods, these viruses are sometimes classi-
fied as the group Arbovirus, and their continuing emergence presents a significant
global health problem (Lwande et al. 2015, Gubler 2002, Gautam et al. 2017).
More specifically, the most common Arboviruses transmitted by the Aedes aegypti
mosquitos (Woolhouse et al. 2016) belong to the Togaviridae and Flaviviridae
families. Both families are categorised, via the Baltimore classification scheme,
as group IV viruses: they have a positive-sense, single-stranded RNA (+ssRNA)
genome and their replication involve the use of a negative ssRNA (-ssRNA) genome
intermediate (Yu et al. 2013). As their genomes are positive-sense, these viral
genomes can be directly translated by host ribosomes to produce virus proteins.
Both families are further categorised into genera, see Table 1.1.
Table 1.1: Virus classification for Arboviruses at the family and genera taxonomic
levels. Notable species, defined as potentially e ecting human health and disease
incidence, are stated (Fauci et al. 2005, Woolhouse et al. 2014).
Family Genera Notable Species




Flaviviridae Hepacivirus Hepatitis C Virus
Flavivirus Dengue Virus, West Nile
Virus, Zika Virus
Pegivirus GB Virus C, Human Pe-
givirus Type 2




Of these viruses, there is a particular focus, in this study, on representatives of the
Alphaviruses and Flavivirus due to their increased incidence of disease within the
human population (Lundström 1999, Figueiredo & Figueiredo 2014, Woolhouse
et al. 2016); these are positive-sense single-strand RNA-viruses with rather simple
physical structures (Mukhopadhyay et al. 2005, Strauss & Strauss 1994). Both
groups of viruses are enveloped, spherical particles containing a single copy of
their respective RNA genome. The ultrastructure, that is the individual viral
capsid components and their stoichiometries, are well known for both virus genera
apart from the lipid component. Lipids are di cult to identify through structural
studies and therefore the stoichiometry of the lipids, and indeed the exact type











Figure 1.3: Ultrastructure diagram of Alphavirus and Flavivirus genera. Virus-
associated membranes are obtained from their host’s cell lipid membrane. C,
capsid; E, envelope; E1, envelope 1; E2, envelope 2; M, membrane.
For a successful modelling methodology to be developed for Alphavirus and Fla-
vivirus infections, the tissue/cell tropism of both virus genera must be considered.
Viral tropism can be defined as the interactions that a virus partakes in, at various
steps in its replication cycle, in order to ensure a full and successful replication
cycle (Nomaguchi et al. 2012). This tropism mediates the specific host species and
cell-types that a virus may infect. Viruses of both families have been observed to
infect many di erent human cell types (Balsitis et al. 2009, Tang 2012), includ-
ing monocyte-derived macrophage cell lines (Fox et al. 2015, Gollins & Porterfield
1985, Balsitis et al. 2009). Selection of a suitable host organism, and cell type, can
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therefore be targeted towards human cell-types and cell-lines, with evidence that
supports the use of macrophage cell models. The selection of a specific computa-
tional model and modelling technique are discussed further on in this chapter.
1.3.2 Antiviral Treatments
As highlighted through data and literature analysis, antiviral availability and dis-
covery remains a significant global challenge. In combination with increasing emer-
gence of viruses (Smith et al. 2014) and an extended timeline in terms of antiviral
discovery and development (Littler & Oberg 2005), new technologies and method-
ologies must be developed and implemented to secure future biosecurity. As previ-
ously discussed, viruses are entirely dependent on their host’s metabolic resources
to replicate and survive. This opens up the possibility of modulating metabolism
as an e ective antiviral therapeutic treatment (Ikeda & Kato 2007).
Antiviral drugs are used in the treatment of viral infections, and are often used or
designed against a specific virus, although broad-spectrum antivirals do exist that
are e ective against a wide variety of viruses (Razonable 2011, Littler & Oberg
2005). Antiviral drugs target at di erent points in the viral infection life cycle,





The majority of antiviral drugs are designed so that they target specific viral
proteins and inhibit their functioning, such as a ecting the attachment and viral
entry into the host cell. Under these conditions, the antiviral target should also be
as dissimilar to the host proteins as possible, in order to limit cross-reacting with
the host and thus limiting side e ects (Clercq 2004, Endy & Yin 2000).
Additionally, some other antiviral drugs work through the inhibition of viral nu-
cleic acid formation or replication. Replication of the genomic material, host or
viral, requires the generation and polymerisation of nucleoside triophoshates (ei-
ther ribose or deoxyribose nucleosides depending on wether it is RNA or DNA
being generated, respectively). Consequently, many of the antiviral drugs target-
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ing viral genome replication and synthesis are nucleoside or nucleotide analogues;
altered nucleic acid molecules that interfere with the synthesis of RNA or DNA,
usually through causing termination of the nucleotide sequence. In this case, the
antiviral targets can be considered as ”metabolic”, due to using specifically al-
tered metabolites to interfere with viral functioning. Some progress has also been
made on putative antiviral targets that are the catalytic enzymes, rather than the
individual metabolite substrates and products, to disrupt the production of key
viral metabolites which is usually focused to the nucleoside producing reaction
pathways (Marquez et al. 1988).
Previous experimental studies have highlighted the potential for metabolic com-
ponents (i.e. reactions) to be a viable therapeutic and drug targets (Munger et al.
2008), and that disturbing the metabolic link between host and pathogen can
result in a perturbation of that pathogen (Heinken & Thiele 2015). Currently,
there are few antivirals that specifically target metabolic processes, with many
antivirals targeting protein-interactions or viral entry/exit (Leyssen et al. 2008).
Whilst these are e ective against specific viruses (and indeed specific strains) they
are both costly and timely to make, and very specific; emerging virus outbreaks
require more broad-acting antivirals due to the speed at which they appear and
spread through a population (Fauci et al. 2005). Additionally, there is a need
to develop antiviral strategies that are able to evade or subvert virus adaptation
(Endy & Yin 2000). Through traditional targeting of physical virus components,
the virus is able to mutate resulting in non-recognition by the drug (due to the spe-
cific targeting of the compound to a receptor and/or coding region). By thinking
of metabolism as the viruses’ ”environment” one can envision how easy a species
could adapt to environmental changes, as opposed to individual selection pres-
sures. Ultimately, altering the metabolic network has the potential to be far more
di cult for the virus to adapt to that than of physical, specific interactions.
Developing these antiviral therapeutics requires the development of an extensive
computational approach, that is able to handle the vast array of compounds,
metabolic targets, host-virus interactions and indeed virus species. Such an ap-
proach would be infeasible through a purely experimental setup, therefore this
study proposes to develop an integrated systems biology framework for antiviral
discovery. Systems biology is based upon the principal of integrating various data
sources into mathematical abstractions, to be able to predict biological outcomes
(Kitano 2002, Soyer & O’Malley 2013). Such a system, if successful, can reduce
the searchable space (in terms of antivirals to be experimentally validated) from
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an untestable quantity to a more manageable one. To fulfill this goal, several
methodologies from systems biology must be synergised into a single develop-
mental platform and framework, that encompasses individual viruses, metabolic
networks and resulting antiviral targets.
1.4 SYSTEMS BIOLOGY AND MODELLING
1.4.1 Models and Modelling
Realising a systems biology approach to host-virus modelling, and indeed any
modelling situation requires the development and implementation of models (Cos-
cia et al. 2011, Dhurjati & Mahadevan 2008). In systems biology, models are
mathematical descriptions of biological systems, for instance a set of mathemat-
ical equations that represent a reaction network. However, models are not able
to describe all components of a biological system (i.e. the concentration of every
metabolite within a cell and its environment), and therefore some aspects of the
biological system must be simplified or excluded from the mathematical model.
Therefore it is important to acknowledge what can and cannot be achieved with a
mathematical model but also how to interpret the results in light of such omissions
and simplifications.
There are significant advantages to computational modelling. Firstly, the creation
of a model may require a much smaller amount of data or information than the
corresponding biological experiment (Dhurjati & Mahadevan 2008). Secondly, if
the model is constructed well and has been compared to biological and experimen-
tal data, the predictions and outputs of the model can be relatively accurate and
indicative of the real-biological response. This, combined with the [usually] quick
nature of computational modelling, makes this a viable approach for simulating
biological systems.
Just as there are many di erent types of biological entities, there are multiple
model types that can be utilised in systems biology. The majority of the work
covered in this thesis involves the construction and analysis of network-based bi-
ological models. As such, the di erent modelling approaches for aforementioned




Applications of Network-Based Models: Representing Metabolism.
Network-based modelling and analysis allows for complex interactions between bi-
ological entities, whether that be infectious and susceptible agents or reactions and
metabolites, to be predicted and analysed and their interactions with the broader
biological-environment assessed (Keeling & Eames 2005, Shlomi et al. 2008, Eu-
bank 2005, Papin et al. 2004). The construction and subsequent methodologies













Figure 1.4: Toy schematic of how various data sources are combined to form
di erent network-based models. Solid arrows indicate direct evolution from one
model type to another. Two di erent groups of entities are shown with blue circles
and orange squares. ODE, ordinary di erential equations.
When constructing a network-based model, one can think of biological entities
(i.e. metabolites and reactions) in isolation, producing a ”System” model of un-
connected entities (or nodes), or in a network-based view, such as ”Interaction”
models. These network models involve the creation of node-to-node connections,
known as edges. The combination of nodes and edges forms the basis of any
network-based model, and can be represent as a graph of the nodes and edges
(as shown in Fig. 1.4 in the ”Interaction” and ”Stoichiometric” examples) or can
be represented mathematically as a combination of vertices and matrices. Whilst
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multiple types of network-based models can be created, the discussions presented
in this thesis concern only metabolic networks. Therefore, here the di erent types
of metabolic network-based constructions and methodologies are discussed.
Stoichiometric Models. Biochemical networks, such as that of metabolism,
can be described using network-based structural models (Thiele & Palsson 2010,
Stincone et al. 2015). The essential components of a metabolic network model are
the metabolites [compounds] and the reactions, including transport processes, that
change/alter the metabolic compound. An additional layer of information is gath-
ered from the enzymes that catalyse reactions, and the proteins associated with
the transport of compounds in the biological system. In this way, each reaction
and transport process can be assigned to a unique identifier.
Stoichiometric models retain the structural information of the reaction network,
where reactions and compounds are considered as separate groups of entities. Com-
pounds usage in reactions is denoted using stoichiometric coe cients, which de-
scribe the proportions of reactants and products in a given reaction, for exam-
ple:
1A + 2B ≠æ 1C (1.1)
The reactants in this equation (Eq.1.1) are A and B and the product is C. The
stoichiometric coe cient, indicated by the number preceding the compound, in-
dicating the proportion of that compound that contributes to the reaction. For
instance, describing that 1 mole of A combined with 2 moles of B yields 1 mole of C.
It should be noted that stoichiometric coe cients are not unique (i.e. a coe cient
of 1 can be assigned to many compounds). The reaction is denoted using the arrow,
and arrow direction indicate directionality (in this case, unidirectional).
A stoichiometric matrix, required to build a mathematical metabolic model, is
a compact description of such a reaction network. Stoichiometric coe cients c
are combined with the metabolites m and reactions r to yield the stoichiometric
matrix S. Using this notation, Eq. 1.1 can be described as
cijmi + cijmi
rj≠æ cijmi (1.2)
for i = 1, . . . , m and j = 1, . . . , r (1.3)
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which yields the stoichiometric matrix S, in this example for this (j) reaction
(r), where each row corresponds to a di erent (i) biochemical compound (m).
The size of the stoichiometric matrix is formally defined as m ◊ r. An example
for a larger reaction network, with multiple branching points, and the associated
stoichiometric matrix is shown in Figure 1.5.
M1 M2 M3
M4























Figure 1.5: A small reaction network system and the corresponding stoichiomet-
ric matrix S. Arrows denote reactions associated with metabolites M , that run
at a certain flux rate v. Stoichiometric coe cients are shown in the S matrix as:
zero (reaction does not produce or consume M); positive value (reaction produces
M); negative value (reaction consumes M).
The stoichiometric matrix only captures the interactions between the di erent bi-
ological entities, the metabolites and the reactions, and how they are connected.
This information can be used to construct a network-graph, detailing the interac-
tions between the various nodes, but is not su cient alone to describe a complex
system such as a metabolic network. To further develop and enhance stoichiomet-
ric models, further information can be applied and considered in order to expand
the modelling approach.
Kinetic Models. The ability to investigate and predict changes in metabolic
systems, through the use of mathematical models, remains one of the significant
challenges in systems biology. In addition to stoichiometric models, kinetic models
provide a means for testing responses of biological systems (i.e. metabolism) to
various e ectors. However, unlike stoichiometric models, kinetic models can be
used for dynamic responses of a system to various perturbations such as changes
in environmental conditions (i.e. glucose availability) or genetic alterations (i.e.
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repressors) (Smallbone et al. 2013).
Small kinetic network models, such as a part of the central carbon metabolic
pathway for E. coli (Jahan et al. 2016), have been created and successfully tested.
However, these studies highlight some problems with the development and imple-
mentation of kinetic models. Firstly, the development of kinetic models is hindered
by the lack of information regarding complex kinetic variables, such as metabolite
concentration and enzyme abundance (Saa & Nielsen 2016, Steuer et al. 2006).
Secondly, even with the availability of adequate information, the computational
cost of running kinetic models increases exponentially as the scale of the reaction
networks increase (Resat et al. 2009). These factors significantly limit the systems
that can and have been successfully modelled with an accurate kinetics-based ap-
proach.
There have however been some smaller studies that focus on subsections of an
organisms reaction network which have extensive levels of details regarding an-
notations and data availability (Jahan et al. 2016, Kerkhoven et al. 2014). There
have been previous attempts at kinetic models for more complex organisms, mainly
eukaryotic organisms such as humans (Bordbar et al. 2015); however these come
with significant assumptions about the modelling approach utilised. Many of the
kinetic and thermodynamic parameters are obtained through estimation, fitting
or simulation, rather than from empirical data sources. While these may yield
plausible modelling parameters, the lack of empirical data means that they cannot
be compared or validated beyond the initial predictions, compounding further the
issue of model accuracy and reproducibility. Overall, kinetic models provide many
advantages over stoichiometric models, mainly their ability to deal with dynamic
and changing variables and include many other non-network based parameters.
However, the lack of information available regarding parameters and thermody-
namic constraints for entire human cells, as opposed to individual reactions and
pathways, makes the stoichiometric model a preferable choice over kinetic for mod-
elling whole-cell metabolism, as used in this thesis.
1.4.2 Structural Models of Metabolism
An extension of the stoichiometric model, metabolic models are constructions of a
stoichiometric matrix directly from a set of metabolic reactions. As previously de-
scribed, reactions are deconstructed into the metabolites (reactants and products)
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and assigned stoichiometric coe cients that denote their reaction-proportions and
whether they are consumed or produced.
The scope of the metabolic model only describes the interactions between metabolic
elements in a network or organism, which are then represented in the stoichiomet-
ric model format. In graph notation, a metabolic network can be considered as a
bipartite graph, with metabolites forming one set of nodes and reactions forming
another set (Fig. 1.6). Stoichiometric metabolic models also include additional
information regarding the directionality of reactions, defined as whether a reaction
can proceed in the forward and reverse direction (bidirectional) or forward direc-
tion only (unidirectional) (Beard et al. 2004). This information is usually encoded
in a vector that is equal in length to the number of reaction entities, and indicates






























Figure 1.6: Representation of a (A) small reaction (r) network with 9 reactions
and 8 metabolites, denoted by capital letter, and (B) a bipartite representation
of the interactions between the metabolite (grey filled circle) and reaction (orange
filled hexagon) nodes. Note that reaction directionality is conserved between both
representations.
It should be noted that in this example (Fig. 1.6) only metabolites and reactions
that are intracellular and are not involved with external-internal transport are
shown. A subset of metabolites in the metabolic model must be supplied from
an ”external” source (usually designated the in silico media), where the supply of
that metabolite is set to a particular uptake rate. For instance, in Figure 1.6A,
metabolite ”A” would be supplied by an external transport reaction from the in
silico media.
Metabolic models, from the networks to the stoichiometric matrices, can be gen-
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erated in many ways (Le Novère et al. 2005). Many types of metabolic model
exist, from small toy or ”core” networks (only composed of a few selected reac-
tions) to the more commonly used genome-scale metabolic model (Thiele & Palsson
2010).
Genome-Scale Metabolic Models
Mathematical metabolic models derived from an organism’s genome sequence are
known as Genome-Scale Metabolic Models (GSMs). GSMs are one of the most
commonly used metabolic models due to their relative ease of creation. They are
derived from the genome of an organism and contain all the information related
to annotated metabolic genes in an organism. Through gene-enzyme association,
this provides a list of all possible enzymes and therefore reactions that are then
translated into the model, generating a stoichiometric model from the genome.
Because the model is derived from gene annotations, the model is only consid-
ered as accurate or representative as the annotations themselves; in other words,
reactions cannot appear in this model that are not associated with an annotated
gene. Additional reactions can be added in after derivation from the genome, to fill
any sections of the network that may be missing due to lack of annotated genes or
genome sequence for that region. The goal of the GSM is to simplify the metabolic
components of an entire organism into a stoichiometric matrix, which can then be
utilised for analysis and predictive outcomes (Henry et al. 2010).
Currently, many di erent GSMs exist and have been used for a variety of metabolic
analysis, engineering and synthetic biology development (Papin et al. 2003, Ro-
drigues et al. 2013, Chang et al. 2010, Kotte et al. 2010, DeBerardinis et al. 2008).
Initially, GSMs were created for so-called ”model organisms”. These are organ-
isms that have been used in experimental studies numerous times, and have well-
annotated genomes, making them excellent candidates for a metabolic model gen-
eration. They were, however, prokaryotic organisms, due to the di culties in
constructing eukaryotic organism metabolic models.
Development of prokaryotic and eukaryotic metabolic models
Initially, metabolic models were considered for small sections (known as ”toy” or
”core” models) of prokaryotic metabolism; specifically, E. coli was selected as the
initial model organism, and the central carbon metabolism pathways (glycolysis,
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the citric acid cycle, the pentose phosphate pathway) were selected for this core
model. This was in part due to the wealth of information that describes E. coli, its
biological processes, and the documentation of individual steps within central car-
bon metabolic pathways (Liu et al. 2014). Additionally, due to prokaryotes having
a single cellular compartment, the identification and organisation of metabolites
and reactions are simple; all reactions and metabolites occur in either the intra-
cellular or extracellular ”compartment” (Vellai & Vida 1999).
Eukaryotic organisms, however, are multi-compartmental, which can make it dif-
ficult when generating a metabolic model (Tanaka et al. 2006). Specifically, this
makes identifying in which compartment reactions and metabolites reside, and
indeed if they reside in specific compartments or are ubiquitous throughout the
cellular system, di cult. There is also the issue of compartment-to-compartment
transport and the identification of the relevant transport links that may exist
within the cellular structure (Hatzimanikatis et al. 2005). To combat this issue,
and in particular, for GSMs, transcriptomic and genomic data can be used to es-
tablish localisation of metabolites and reactions within cells (Gutierrez & Lewis
2015). This is also useful for multi-cellular eukaryotic organisms, where multi-
ple cell types, with potentially di erent metabolic network topologies, exist. The
transcriptomics and genomic data can be used to ”prune” the genome of the organ-
ism to identify cell-specific metabolic genes, further di erentiating the metabolic
network to a genuinely cell-specific one.
Human Metabolic Models
Expanding upon the developments of eukaryotic model creation, human metabolic
models have also been created for both the entire genome and various specific cell
types (Chowdhury & Maranas 2015). Most notably, collaborative e orts with
many research groups lead to the creation of the human GSM titled ”Recon 1”
(Duarte et al. 2007). This GSM was created utilising data from the human genome
project, as well as integrating previous attempts at creating a human GSM; The
Edinburgh Human Network (Ma et al. 2007). This GSM encompassed all anno-
tated metabolic genes within the human genome, and in doing so represented the
metabolic potential of every combined cell-type. However, this presents the issue
that no single cell type has access to the network topology of every other cell type,
requiring the development of cell-specific metabolic models. This also aids in the
analysis and prediction of cell-specific experiments.
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The first primary human cell-specific model was HeptaoNet1 (Gille et al. 2010),
which was created by combining reactions and metabolites from both Recon 1
and The Edinburgh Human Network (Duarte et al. 2007, Ma et al. 2007). Fur-
ther developments led to the creation of a metabolic reconstruction of a human
macrophage (Bordbar et al. 2010), which utilised Recon 1 as a base model with
several sets of clinical gene expression data to refine the metabolic model. A
metabolic model for human astrocytes was also created to study the e ect of neu-
rological disorders and how the pathology of these diseases may either a ect or be
influenced by the astrocyte’s metabolic network function (Mart́ın-Jiménez et al.
2017). Further refinements were conducted on the original Recon model, to yield
Recon 2 (Thiele et al. 2013, Swainston et al. 2016) which increased the number
of metabolic components (due to increases in gene annotations) and was curated
by a more extensive consortium than before. Ultimately, while there are fewer
metabolic models for humans (concerning GSMs), the selection of models that
are available are well curated and supported by continued research and develop-
ment.
1.5 LINEAR OPTIMISATION AND FLUX BALANCE ANALYSIS
Once a metabolic model has been created, whether it be a toy, core or genome-scale
model, it can be analysed using a variety of linear optimisation techniques.
1.5.1 Linear Optimisation
Linear optimisation is a mathematical method of optimising a model, for an objec-
tive, given a set of linear equality and inequalities in order to achieve an outcome
for a given objective (Broyden 1994, Stroud 1990). This objective, also known as
the objective-function, is a linear objective function that in combination with the
equalities and inequalities is used to find a feasible solution; this can be considered
as the ”outcome” of a system given a set of pre-determined constraints. A formal
definition of linear optimisation is described in Eq. 1.5.
maximise c|x





where x is the vector of variables that are being determined, and a and c are
vectors of coe cients. The matrix N is of coe cients also. The objective func-
tion is defined as the expression that is maximised (or minimised), cT · x in this
example.
Once a linear optimisation problem (LP) has been created, using a set of linear
constraints and an objective function, the LP is then fed into an LP solver which
applies an algorithm to solver the LP for the given objective. The algorithm
utilised by most LP solvers is the simplex method.
Linear constraints from the LP define an LP solution space, known as the feasible
space, which forms a convex polyhedron; an n-dimensional shape with vertices,
edges and faces that contains a finite number of points. The simplex method
calculates a solution to the LP in an iterative process (Stone & Tovey 1991).
Initially in the first phase, a starting vertex is selected, and the simplex algorithm
moves along the edges from this vertex until a feasible solution is found. If a
solution cannot be found within the given feasible space, then the LP result is
infeasible. Upon finding a feasible solution, phase two describes the application
of the simplex algorithm using the solution found in the first phase as a starting
point. Again, the movement along the edges is iterated until a point is reached that
any further movement along any of the edges will reduce the objective function;
essentially this point is the optimum solution for the LP (Nering & Tucker 1992,
Dantzig & Thapa 1997).
Linear optimisation forms the basis for the most common form of stoichiometric
metabolic model analysis: flux balance analysis.
1.5.2 Flux Balance Analysis
Linear optimisation can be used for the optimisation of network flow, and therefore
can be applied to the stoichiometric models of metabolism. More formally, linear
optimisation of a metabolic model is known as flux balance analysis.
Flux balance analysis (FBA) is a mathematical, constraint-based modelling method
used to simulate reconstructions of metabolic networks (Orth et al. 2010). FBA
is computationally inexpensive; both the linear optimisation and requirements for
input data (in terms of model construction) are considered less intensive than other
modelling techniques, such kinetic modelling discussed in in §1.4. No information
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is required regarding dyanmics, metabolite concentrations or other thermodynamic
constraints. This is achieved due to two assumptions: steady-state and optimal-
ity.
The steady-state assumption considers that in a reaction mechanism (i.e. a metabolic
reaction) that a compound or intermediate is consumed at the same rate as it is
produced; there is a net change in concentration of 0 (Orth et al. 2010, Beard et al.
2004). When applied to an entire metabolic network, this assumption enforces that
the overall net change in total rate of metabolite production and consumption is
0.
FBA describes and predicts how the flow of metabolites through the metabolic
network, here called reaction ”flux”, is distributed optimally for a cell. This no-
tion of optimality is achieved through multiple constraints on the metabolic flux
distribution. Firstly, individual reactions (columns in the stoichiometric matrix)
are constrained by a minimum and maximum flux value, known as the lower and
upper bounds (respectively). The flux bounds acknowledges that enzymes have
limited capacity to catalyse a reaction, and a maximum value can be set using
the upper bound. The lower bound is to signify reactions that may be reversible
(bidirectional) if it is a non-zero negative number, and irreversible (unidirectional)
if it is zero or a non-zero positive number. The linear inequalities that arise from
the setting of these flux bounds are shown in Eq.1.6.
lbi Æ vi Æ ubi (1.6)
where indexation i is over all reactions in the metabolic model. The lower (lb) and
upper (ub) bounds are determined from experimental data or literature. If bound
values are not available they are traditionally set to lower bound = 0 and upper
bound = +inf (Orth et al. 2010).
Secondly, the flux distribution steady-state assumes that the metabolic model
[organism] has entered a state where the influx of metabolites equals the e ux; the
change in a specific metabolites concentration does not change as the producing
and consuming fluxes cancel each other out. This assumption ensures that all
variables remain constant over time. More formally, steady-state is defined as Eq.
1.7.
Sv = 0 (1.7)
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where S is the stoichiometric matrix of the metabolic model, and v is the flux
vector that satisfies the steady-state assumption.
Finally, an additional constraint is added to the flux distribution so that a unique
optimal solution is yielded. On their own, the steady-state assumption (Eq.1.7)
and flux distribution vector constraints (Eq.1.6) provide a set of feasible solutions
for the metabolic model, but do not result in a unique solution; this is due to the
linear optimisation problem being underdetermined as there are generally many
more reactions than there are metabolites. To solve this, the metabolic model flux
distribution is optimised [maximised] for a biological-relevant objective function Z
(Eq.1.8).
Z = c|v (1.8)
where Z is the optimal value for the objective function c|v. c is a vector of zeros
with a non-zero value (usually 1) at the index position of the reaction selected
as the objective function. This objective function, in most cases, is the produc-
tion of biomass for replication (Orth et al. 2010, Schuster et al. 2008), which is
known as the biomass psuedo-reaction. This objective function is derived from
the turnover of biomass precursors, and formulated in such a way that it provides
the proportion that each biomass precursor contributes, in one hour, to a gram of
biomass. This results in all flux units, for the reactions in the model, being given
a unit of mmol/gDW/h≠1, where gDW is the gram of dry-weight biomass. A
metabolic network may have many objective functions, which can represent di er-
ent physiological states, biomass compositions or other metabolic phenotypes. To
summarise, the final [total] linear optimisation problem for FBA and the analysis
of a metabolic network, is an adaptation of Eq. 1.5, defined formally below (Eq.
1.9).
maximise Z = c|v
subject to Sv = 0
lbi Æ vi Æ ubi
(1.9)
where indexation i is over all reactions in the metabolic model, Z is the optima
for the objective function cT · v, S is the stoichiometric matrix, and v is the flux
distribution vector which is bound by the lower (lb) and upper (ub) flux bounds.
A summary of the FBA method, including translation of metabolic model from
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lb ≤ v ≤ ub
Sv = 0Unconstrained
Figure 1.7: Summary of the application of flux balance analysis for metabolic
network analysis, from biochemical network to final computational output. (A) a
network representation of a small toy metabolic network, with metabolites (cir-
cles) and reactions (arrows) shown. (B) a stoichiometric matrix representation
of the small toy metabolic network, where values are stoichiometric coe cients of
metabolites (rows) partaking in reactions (columns). (C) cartoon representation of
the unconstrained linear optimisation problem, with no information regarding re-
action minimum and maximum fluxes. (D) cartoon representation of the bounded
linear optimisation problem under the constraints of steady-state (Sv = 0) and
reaction flux (v) lower and upper bounding (lb Æ v Æ ub). (E) cartoon represen-
tation of the constrained linear optimisation problem with an objective function
definition (Z = c|v), yielding an optimal solution (red dot) upon solving the
corresponding linear optimisation problem.
FBA is a valuable tool for a variety of scientific industries and academia. It
Sean Aller 22
1 | Introduction
has been used to predict metabolic fluxes through numerous GSMs for appli-
cations in bioengineering (Bonomo & Gill 2005), synthetic biology(Rudge et al.
2012), and manipulation of metabolism for healthcare and pharmaceutical appli-
cations(Bordbar et al. 2015, Heinken & Thiele 2015, Shen et al. 2010). However,
many advancements and extensions have been created for FBA since its conception,
each created for a particular scenario or to increase the accuracy and predictability
of the metabolic models.
1.5.3 Expansions of Flux Balance Analysis
FBA has proved to be a useful tool in the analysis of metabolic networks, especially
in lieu of data regarding various aspects of the cellular environment that a ect the
metabolic network (i.e. internal pH, reaction kinetic parameters) (Price et al. 2003,
Smallbone & Simeonidis 2009). However, metabolism and by virtue metabolic
networks are a ected by a number of highly complex and varied parameters, and
there are a number of methods developed that expand upon the foundations laid
by FBA (Kau man et al. 2003, Antoniewicz 2015). These mainly focus on the
application of additional linear inequalities to the linear optimisation problem,
or through integration of other data sets, where available. A brief overview of
the various expansions of the FBA methodology, including specific aims of these



















Figure 1.8: Summary of the various expansions of flux balance analysis (FBA).
New, expanded FBA methods are highlighted with a blue underline. Solid lines




FBA assumes optimality of a metabolic system for a given objective, of which
biomass production is often selected as the objective function (Thiele & Palsson
2010, Orth et al. 2010) as it signifies the biomass that is accumulated to facilitate
reproduction of an organism, particularly for prokaryotic organisms. This has also
been observed to be a driving force in the evolution of bacterial strains (Lenski
& Travisano 1994, Ibarra et al. 2002, Molenaar et al. 2009); there is a selection
pressure to select for strains that grow the quickest, but also are more e cient in
their use of substrates and metabolic network for growth. Combining these ideas
yields the assumption that the fastest growing strains have a more e cient enzyme
usage.
To achieve this, parsimonious FBA (pFBA) was created as an expansion of FBA.
Essentially, pFBA considers the optimal solution as predicted by FBA, whilst
attempting to minimise the summation of all gene-associated reaction fluxes, where
reactions that are not associated with genes are omitted from such minimisation,
and yields the resulting pFBA optima (Lewis et al. 2010). The predicted flux vector
(v) yielded by pFBA is considered to be the minimal-flux values that achieve the
maximum optima; a set of reactions considered to be [stoichiometric] the most
e cient in terms of reaching the desired optima.
As discussed, the basis for the development of pFBA comes from the assumption
that biomass accumulation is the driving force of strain selection, and that e cient
enzyme use is beneficial for this goal. However, whilst this may apply to prokary-
otic organisms, eukaryotic organisms have been and are under di erent evolution-
ary pressures (Molenaar et al. 2009). Under this assumption, pFBA appears more
applicable to prokaryotic organisms than eukaryotic, which is a consideration that
needs to be enacted when designing a metabolic modelling study.
Loopless Flux Balance Analysis
The predictive solutions of FBA (and derivates) are subject to e ects of network
architecture and reaction parameters. Specifically, thermodynamically infeasible
flux distributions can exist, whereby ”loops” of reactions are cycled. To combat
this, a version of FBA has been developed that seeks to minimise the number of
these loops (Desouki et al. 2015). This loopless FBA (lFBA) is a post-processing
step to the constraint-based solution, and removes internal cycles (that is, cycles
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that are not associated with the exchange of metabolites) from the flux distribu-
tion. As a comparison, for a toy model, of this method and its e ect on the flux




















Figure 1.9: Comparison of (A) the metabolic network structure, (B) the pre-
dicted flux distribution with thermodynamically infeasible loops, and (C) the pre-
dicted flux distribution with elimination of infeasible loops. In this toy model,
metabolites a and b can be interconverted either directly or via the c intermediary
metabolite. Reaction fluxes (v) are considered reversible, apart from the import
(vin) and export (Vout) reactions. Metabolites are denoted with lower case let-
ters (a, b, c). Numbers above reaction arrows indicate predicted flux value for the
appropriate condition.
There are two main components to lFBA. One is the removal of internal cycles
and the preservation of fluxes that are not associated with loops (to preserve
optimality of the prediction and network). The second is the minimisation of the
sum of absolute fluxes, using the original flux predictions from FBA to bound the
fluxes to a feasible range. It should be noted that exchange fluxes are omitted
from all steps. The full optimisation problem for lFBA, in conjunction with the





subject to c|v = Z0
Sv = 0
0 Æ vi Æ v0i for i : v0i Ø 0
v
0
i Æ vi Æ 0 for i : v0i < 0
vj = v0j for exchange fluxes vj
(1.10)
where indexation i is over all non-exchange or objective reaction fluxes. The
original optima value is maintained by setting the value of the objective function to
the original (0) FBA solution Z0. Reaction fluxes are bound so that directionality
Sean Aller 25
1 | Introduction
of reactions is also conserved; forward reaction fluxes v0i Ø 0 and reverse reaction
fluxes v0i < 0. Exchange fluxes vj remained unaltered in this process.
In contrast to FVA, which does not enforce the exchange flux conditions or the
constraints regarding reaction reversibility, lFBA yields a flux distribution where
at least one reaction in every possible cycle is inactive, thus removing the thermo-
dynamically infeasible loops from the prediction. This method has been refined to
a level that it can now be ran with little computational cost.
1.5.5 Dynamic FBA
Due to the lack of kinetic parameters and the constraint of the steady-state as-
sumption, FBA cannot be used to model changes in a metabolic system over time
(Smallbone et al. 2010, Orth et al. 2010). However, the FBA method has been
expanded and adapted to capture some dynamics of a metabolic network by mod-
elling the change in metabolite concentrations over time. This is achieved through
the method of dynamic FBA (dFBA).
dFBA requires the relaxation of the steady-state assumption in combination with
multiple, individual linear optimisation problems (Eq. 1.9), which represent a
set of time intervals. The initial metabolite concentrations, as defined in the
original FBA optimisation problem, are used to calculate the subsequent change
in metabolite concentration over time. Because it is only the exchange metabolite
that have an initial concentration defined, these are the only metabolites that can
be simulated as changing in concentration over time. At each optimisation step,
the metabolite fluxes are predicted by re-running FBA, and then updating the
remaining concentrations of exchange metabolites. These values are then used to
update the exchange fluxes, through flux bound alterations, to simulate a time
step in a linear fashion. These assumptions, combined with the relaxation of the
steady-state assumption, are known as a pseudo steady-state (Mahadevan et al.
2002, Meadows et al. 2010, Hoppe et al. 2007).
Flux Variability Analysis
FBA does not necessarily provide a unique solution for a given objective function
(Mahadevan & Schilling 2003), and for any particular optimum there may be











Figure 1.10: Cartoon repre-
sentation of the flux (v) min-
imum (min) and maximum
(max) values that are calculated
for a given optimal solution
space (blue shape). The multi-
ple optima (red circles) achieve
the same value for the objective
function and define the optimal
flux range for reactions in the
model.
instance, glucose may be converted to biomass precursors through a variety of
di erent pathways or metabolites. Flux variability analysis (FVA) provides an
additional layer of information to FBA by predicting the possible flux range for
each reaction: the ranges of specific values for a particular reaction flux vi in which
the final optimal solution remains the same (Fig. 1.10).
Under these conditions, the fluxes predicted are the minimum and maximum flux
values that a reaction can have, given both the steady-state assumption and the
optimality conditions for the system; this is usually the optimal state solution
obtained from FBA for a given objective function. more formally, the FVA linear
problem can be described as a continuation of the FBA one, laid out in Eq. 1.9.
The FVA linear optimisation problem requires two optimisations, a maximisation
(max) and a minimisation (min), shown in Eq. 1.11.
max/min vi
subject to Sv = 0
b|v Ø “Zo
lbi Æ vi Æ ubi
(1.11)
where c = b (from Eq. 1.9) and Zo = b|v0 is the optimal solution for FBA (Eq.
1.9). “ is a parameter that controls the type of analysis conducted; if “ = 1 then
the optimal state is analysed, whereas if 0 Æ “ < 1 then the sub-optimal state is
analysed.
The output of FVA is two flux distribution vectors, one minimum and one maxi-
mum flux vector, subsequently predicting the flux range for each individual reac-
tion given the optimality constraints. Generally, these ranges are interpreted in
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terms of how the flux range may relate to the optimal solution: wide flux ranges
are associated with reactions that are less important to the optimal solution (par-
ticularly if the flux range crosses zero), whereas narrow ranges are associated with
reactions that are more important to the optimal solution (Motamedian 2015,
Mahadevan & Schilling 2003). The reasoning for this trail of thought is that if a
reaction has small variance in the flux value it can have, given the current optimal-
ity enforced, then small perturbations to this reaction flux will more greatly a ect
the optima predicted than that of a reaction with large flux variance. Whilst this
presents an interesting point of view in terms of how flux values relate to optima
predictions, the flux-range to biological mapping is not one that is yet fully ex-
plored. The usefulness of FVA lies in the fact that it can predict multiple ranges of
solutions for a given optima, which can narrow down exploration (in terms of reac-
tion targets) for further computational exploration (Motamedian 2015, Mahadevan
& Schilling 2003).
Computational Toolboxes
Many software packages exist to facilitate the study of stoichiometric metabolic
models. The most notable is the Constraint-Based Reconstruction and Analysis
(COBRA) toolboxes. As most analyses in this thesis were conducted in a Python-
environment, the appropriate COBRA package was used: CobraPy (Ebrahim et al.
2013). A suitable linear optimisation solver was selected for this study, the IBM
CPLEX solver. A full set of definitions for both the personal and server computers
used to run the simulations are found in Table 1.2.
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Table 1.2: Definitions of computational tools and packages used throughout this
thesis.
Computer Description Version








All forms of FBA discussed (FBA, FVA and lFBA) have been utilised throughout
this study, with the appropriate method stated for each research component. The
majority of the flux predictions were done using lFBA, due to the reduction of
thermodynamically infeasible predictions.
1.6 PREVIOUS METABOLIC MODELLING STUDIES
Metabolic modelling, and more specific FBA, have been used in multiple studies
across di erent scientific fields. Most often, FBA has been used as a predictive
tool to facilitate bioengineering and metabolic studies, in particular to predict the
ability of an organism to produce a particular compound. There have also been
a number of explorative studies, with the aim of being able to describe metabolic
phenotypes of organisms. Here, an overview of the applications of FBA in previous
studies is discussed.
Evolution of Metabolic Systems. Concepts and theories surrounding evo-
lutionary biology, particularly in regards to the emergence of metabolism and
metabolic pathways, has been explored numerous times through computational
studies (Schmidt et al. 2003). Building upon these studies, there has been a focus
on using FBA to explore the adaptability of a metabolic network, most notably
for E. coli, to be able to identify how horizontal gene transfer may e ect the evolu-
tion of bacterial metabolic networks (Pál et al. 2005) or the minimal components
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required for a functional metabolic network (Pál et al. 2006). The latter presents
the most interesting case of metabolism in the context of infection. FBA predic-
tions can be used to establish the minimal set of genes for a given objective, for
instance the minimum metabolic genes required for a pathogen to be pathogenic.
This, in combination with evolutionary studies, presents a possibility for predictive
infection tools using computational modelling through gene analysis of host and
pathogen.
Drug Target Predictions. Expanding upon the identification of metabolic
genes that are essential to an organisms pathogenicity, further application of
metabolic modelling can be used for potential drug target identification. Pre-
vious experimental studies have identified that metabolic flux analysis (MFA) can
be used in combination with gene expression data to predict the e ect of drugs
on Mycobacterium tuberculosis metabolism(Colijn et al. 2009). Subsequently, this
data was combined with predictive metabolic models of M. tuberculosis to fur-
ther predict the e ects of mycolic acid on metabolic pathways (such as fatty acid
synthesis).
Other pathogenic organisms have also be the subject of metabolic analysis, such as
the GSM of Plasmodium falciparum. This study demonstrated the viable systems
biology cycle of in silico drug target predictions (against metabolic genes) and
subsequent in vitro experimental studies (Plata et al. 2010).
Phage and Virus Infections. Beyond network analysis and drug prediction,
metabolic modelling has also been used to understand the interplay between host
and pathogen during an infection (Durmuş et al. 2015, Jamshidi & Raghunathan
2015). Specifically, multiple studies have identified that there are significant re-
arrangements of host metabolic resources in response to infection of E. coli with
phage (Jain & Srivastava 2009, Birch et al. 2012). In these cases, the phage
(MS2 and T7) were described in the metabolic model as a pseudo-reaction that
contained the precursors, generated in the same manner as a biomass objective
function (Thiele & Palsson 2010), for phage biomass production. This pseudo-
reaction becomes the objective function for the phage, and can then be optimised




Human Infections. Further to the bacteria-phage (Law et al. 2013) studies
discussed above, and other mammalian-pathogen studies (Eisenreich et al. 2013,
Ryu et al. 2015, Quek et al. 2010, Aderem et al. 2011), a model was created of
a human macrophage infected with the intracellular bacterial pathogen M. tuber-
culosis and analysed using FBA to predict the interactions between the human
host and pathogen (Bordbar et al. 2010). A co-optimisation between the human
macrophage objective function and the M. tuberculosis associated pseudo-reaction
was used as the objective function of the model. As bacteria contain their own
metabolic networks and machinery, they can be considered in terms of a separate
model that is integrated or appended to the existing host metabolic model (Swann
et al. 2015). A virus, with no metabolic network or metabolic resources of its own,
is entirely dependent on the host metabolic network (Gilbert et al. 2012), hence
why virus infection can be modelled using just a pseudo-reaction append into the
existing model.
1.7 AIMS AND OBJECTIVES
This thesis aimed to investigate how a virus-infection can be represented in a hu-
man genome-scale metabolic model, to aid in antiviral discovery and experimental
design (concerning compound selection), and create an antiviral drug systems bi-
ology cycle. The rationale for the need of such a system is the lack of antiviral
therapeutics for viruses deemed a potential disease or biosecurity risk. This thesis
attempts to provide a suitable framework for host-virus metabolic modelling stud-
ies and develops strategies that can be utilised by experimentalists to tackle the
lack of viable antivirals. This was done by achieving the following objectives:
1. Creation of a method to describe a virus as a metabolic pseudo-reaction that
can be used to represent an infected state when integrated into a suitable
host metabolic model
2. Construction of an integrated host-virus metabolic model, for species of the
Alphavirus and Flavivirus families, to:
(a) Understand the changes in the metabolic network during an infection
(b) Identify potential antiviral targets based upon the use of the metabolic
network by the virus-controlled system
3. Develop strategies for antiviral discovery through:
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(a) Simulation of reaction perturbations via reaction knockouts and other
inhibitory methods
(b) Develop an antiviral strategy that considers host viability and attempts
to maintain this while disrupting virus production
(c) Evaluate the e ect of single and multiple reaction antiviral strategies
4. Provide testable hypothesis from computational simulations, through the
identification of novel drug compounds from antiviral modelling predictions
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CHAPTER 2
Integrated Host-Virus Metabolic Models of
Chikungunya, Dengue and Zika Viruses
2.1 INTRODUCTION
Recent disease-causing emergent viruses, such as Zika virus (Fauci et al. 2005,
Mlakar et al. 2016), illustrate the need for rapid characterisation of the interac-
tions between viruses and their potential hosts to facilitate the development and
implementation of antiviral strategies. However, this understanding remains a sig-
nificant challenge due to lack of virology knowledge and scientific resources, such as
lack of experimental data; availability and implementation of suitable host-virus
systems; and antiviral drug candidate selection. Development of a system that
could facilitate across all these fronts would prove valuable in the understanding
of these viral infections, but also towards the goal of e ective antiviral development
(Littler & Oberg 2005, Geisbert & Jahrling 2004).
Viruses are entirely dependent on their hosts’ cellular resources for their replica-
tion. This relationship is highlighted by observed variations in virus production
levels, correlating with cell-to-cell variance in growth rate and phase (Zhu et al.
2009), as well as virus infection leading to changes in host metabolism (Yu et al.
2011b). In particular, virus infection leads to significant metabolic alterations in
the host, in some cases resulting in up to 3-fold increase in glycolysis rates (El-
Bacha et al. 2004, Jain & Srivastava 2009, Yu et al. 2011a) and changes in ATP
production rates (Zhu et al. 2009). This observation can be seen as an emergent
property of the combined host-virus metabolic system and could be related to
changes in host cellular demands arising from viral production (Molenaar et al.
2009, Weiße et al. 2015). More specifically, these alterations in host metabolism
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upon infection are interpreted either a virus actively manipulating the host system
to their advantage (Maynard et al. 2010), or the additional draw of metabolic com-
ponents for viral production merely resulting in a re-arrangement of host metabolic
fluxes.
These re-arrangements alter the metabolic profile of the network, in terms of degra-
dation and synthesis of metabolic compounds; these are known as catabolic and
anabolic states, respectively. Catabolism defines the use of metabolic reactions to
break-down larger molecules into smaller ones, and is utilised to extract energy
from various compounds (i.e. glucose) or for use in anabolic reactions. In contrast,
anabolism refers to the synthesis of larger molecules from various smaller ones (i.e.
amino acid biosynthesis). Both states of metabolism can be interchangeable and
this change can represent a shift in the metabolic network, in terms of resource allo-
cation. For example, in eukaryotic organisms the citric acid cycle is predominantly
fed via pyruvate (from the cytosol) although it may be supplemented, or indeed
ran entirely independently, by the anabolism of glutamine (DeBerardinis et al.
2007). This type of metabolism, where biopolymers are used to feed metabolic
pathways, is known as anaplerosis (in this particular example. this is known as
glutamine anaplerosis). Observing the shift in networks, between catabolic and
anabolic states, has been highlighted in previous viral infection studies and is some-
thing that can also be observed (Thai et al. 2015, 2014, Goodwin et al. 2015), and
potentially more well understood, in a metabolic modelling environment.
Previous studies of viruses and their interaction with host metabolism, in the
context of metabolic modelling, have focused on the metabolic interactions of Es-
cherichia coli bacteria infected with T7 (Birch et al. 2012) and MS2 (Jain & Srivas-
tava 2009) bacteriophage. These studies have demonstrated the potential of a fully
realised systems biology approach to host-pathogen interactions, highlighting the
low-resource and relatively small computational costs of such a method. To further
develop these approaches to a human-virus study, a suitable host metabolic model
is selected along with clinically and scientifically important viral pathogens.
A stoichiometric metabolic model of a human macrophage cell was used to es-
tablish an integrated host-virus metabolic model for three viruses causing current
(or previously) epidemic outbreaks: Chikungunya virus (CHIKV); Dengue virus
(DENV); and Zika virus (ZIKV). These are representatives of the virus genera Al-
phavirus (CHIKV) and Flavivirus (DENV, ZIKV), which are positive-sense single-
strand RNA viruses with simple physical structures (Mukhopadhyay et al. 2005,
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Strauss & Strauss 1994). All three of these viruses have been highlighted as being
detrimental to global human health and biosecurity (Luz 2016).
Viruses of both families have been observed to infect many di erent human cell
types (Balsitis et al. 2009, Tang 2012), including monocyte-derived macrophage
cell lines (Fox et al. 2015, Gollins & Porterfield 1985, Balsitis et al. 2009), and
are usually transmitted to humans via arthropod vectors, the most common being













Virus Biomass Objective Function
Figure 2.1: Schematic of virus biomass integration with existing host network,
and the relevant macromolecules that link them.
The development of host-virus metabolic models, between the human macrophage
model (MO) and CHIKV, DENV and ZIKV require the development of a novel
methodology to describe viruses as metabolic pseudo-reactions; virus biomass ob-
jective functions (VBOFs). The VBOFs capture all the required information about
a virus particle to model the infection process within a host, and links the virus pro-
duction to preexisting metabolic resources allocated by the host (Fig. 2.1). These
VBOFs are used to model di erent virus-infected systems through integration of
individual reactions, for each virus, into its own integrated host-virus metabolic
model (iHVM). The analysis of the three iHVMs predicts that viral production
(in all models) results in alterations to host metabolic fluxes.
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2.2 MATERIALS AND METHODS
2.2.1 Virus Species Definition
Chikungunya (Alphavirus), Dengue and Zika (Flavivirus ) viruses (formal species
definitions given in Table. 2.1). were selected based upon their disease caus-
ing potential and risk to biosecurity (Woolhouse et al. 2016, Lwande et al. 2015,
Figueiredo & Figueiredo 2014).
Table 2.1: Virus species used for creation of integrated host-virus metabolic mod-













NC 001474 Dengue Virus
2
Flavivirus 16681 DENV
NC 012532 Zika Virus Flavivirus MR 766 ZIKV
Genbank files for the viruses were downloaded from the NCBI database (Geer et al.
2010) using the corresponding NCBI reference for each virus species. These files
were access on 2017-07-18. These GenBank files contain the nucleotide and amino
acid sequences of the genome and virus proteins, respectively.
2.2.2 Generation of virus biomass objective functions
Implementation of the constraint-based modelling approach to study virus infec-
tions from a metabolic stance requires the definition of a pseudo reaction that
accounts for the production of virus particles from the biomass associated metabo-
lites. These metabolites consist of amino acids and nucleotides, which are fur-
ther categorised into the proteomic and genomic macromolecular categories, re-
spectively. This pseudo reaction represents the virus biomass objective function
(VBOF). To account for metabolic fluxes associated with the virus production,
the VBOF captures the stoichiometry of the nucleotides and amino acids required
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for virus production. This information is identified from the genome sequence,
along with the associated viral protein sequences and how many copies of these
proteins are required per viral genome. Additionally, the VBOF also captures the
associated energy metabolites (i.e. ATP) required for viral genome and protein
production, in a similar manner to biomass production functions used for genome-
scale metabolic models (Thiele & Palsson 2010).
Defining Metabolite Stoichiometries
The metabolite stoichiometries required for the VBOF are derived from the viral
genome sequence, the subsequently encoded proteins, the copy number of those
proteins, and knowledge of the energetic requirements for the formation of peptide
bonds (amino acid polymerisation) and phosphodiester bonds (RNA nucleotide
polymerisation). For this modelling approach, we do not include in the VBOF a
metabolic component that describes the virus envelopes or virus-associated lipids.
This is due to a lack of information regarding the stoichiometry of virus associated
lipids for species of the Alphavirus and Flavivirus families.
Genomic and Proteomic Information for the Viruses
The approach outlined in this Methods is best suited to viruses with known nu-
cleotide and amino acid stoichiometry and simple, symmetrical capsid structures.
Alphavirus and Flavivirus virus families meet these criteria and as such mean
that Chikungunya, Dengue and Zika viruses are suitable for this modelling ap-
proach.
Viruses can be classified by their replication methods, known as the Baltimore
Classification System (Yu et al. 2013). Depending upon the classification of a virus,
the viral particle may contain more than a single copy of the virus genome. As
such, this is factored into the calculation of the nucleotide counts for a given VBOF.
All viruses presented in this study, unless explicitly stated otherwise, fall into the
Group IV classification: the positive single-stranded RNA (+ssRNA) genome is
replicated via a negative ssRNA (-ssRNA) intermediate. Therefore, the overall
count of nucleotides required to produce a virus particle are the combined counts
of the nucleotides in the +ssRNA sequence and the complementary nucleotides in
the -ssRNA sequence, as per the relationships defined in Table 2.2.
Sean Aller 37
2 | Creation and Analysis of Integrated Host-Virus Metabolic Models
Table 2.2: Relationship of nucleotide counts between positive and negative single-
sense RNA virus genomes.






The count for each RNA nucleotide (adenosine (A), cytidine (C), guanine (G) and
uracil (U)) can be taken directly from the virus genome sequence: RNA utilises
U in place of thymine (T) in DNA sequences; therefore T is replaced with U for
virus genome sequence readouts.
All viruses in this study, unless explicitly stated otherwise, are comprised of
two categories of protein that compose the virus proteome: structural and non-
structural. The amino acid sequence of these, and indeed any genome derived
protein sequence, are obtained from gene annotations of the viral genomes as in-
dicated in the NCBI genome entries (defined in each subsequent chapter). The
number of individual proteins, per virus particle, within these categories, is known
as the copy number. Copy numbers di er between virus species/ genera/families.
For viruses used in this study (from the Alphavirus and Flavivirus virus families),
the structural and nonstructural proteins are expressed in a ratio of copy numbers
that are derived from the overall virus structure (i.e. proteins in the capsid and
the nucleocapsid). Copy numbers for both of these virus families, for both protein
categories and the virus genome are listed in Table 2.3 (Strauss & Strauss 1994,
Mukhopadhyay et al. 2005). More broadly, the ratio of di erent protein classes in
a single virus particle can be derived from the overall virus structure or directly
from literature and experimental evidence.
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Table 2.3: Copy numbers per virus particle for Alphavirus and Flavivirus virus
families.
Virus Component Alphavirus Flavivirus
Genome 1 1
Nonstructural Protein 1 1
Structural Protein 240 180
Once the genomic and proteomic composition of a virus particle has been identified,
a VBOF can be created. This is done through the assignment of stoichiometric
coe cients for each biomass associated metabolite (amino acids, nucleotides and
the energy requirement metabolites). These stoichiometric coe cients are defined
using the per virus particle frequency of the associated metabolite (i.e. adenosine
count for nucleotides). The full method for calculating all virus macromolecular
components are detailed below.
Calculating nucleotide investment per virus
The total moles of each nucleotide in a mole of virus particle (NT OTi ) are obtained
from their frequency in the virus genome (NGi ) and replication intermediates (NRi ),










where the indexation i is over nucleotides. The moles of nucleotides are then
converted into grams of nucleotides per mole of virus (gNT P Smol≠1virus; GNi ) by




i = NT OTi MNi (2.2)
where the indexation i is over nucleotides. Summing GNi over all nucleotides and
combining this with the similar calculation for amino acids calculates the total
molar weight of the virus in terms of the main macromolecular constituents (Mv,
see Equation 2.15). Finally, the stoichiometric coe cients of each nucleotide in the
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where the indexation i is over nucleotides.
Calculating amino acid investment per virus
The total moles of each amino acid per mole of virus particle (XT OTj ) is obtained
using the sequence information of the structural (XSPj ) and non-structural (XNPj )
proteins. Frequencies of each amino acid in these proteins are multiplied by the
















where the indexation j is over amino acids. Copy numbers are as previously defined
in Table 2.3. The moles of amino acid per mole of virus are then converted into
grams of amino acid per mole of virus (gAAmol≠1virus; GXj ) by multiplying (XT OTj )
with the respective molar mass (g mol-1) of each amino acid (MX):
G
X
j = XT OTj MXj (2.5)
where the indexation j is over amino acids. Finally, the stoichiometries of each














where the indexation j is over amino acids.
Calculating the energy requirements per virus
Calculating ATP requirement for amino acid polymerisation (mmol g≠1virus).
The polymerisation of amino acid monomers requires approximately 4 ATP molecules
per peptide bond (Haynie 2009), defined as the constant kAT P (= 4). The overall
moles of ATP (AT OT ) required to form the structural (ASP ) and non-structural
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where the indexation is over amino acids. From AT OT , the stoichiometry of ATP
in the VBOF as millimoles per gram of virus (SAT P ):
S







The polymerisation of the amino acids forms peptide bonds, which requires the
hydrolysis of ATP. The water requirement for Polymerisation (SH2O) is equal to
that of ATP (SAT P ). The products from the hydrolysis of ATP (ADP, Pi and H+)
are also accounted for in the VBOF with negative stoichiometric terms that are
equal to that of ATP (see Equation 2.16).
Calculating the pyrophosphate (PPi) liberation from RNA nucleotide
polymerisation (mmol g≠1virus) . The polymerisation of RNA nucleotide monomers
to form the viral genome (+ssRNA or -ssRNA) liberates a PPi molecule (Haynie
2009), defined as the constant kP P i (=1). The overall moles of PPi (P T OT ) required
to form the viral genome (P G) and replication intermediates (P R) are calculated
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where the indexation i is over nucleotides. Conversion of this value into the PPi
stoichiometry for the VBOF as millimoles per gram of virus (SP P i) requires the
use of the overall molar mass (g mol-1) of one mole of virus:
S







Calculating total viral molar mass
The total molar mass of the virus (Mv) is calculated from the total mass of the



















where i, j are indexation over nucleotides and amino acids (respectively).
Final construction of the virus biomass objective function
Left and right terms of the VBOF reaction are based on the above calculations
of the nucleotide, amino acid and energy requirement metabolite stoichiometric
coe cients. The final stoichiometry for the VBOF pseudo-reaction is:
S
N
i + . . . + SXj + . . . + SAT P + SH2O æ SADP + SP i + SH
+ + SP P i (2.16)
This pseudo-reaction accounts for the virus’ biomass and the energy requirements
associated with its production. The VBOF is incorporated into stoichiometric
metabolic models representative of a host organism to simulate the metabolic
demands of a virus within that system. The full VBOF workflow is summarised
in Fig. 2.2.
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Figure 2.2: Schematic of virus biomass objective function (VBOF) generation.
Diagram outlines the process of forming the necessary components for the pseudo-
reaction that represents the production of virus particles (biomass).
Sean Aller 43
2 | Creation and Analysis of Integrated Host-Virus Metabolic Models
2.2.3 Human Macrophage Metabolic Model
To model the host-virus metabolic interactions of Chikungunya, Dengue and Zika
virus infections, a suitable model was selected. Experimental evidence has shown
that human monocyte-derived macrophage cell lines can support the growth of
viruses from Alphavirus and Flavivirus families (Gollins & Porterfield 1985, Fox
et al. 2015, Balsitis et al. 2009). The human macrophage model iAB-AMO-1410
(Bordbar et al. 2010) was selected as the suitable host metabolic model for this
study.
Model Definition
The reconstruction of the human macrophage metabolic model iAB-AMO-1410 is
detailed in a previous publication (Bordbar et al. 2010). Briefly, this reconstruction
is generated using gene expression data from human alveolar macrophages (n = 11 )
obtained from the Gene Expression Omnibus (Kazeros et al. 2008). This expression
data is used to derive the human macrophage cell type-specific metabolic model
from the global human metabolic network reconstruction, Recon 1 (Thiele et al.
2013). The breakdown of the iAB-AMO-1410 model components are listed in
Table 2.4.








In the context of this model, only metabolic genes are characterised. These genes
are associated with a reaction, which is defined as the interactions between metabo-
lites within the metabolic network. These reactions can be grouped into subsys-
tems, which are defined as a group of reactions that are attributed to the same
metabolic pathway per the KEGG notation (Kanehisa et al. 2017). Subsystems
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of the iAB-AMO-1410 metabolic model, along with some associated reactions, are
detailed in Table 2.5.
Table 2.5: Subsystems of the human macrophage metabolic model iAB-AMO-
1410 (ranked in alphabetical order).
Model Subsystem Number of Reactions
Alanine and Aspartate Metabolism 8
Alkaloid biosynthesis II 3
Aminosugar Metabolism 19
Arginine and Proline Metabolism 21
Ascorbate and Aldarate Metabolism 13
Beta-Alanine metabolism 8
Bile Acid Biosynthesis 28
Biotin Metabolism 6
Blood Group Biosynthesis 39
Butanoate Metabolism 3
C5-Branched dibasic acid metabolism 4
Carnitine shuttle 109
Cholesterol Metabolism 42
Chondroitin / heparan sulfate biosynthesis 44
Chondroitin sulfate degradation 26








Fatty acid activation 36
Fatty acid elongation 21
Fatty Acid Metabolism 26
Fatty acid oxidation 29
Fatty acid oxidation, peroxisome 19
Folate Metabolism 50
Fructose and Mannose Metabolism 16
Continued on next page
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Table 2.5 – continued from previous page





Glycine, Serine, and Threonine Metabolism 22
Glycolysis/Gluconeogenesis 28
Glycosylphosphatidylinositol (GPI)-anchor biosynthesis 31
Glyoxylate and Dicarboxylate Metabolism 9
Heme Biosynthesis 5
Heme Degradation 2




Inositol Phosphate Metabolism 59
Keratan sulfate biosynthesis 59
Keratan sulfate degradation 60









Nucleic acid degradation 9





Pentose and Glucuronate Interconversions 11
Continued on next page
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Table 2.5 – continued from previous page
Model Subsystem Number of Reactions











Selenoamino acid metabolism 11
Sphingolipid Metabolism 62
Starch and Sucrose Metabolism 20
Steroid Metabolism 40
Taurine and hypotaurine metabolism 3
Tetrahydrobiopterin 9
Thiamine Metabolism 6
Transport, Endoplasmic Reticular 93
Transport, Extracellular 505







Tyr, Phe, Trp Biosynthesis 1
Tyrosine metabolism 31
Ubiquinone Biosynthesis 14
Urea cycle/amino group metabolism 22
Valine, Leucine, and Isoleucine Metabolism 30
Vitamin A Metabolism 29
Continued on next page
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Table 2.5 – continued from previous page
Model Subsystem Number of Reactions
Vitamin B12 Metabolism 2
Vitamin B6 Metabolism 9
Vitamin D 14
The stoichiometric matrix is derived from the reactions within the model, and are
written such that metabolites with negative stoichiometric coe cients are left-side
entities and metabolites with a positive stoichiometric coe cient are considered
right-hand entities. Reactions may be reversible (they can proceed in either for-
ward or reverse direction, and therefore have a positive or negative flux value
respectively) and this reversibility is incorporated via the reaction bounds (Table
2.6).
Table 2.6: Definition of reaction reversibility in the metabolic model.
Reaction Description Reaction Bound Conditions
Non-reversible lower bound = 0; upper bound > 0
Non-reversible lower bound < 0; upper bound = 0
Reversible lower bound < 0; upper bound > 0
The metabolic model consists of several compartments; distinct areas of the net-
work that represent the various compartments, which represent di erent organelles,
of the macrophage cell. These compartments are abbreviated using a single letter
and are appended to each model metabolite identifier to indicate compartment-
specific metabolites (Table 2.7. While metabolites can have identical identifiers,
the compartment abbreviation indicates (regarding model entities) that these are
not the same (i.e. ’ATP(c)’ and ’ATP(m)’ represent the cytosolic and mitochon-
drial versions of ATP and are considered as separate metabolic entities).
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Table 2.7: Compartment definitions for the iAB-AMO-1410 metabolic model.









Reactions and metabolites can be interchanged between compartments, in what
is defined as a transport reaction. A select subset of these transport reactions
are the exchange reactions. These are responsible for the defining the availability
of metabolites in the extracellular in silico media for uptake by the metabolic
model.
Media Definition
Flux balance analysis of stoichiometric metabolic models requires the definition
of an in silico media. This is defined using a set of exchange reactions that im-
port metabolites into the modelling environment to be accessible to the metabolic
model. This import is defined (as with any other reaction in this modelling ap-
proach) as a flux rate that has a non-zero lower bound. Contrary to most reactions
in the metabolic model, the exchange reactions are written with the imported
metabolite (m (e)) as a left-hand term, and the right-hand term is empty set (Eq.
2.17).
m (e) æ ? (2.17)
Using this reaction notation, import of the exchange metabolite is denoted as a
negative flux value. The model consists of 382 exchange reactions, of which 27 have
a non-zero lower bound. This indicates that these reactions form the in silico im-
portable media (Table 2.8). These exchange reaction constraints are derived from
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previous literature that explored in vitro murine macrophage metabolite media
uptake rates (Newsholme et al. 1999, 1986, Sato et al. 1987).
Table 2.8: In silico Media Definitions for iAB-AMO-1410.
Exchange Reaction ID Exchange Metabolite Name Exchange Reaction
Lower Bound
EX hco3(e) Bicarbonate -10
EX but(e) Butyrate (n-C4:0) -0.0038
EX ca2(e) Calcium -inf
EX cl(e) Chloride -inf
EX glc(e) D-Glucose -0.2718
EX h(e) Hydrogen -inf
EX arg-L(e) L-Arginine -0.02375
EX gln-L(e) L-Glutamine -0.0765
EX his-L(e) L-Histidine -0.01
EX ile-L(e) L-Isoleucine -0.01
EX leu-L(e) L-Leucine -0.0362216
EX lys-L(e) L-Lysine -0.01
EX met-L(e) L-Methionine -0.01
EX phe-L(e) L-Phenylalanine -0.01
EX thr-L(e) L-Threonine -0.01
EX trp-L(e) L-Tryptophan -0.01
EX val-L(e) L-Valine -0.01
EX ocdca(e) Octadecanoate (n-C18:0) -0.1
EX ocdcea(e) Octadecenoate (n-C18:1) -0.0192
EX o2(e) Oxygen -0.3066
EX pi(e) Phosphate -10
EX k(e) Potassium -inf
EX pyr(e) Pyruvate -0.0568
EX na1(e) Sodium -inf
EX so4(e) Sulfate -inf
EX ttdca(e) Tetradecanoate (n-C14:0) -0.1
EX h2o(e) Water -inf
Most metabolites exchanged between the in silico media, and the model are
bounded with non-zero, non-infinite fluxes. These metabolites do not have a lim-
itless supply and are considered constrained. Metabolites such as hydrogen, water
and some ions are considered to be in abundant supply; this is denoted as ≠inf
in the exchange reaction lower bounds. All exchange reactions also have an upper
bound value of +inf , indicating that all these metabolites are exportable from
the model. It should be noted that these ”export reactions” are considered an
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abstraction: the exchange reactions are artificial reactions, in that they do not
arise from the organisms genome and associated metabolic genes, that define the
availability of metabolites in the accessible extracellular environment.
Objective Function Definition
The objective function for iAB-AMO-1410 was formulated using the standard
biomass objective function methods for metabolic model generation (Bordbar et al.
2010, Feist & Palsson 2010, Thiele & Palsson 2010). The objective function con-
siders the maintenance of cell biomass, as opposed to the more commonly used
accumulation of biomass(Feist & Palsson 2010). The latter is often assumed for
microbial metabolic models; in mammalian models, the maintenance of biomass
for cell viability is selected as a more appropriate objective.
The iAB-AMO-1410 objective function, named ’biomass mac’ in the metabolic
model, consists of several metabolite categories, known as macromolecule types,
and considered concerning total biomass objective function abundance (Fig. 2.3).
The abundance of the di erent macromolecule types, concerning a whole macrophage
cell, were obtained from literature: protein and sugars (Iyengar & UK 1985), lipids
(Schmien et al. n.d.), and DNA (Grutman & Orgel 1970). While RNA is also
present in the macrophage biomass, during model creation there was no literature
on RNA content; therefore the overall RNA content was adapted from yeast and
mouse hybridoma reconstructions (Sheikh et al. 2005).
0 20 40 60 80 100






Figure 2.3: Breakdown of the human macrophage (iAB-AMO-1410) biomass ob-
jective function for macrophage biomass maintenance in terms of macromolecular
types. Full breakdown of each individual type is listed in Appendix B.
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2.2.4 Additional Pseudo-reactions
In addition to the objective function that is added to the model, other artificial
(reactions that are not identified from the organisms annotated genome) are also
present within the metabolic model. These reactions are mainly comprised of the
exchange reactions that supply the in silico media. They also consist of cellular
transport reactions (i.e. between intracellular compartments or between the cellu-
lar system and external media), spontaneous reactions and disassociations.
Integration of model with virus biomass objective functions
The individual integrated host-virus stoichiometric metabolic models were created
for CHIKV, DENV and ZIKV (MO-CHIKV, MO-DENV and MO-ZIKV respec-
tively) through the integration of the respective VBOFs into a virus-specific in-
stance of the iAB-AMO-1410 human macrophage metabolic model. The VBOF
is appended to the iAB-AMO-1410 metabolic model stoichiometric matrix so that
the matrix S is redefined as m x n + 1.
2.2.5 Metabolic Modelling Computational Parameters
Flux Balance Analysis
All simulations were performed within the Python version 3.5.2 environment (Mill-
man & Aivazis 2011). FBA and all associated FBA-variants were run using the
Python package cobraPy version 0.10.1 (Ebrahim et al. 2013) with IBM CPLEX
optimisation studio version 12.7.0 as the linear optimisation solver (Barsoum et al.
2008). The FBA performed in this chapter was the loopless FBA variant (Desouki
et al. 2015). Fluxes predicted from FBA of the metabolic models are reported ei-
ther in the original units of mmol.gDw.h-1 or normalised to the glucose exchange
rate. The glucose exchange rate is defined as the predicted flux absolute value for
the glucose exchange reaction EX glc(e), and all flux values are normalised to the
absolute value of it. The redefined unit, in this case, is mmol/glucose/h-1.
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Host and Virus Optimised Network Definitions
For the modelling approach, the model is only considered as either host-optimal
or virus-optimal. The latter represents a thought experiment where the virus has
complete control of the metabolic rearrangements of the host’s network, without
maintaining host function, for viral production.
Host optimised network is defined as the host-virus integrated metabolic model
optimised for the pseudo-reaction objective function ’biomass mac’. The corre-
sponding optimisation results in the host-optimal network state and associated
predicted flux values for the reactions in this model.
Virus optimised network is defined as the host-virus integrated metabolic model
optimised for the VBOF. The corresponding optimisation results in the virus-
optimal network state and associated predicted flux values for the reactions in the
model.
2.2.6 Host-Virus Metabolic Comparisons
Comparisons between host and virus usage of the integrated host-virus metabolic
network can be performed with analysis which includes a combination of their
(respective) biomass pseudo-reaction objective functions and the optimisation of
the metabolic network for host and virus.
Characterisation of the stoichiometric di erences between host and virus
Comparisons between the metabolite stoichiometries in the host and virus pseudo-
reactions quantify the di erences in amino acid and nucleotide requirements that
fulfil the host or virus objective functions. The individual stoichiometric coe -
cients for all metabolites that are not associated with energy requirements (section
2.2.2) are normalised against the sum of stoichiometries of metabolites present in
the objective function (Eq. 2.18). In the case of ATP only the nucleotide asso-
ciated stoichiometric coe cient is considered, the calculated energy requirement
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where the indexation i is over nucleotides or amino acids, and k is over all biomass
precursors (as defined above). These normalised stoichiometric values ( ÂS) are then
used to calculate the log2 fold-change (FC) of amino acids and nucleotides between






where indexation i is over nucleotides or amino acids, H and V indicate the use
of host and virus biomass function associated normalised stoichiometries, respec-
tively. A positive value indicates a higher usage of metabolite i by the virus than
the host, while a negative value indicates a lower usage.
Comparison of host and virus optimised states
The integrated host-virus metabolic models are optimised for the host and virus
objective functions resulting in predictions of sets reaction flux vectors that satisfy
the host-optimal and virus-optimal networks, respectively. This is done using the
loopless FBA approach, as it has been shown to be more robust to instabilities
associated with prediction and comparison of single optimal flux sets (Desouki
et al. 2015). Comparisons between host and virus optimised systems utilise the
predicted flux values (f) for host and virus optimised metabolic networks.
Glucose Normalised Flux Results for individual reactions are compared by
normalising the reaction flux to the predicted optimal glucose uptake flux (f g).
This is done in order to provide a sensible comparison between the host- and virus-
optimised states, but also to put the predicted fluxes in context of glucose usage.
This is defined as the flux value for the ’EX glc(e)’ metabolic model reaction. The




where the indexation i is over all reactions. Superscript g denotes the flux associ-
ated with the glucose exchange reaction. Glucose normalised flux values Âf are then
reported for each reaction. This is performed for both host- and virus-optimised
metabolic networks.
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2.2.7 Development of ViraNet package
To facilitate the creation, analysis and processing of these integrated host-virus
metabolite models (iHVMs) an in-house Python package was developed to auto-
mate the procedure of VBOF creation, model integration and comparison of host
and virus optimised states. This package is titled ViraNet, and is built utilising
existing Python packages: cobraPy for metabolic modelling approaches (includ-
ing FBA and variants) (Ebrahim et al. 2013), NumPy for mathematical opera-
tions (van der Walt et al. 2011), and Pandas for dataset processing (McKinney
2010). This package can automatically construct a VBOF from the GenBank file
for viruses of the Alphavirus and Flavivirus families, and integrate with a user-
supplied stoichiometric model. The package then performs the analyses outlined
in this chapter. The code for ViraNet is supplied in Appendix A.5.
2.2.8 Creation of virus biomass objective functions and integrated
host-virus metabolic models
To analyse virus infections regarding the metabolic interactions between the viruses
CHIKV, DENV and ZIKV and the host human macrophage iAB-AMO-1410,
a set of VBOFs were created and integrated into three separate stoichiometric
metabolic models. A full description of each of the VBOF pseudo-reactions, in-
cluding biomass metabolite stoichiometric coe cients, are detailed below.
Chikungunya Virus Biomass Objective Function Equation (CHIKV bm)
0.49 ala(c) +0.27 arg(c) +0.25 asn(c) +0.21 asp(c) +23.94 atpc +0.11 ctpc +0.23 cys(c) +
0.25 gln(c) +0.29 glu(c) +0.36 gly(c) +0.11 gtp(c) +23.82 h2o(c) +0.20 his(c) +0.29 ile(c) +
0.39 leu(c) +0.37 lys(c) +0.14 met(c) +0.16 phe(c) +0.43 pro(c) +0.34 ser(c) +0.43 thr(c) +
0.07 trp(c) + 0.23 tyr(c) + 0.11 utp(c) + 0.48 val(c) ≠≠æ 23.82 adp(c) + 23.82 h(c) +
23.82 pi(c) + 0.46 ppi(c)
Dengue Virus Biomass Objective Function Equation (DENV bm)
0.23 ala(c) +0.26 arg(c) +0.18 asn(c) +0.13 asp(c) +19.67 atp(c) +0.16 ctp(c) +0.11 cys(c) +
0.16 gln(c) +0.30 glu(c) +0.44 gly(c) +0.16 gtp(c) +19.48 h2o(c) +0.11 his(c) +0.32 ile(c) +
0.43 leu(c) +0.32 lys(c) +0.24 met(c) +0.18 phe(c) +0.18 pro(c) +0.26 ser(c) +0.44 thr(c) +
0.10 trp(c) + 0.07 tyr(c) + 0.19 utp(c) + 0.32 val(c) ≠≠æ 19.48 adp(c) + 19.48 h(c) +
Sean Aller 55
2 | Creation and Analysis of Integrated Host-Virus Metabolic Models
19.48 pi(c) + 0.73 ppi(c)
Zika Virus Biomass Objective Function Equation (ZIKV bm)
0.38 ala(c) +0.27 arg(c) +0.14 asn(c) +0.22 asp(c) +19.93 atp(c) +0.18 ctp(c) +0.11 cys(c) +
0.10 gln(c) +0.24 glu(c) +0.47 gly(c) +0.18 gtp(c) +19.75 h2o(c) +0.14 his(c) +0.27 ile(c) +
0.46 leu(c) +0.31 lys(c) +0.18 met(c) +0.15 phe(c) +0.16 pro(c) +0.33 ser(c) +0.36 thr(c) +
0.10 trp(c) + 0.11 tyr(c) + 0.18 utp(c) + 0.36 val(c) ≠≠æ 19.75 adp(c) + 19.75 h(c) +
19.75 pi(c) + 0.73 ppi(c)
Each VBOF is representative of the infected state when optimised in a metabolic
network, for that particular virus. While the VBOFs include the amino acid,
nucleotide and associated energy metabolite requirements they omit the presence
of lipids within the virus envelopes. This is due to a lack of information regarding
the ultrastructure and stoichiometry of the lipids in the virus envelopes.
The VBOFs were successfully integrated into three virus-specific human macrophage-
based metabolic models: MO-CHIKV, MO-DENV and MO-ZIKV for the CHIKV,
DENV and ZIKV infected metabolic networks respectively. To enable the visual-
isation and analysis of predicted flux values, using loopless FBA on these iHVMs,
a series of visual representations of the metabolic networks were created in Escher
(King et al. 2015) with mapping of flux values and directionality added manu-
ally.
2.3 RESULTS
To explore the di erences in metabolic resource usage (reactions, metabolites) be-
tween the host and virus optimised systems, multiple comparisons and predictions
were done for the MO-CHIKV, MO-DENV and MO-ZIKV integrated host-virus
metabolic models. Stoichiometric comparisons are conducted between the three
viruses regarding their biomass objective function composition. Specifically, the
usage of amino acids and nucleotides is compared between the three viruses to
highlight biomass-associated components that exhibit di erential demands. This
comparison is also applied to host-virus pairs, highlighting di erential usage of
amino acids and nucleotides between the host and virus objective functions. This
latter analysis informs the comparison between the flux predictions for host and
virus optimised states, and aids in explanation of the potential metabolic network
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rearrangements from host-controlled to virus-controlled systems.
2.3.1 Biomass objective function compositions vary between virus species
and host
The objective functions of CHIKV, DENV and ZIKV, were compared to identify
potentially critical di erences in their biomass compositions. Consideration of the
viral proteome, genome and viral structure (regarding protein copy number for all
structural and non-structural proteins), and the virus replication cycle. This anal-
ysis highlights predicted di erences in amino acid and nucleotide usage between
CHIKV, DENV and ZIKV (Fig. 2.4). The three VBOFs all exhibit varying levels
of amino acid and nucleotide usage. In essence, this analysis highlights how virus
amino acid and nucleotide usage varies within virus genera (Flavivirus - DENV vs.
ZIKV) and across virus genera (Alphavirus - CHIKV vs. Flavivirus - DENV and
ZIKV) . The usage of amino acids can also be considered regarding the precursors
they are produced from, indicated by colour coding.
For both the host and viruses (CHIKV, DENV and ZIKV), comparisons can be
made between the usage of amino acids and nucleotides in their respective biomass
pseudo-reactions. Quantifying this comparison requires the stoichiometric coe -
cients of the pseudo-reaction metabolites to be normalised and compared through
log2 fold change (Fig. 2.5 and 2.6). The stoichiometric coe cients are normalised
to the summation of all non-energy requirement reactant metabolites. Non-energy
requirement metabolites are defined as metabolites that contribute to the biomass
and are not utilised as energy sources for biomass production.
This analysis identifies amino acids or nucleotides that are used in larger (positive
values) or smaller (negative values) in the virus pseudo-reaction than that of the
host. Many of the amino acids show a substantial di erence in their usage between
the virus and host pseudo-reactions, as shown in Fig. 2.5. To relate how virus
infection and composition a ects the di erence between uninfected and infected
states, we explore the stoichiometric di erences further. CHIKV has a substantial
increase in the usage of cysteine when compared to the host. DENV and ZIKV
both share an increased usage of methionine, whilst specifically ZIKV has increased
in the use of tryptophan and glycine as well. The greatest fold-change di erences
for amino acids are methionine (DENV, +1.21) and glutamine (ZIKV, -1.16).
These di erences aid in the interpretation of the metabolic modelling results.
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Figure 2.4 (previous page): Amino acid and nucleotide associated normalised
stoichiometric coe cients for the (a) Chikungunya, (b) Dengue and (c) Zika virus
biomass objective function. The normalised (against the summation of individ-
ual virus) stoichiometric coe cient values are calculated and extracted from the
virus biomass objective functions in the MO-CHIKV, MO-DENV and MO-ZIKV
integrated host-virus metabolic models, respectively. Bar colour (amino acids)
indicates the metabolite precursor that is associated with the biomass compo-
nent: blue, 2-Oxobutanoate; green, essential amino acids (no de novo biosyn-
thesis, external supply); orange, Phenylalanine; purple, Oxaloacetate; red, 3-
Phosphoglycerate; yellow, Pyruvate. Common single letter abbreviations are used
























Figure 2.5: Comparison of host and virus amino acid normalised stoichiometries
from their respective biomass pseudo-reactions: Chikungunya ( ), Dengue ( ),
and Zika ( ) viruses. Common single-letter abbreviations are used for amino acid
metabolites.
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Figure 2.6: Comparison of host and
virus nucleotide normalised stoichiome-
tries from their respective biomass
pseudo-reactions: Chikungunya ( ),
Dengue ( ), and Zika ( ) viruses. Com-
mon single-letter abbreviations are used
for nucleotide metabolites.
Comparison between the usage of nucleotides in the biomass functions of the host
and the individual viruses shows that they are considerably increased in their usage
in the virus pseudo-reactions (Fig. 2.6), especially in comparison to the di erences
in terms of amino acid usage (Fig. 2.5); the maximum absolute di erence between
host and virus usage of nucleotides is 2.4 log2 fold-change compared to 1.3 log2 fold-
change for amino acids. Again, this signifies that the viruses use proportionally
more nucleotides for their biomass than the host. ZIKV has the most substantial
di erence in nucleotide usage compared to the host, with a log2 fold-change value
for, cytidine and uracil, of +2.39. CHIKV
To compare the host- and virus-optimal states of the model, the metabolic fluxes
directly feeding into the biomass pseudo-reactions (host and virus) were assessed.
As to be expected from linear optimisation, the predicted fluxes into the biomass
pseudo-reaction reflect the stoichiometric di erences in the amino acid and nu-
cleotide requirements of the host cell and the individual viruses, thus achieving
perfect fulfilment of host or virus biomass requirements. Overall, however, the
stoichiometric di erences in metabolic requirements for virus production vs host
maintenance reaction result also in di erent metabolic flux states in di erent parts
of the host metabolic model.
In addition to the fulfilment of the respective biomass objective functions, the flux
distributions for host- and virus-optimised states can be analysed through reaction
and pathway analysis.
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2.3.2 Predicted flux distributions for host and virus optimised models
highlight di erences in metabolite states and flows
To assess the di erences in network usage, multiple reaction subsystems were in-
dividually analysed for the host and virus optimised states. These subsystems fall
into three categories shown in Table 2.9.
Table 2.9: Category definitions for reaction pathways analysed
Category Description Subsystem Name
Media Exchange In silico media exchange
Central Carbon Metabolism Glycolysis
Pentose Phosphate Pathway
Citric Acid Cycle
Amino Acid Biosynthesis Serine, Glycine and Cysteine
Aspartate and Asparagine
Arginine and Proline
These subsystems were selected as they represent the main branches of central
carbon metabolism (Almaas et al. 2005, Fell 2010) and include the de novo biosyn-
thesis of nucleotides and amino acids which are essential for the host and virus
biomass objective functions. We next report results from each subsystem individu-
ally, in order to evaluate the di erences between host- and virus-optimised systems
on a case-by-case basis.
In silico media exchange
Comparison of the model media exchange provides insights into the general state
of flows in the metabolic network. Negative and positive flux values related to the
directionality of a reversible reaction. In the case of exchange reactions, a negative
flux value indicates the exchange metabolite is being imported, and a positive flux
value indices import of the exchange metabolite. Comparison of host and virus
optimised exchange reaction fluxes are shown in Fig 2.7.
All virus-optimised systems exhibit a higher import flux of oxygen (O2), glutamine
and various other amino acids, along with some increases in phosphate and fatty
acid (OCDCA) importation. An increase in the export of carbon dioxide and
bicarbonate (CO2 and BHB) is also exhibited for all three viruses. CHIKV is the
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Figure 2.7: Comparison of In silico media exchange reaction fluxes (normalised)
across host and virus optimised states. Only reactions that have a non-zero flux in
at least one optimisation condition (host or virus) are shown (n = 41). Two
categories of reactions shown: (a) exchange reactions that are reversible (im-
port and export); (b) exchange reactions that are unidirectional (export only).
Biomass precursor metabolites (present in the objective function) are indicated
as present in host (grey-filled half-circle) and/or virus (orange-filled half-circle).
Metabolite abbreviations: 3MLDA, 3-methylimidazoleacetic acid; BHB, (R)-3-
hydroxybutanoate; HDCA, hexadecanoate (n-C16:0); OCDCA, octadeconate (n-
C18:0); OCDCEA, octadeconate (n-C18:1); TTDCA, tetradeconate (n-C14:0).
Optimisation abbreviations: MO, Host Macrophage; CHIKV, Chikungunya virus;
DENV, Dengue virus; ZIKV, Zika virus.
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only virus-optimised state that exhibits any flipping of import-export metabolites
when compared to the host optimised system. In this case, a CHIKV optimised
state results in the export of pyruvate from the metabolic model. Lactate is only
produced by the DENV optimised model. There is an increased export of nitrogen-
containing compounds across all virus-optimised systems (ammonia, CHIKV and
DENV; urea, CHIKV and ZIKV). The export of acetoacetate is observed in both
DENV and ZIKV optimised systems (as well as host), while only CHIKV and
ZIKV optimised systems exhibit an increase in the export of carbon dioxide.
Overall, the virus-optimised states exhibit an increased demand for amino acid
import and indeed exhibit increased import fluxes for all virus-biomass associated
metabolites.
Central Carbon Metabolism
To further investigate the intracellular flux prediction di erences between host
and virus optimised systems, components of the previously-defined central carbon
metabolism were analysed.
Glycolysis In the host optimised state (Fig. 2.8A), glycolysis runs from glucose
through to pyruvate synthesis via the traditional aerobic pathway, resulting in no
lactate production. Initially, glucose-6-phosphate is converted into 6PGL, used for
the oxidative branch of the pentose phosphate pathway; F6P, used for continuation
of glycolysis; G1P, used for glycogenesis. The production of G1P indicates that
the host-optimised metabolic network is undergoing glycogenesis (the creation of
glycogen). G1P activates UTP-glucose-1-phosphate uridylyltransferase and initi-
ates the synthesis of UDP-glucose, utilised for glycogen synthesis. UDP-glucose
acts as a glycosyltransferase, adding to existing glycogen molecules and liberating a
UDP (produced from the initial G1P-UTP investment). The activation of glycoge-
nesis supports existing experimental data in the analysis of activated macrophages
(Galván-Peña & O’Neill 2014).
Following the continuation of the glycolytic pathway, 3-phosphoglycerate is con-
verted to 3PHP and 2-phosphoglycerate at a ratio of 0.35:1. 3PHP is used as a
precursor for serine biosynthesis (and resulting glycine and cysteine biosynthesis).
Glycolysis continues through to PEP, which is supplemented by conversion from
a cytosolic source of oxaloacetate as well as transport from the mitochondria, a
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phenomenon seen in pancreatic —-cells (Stark et al. 2009). Finally, PEP is fully
converted in a 1:1 ratio into pyruvate, which is transported to the mitochondria
and converted to alanine (at a ratio of 8.73:1).
Under CHIKV optimisation, the flux distribution for the glycolytic pathway di ers
from that of the host optimised system (Fig. 2.8A and B). Glycolysis only proceeds
to 3PG, where there is then full conversion to 3PHP and commitment to the
serine biosynthesis pathway. Unlike in the host optimised system, there is no
glycogen synthesis via the conversion of G6P to G1P. However, G6P is converted
to 6PGL indicating the use of the oxidative branch of the pentose phosphate
pathway. Pyruvate is synthesised via mitochondrial-sourced PEP but also through
the conversion of DHAP via methylglyoxal synthase (MGSA), eventually forming
methylglyoxal (the reduced penultimate intermediate to pyruvate). Pyruvate is
then exclusively utilised in alanine biosynthesis with the remainder exported to
the extracellular compartment. There is no cytosol-mitochondria transport of
pyruvate.
DENV optimisation predicts that glycolysis (Fig. 2.8A and C), like CHIKV, runs
through to 3PG synthesis, where there is the full conversion to 3PHP synthesis
and the serine biosynthetic pathway. However, in the upper stages of glycoly-
sis, G6P is not converted to 6PGL indicating that there is no activation of the
non-oxidative branch of the pentose phosphate pathway. Instead, glycolytic inter-
mediates F6P and G3P are utilised for the non-oxidative branch of the pentose
phosphate pathway. Again, in a similar manner to CHIKV, DHAP is not solely
converted to G3P but instead is also metabolised to pyruvate via MGSA, with a
higher flux value for the DENV-optimised system (0.19 mmol glucose-1 h-1) than
the CHIKV-optimised system (0.41 mmol glucose-1 h-1). Lower glycolysis is sup-
plemented via mitochondrial-sourced PEP which, along with the byproducts of
methylglyoxal metabolism, drives the synthesis of pyruvate. Lactate dehydroge-
nase is active in the DENV optimised system, resulting in the production of lactate
from pyruvate (≠0.65 mmol glucose-1 h-1) which is exported to the extracellular
compartment. Pyruvate is also utilised for alanine biosynthesis, at a ratio of 1:0.15
(alanine:lactate). There is no cytosol-mitochondria transport of pyruvate.
Finally, the optimisation of ZIKV predicts that glycolysis only runs from glucose
to the first glycolytic intermediate G6P (Fig. 2.8A and D). There is the full
commitment (1 mmol glucose-1 h-1) of G6P to the production of 6PGL, and thus
glucose is fully utilised for the oxidative branch of the pentose phosphate path-
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Figure 2.8 (previous page): Glycolysis metabolic pathway map (A) with com-
parison of predicted host- and virus- optimised flux values (loopless FBA) for
(B) CHIKV, (C) DENV, and (D) ZIKV host-virus integrated metabolic models.
Arrows indicate reactions, arrowheads indicate potential directionality (two ar-
rowheads indicate a bi-directional reaction). Dashed arrows indicate a connecting
set of reactions or pathway where flux has not been explicitly indicated. Host
fluxes are indicated through black arrows (:) with directionality indicated by
black arrowhead (grey arrows : and arrow heads indicate no usage of reaction or
directionality). Virus optimisations and directionality are indicated by coloured
arrows for CHIKV (:), DENV (:) and ZIKV (:). Virus optimised fluxes are
compared to host optimised fluxes through normalisation against glucose. Opti-
mised fluxes are indicated through circle markers: Host ( ); CHIKV ( ); DENV
( ); ZIKV ( ). Full reaction and metabolite names are given in Appendix B and
C, respectively. CHIKV, Chikungunya virus; DENV, Dengue virus; ZIKV, Zika
virus.
way. Unlike the CHIKV and DENV optimised systems, ZIKV has some reversed
segments of the lower glycolytic pathways. Specifically, mitochondrial PEP drives
the synthesis of 3PG (via 2PG) which is then exclusively used for the production
of 3PHP for the serine biosynthetic pathway. Pyruvate is imported from the ex-
tracellular environment (≠1.95 mmol glucose-1 h-1), and subsequently only used
for alanine biosynthesis; there is no lactate production or cytosol-mitochondria
transport. There is also no activation of methylglyoxal associated pathways or
glycogen synthesis.
Overall, ZIKV is predicted to have the largest allocation of flux to both serine
(PGCD) and alanine (ALATA L) biosynthesis, with flux values of 1.95 mmol
glucose-1 h-1and ≠0.51 mmol glucose-1 h-1respectively. For comparison, the val-
ues for the other viruses are approximately half of ZIKV: CHIKV, PGCD (0.92
mmol glucose-1 h-1) and ALATA L (≠0.33 mmol glucose-1 h-1); DENV, PGCD
(0.92 mmol glucose-1 h-1) and ALATA L (0.78 mmol glucose-1 h-1).
Pentose Phosphate Pathway The host optimised system predicts activation
of the oxidative branch of the pentose phosphate pathway (Fig. 2.9 A). There
is the full conversion of 6PGl (G6P-derived) to R5P. The synthesis of R5P is
supplemented via nucleotide salvage pathways, specifically by adenosine salvage
(purine-nucleoside phosphorylase PUNP1) to produce the R5P precursor R1P. R5P
is then converted to PRPP, which is subsequently used for purine and pyrimidine
nucleotide biosynthesis with a ratio of 1.03:1. There is also some diversion of PRPP
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to be utilised as a co-factor for the conversion of guanine (deoxyguanine derived)
to GMP (via GUARPT) ultimately generating ribose-purines from deoxyribose-
purine salvage.
Metabolic analysis predicts that CHIKV and ZIKV qualitatively utilise the pen-
tose phosphate pathway similarly to the host (Fig. 2.9B and D), and each other,
although the absolute flux through ZIKV-active reactions is higher than that of
the CHIKV-active counterparts. This is due to the exhaustive use of glucose to
drive the pentose phosphate pathway in the ZIKV-optimised system: the flux
through the initial step of the pentose phosphate pathway for ZIKV compared
to CHIKV is 1 mmol glucose-1 h-1and 0.44 mmol glucose-1 h-1respectively. Both
viruses utilise the oxidative branch to produce PRPP, which proceeds on to purine
and pyrimidine nucleotide biosynthesis at ratios of 1.83:1 (CHIKV) and 1.29:1
(ZIKV). However, in the CHIKV-optimised system there is no recruitment of nu-
cleotide salvage pathways, whereas, for the ZIKV-optimised system, guanosine (via
purine-nucleoside phosphorylase PUNP3) is utilised as a catabolic reactant (rather
than adenosine in the host). Nucleotide salvage pathways (via PPM) supplement
the production of nucleotides with a flux of 0.14 mmol glucose-1 h-1, much higher
than the host-optimised flux of 0.0025 mmol glucose-1 h-1.
DENV, unlike the host-, CHIKV- or ZIKV-optimised systems, utilises the non-
oxidative branch of the pentose phosphate pathway (Fig. 2.9A and C). F6P and
G3P are utilised as products to produce XU5P-D and R5P, the former of which
is converted into R5P via the RU5P-D intermediate. There is no activation of
nucleotide salvage pathways, and R5P is converted into PRPPS which is utilised
for purine and pyrimidine biosynthesis in a 1:1 ratio. DENV exhibits similar
reaction fluxes through the final steps of the pentose phosphate pathway, phos-
phatidylserine decarboxylase (PRPPS), as CHIKV (0.48 and 0.44 mmol glucose-1
h-1, respectively). The ZIKV-optimised flux of PRPPS, however, is 2.4 ≠ 2.6x the
flux of CHIKV and DENV, at 1.15 mmol glucose-1 h-1. This flux includes the
entire contribution of the in silico glucose to the pentose phosphate pathway and
supplementation via the guanosine-nucleotide salvage pathways.
Citric Acid Cycle
Under host control, the citric acid cycle (CAC) is predominantly run via cytosol-
sourced pyruvate produced via glycolysis (Fig. 2.10A). Pyruvate is used to regener-
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Figure 2.9: Pentose Phosphate Pathway metabolic pathway map (A) with com-
parison of predicted host- and virus- optimised flux values (loopless FBA) for
(B) CHIKV, (C) DENV, and (D) ZIKV host-virus integrated metabolic models.
Arrows indicate reactions, arrowheads indicate potential directionality (two arrow-
heads indicate a bi-directional reaction). Dashed arrows indicate a connecting set
of reactions or pathway where flux has not been explicitly indicated.
(continued on next page...)
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Figure 2.9 (previous page): Host fluxes are indicated through black arrows (:)
with directionality indicated by black arrowhead (grey arrows : and arrow heads
indicate no usage of reaction or directionality). Virus optimisations and direction-
ality are indicated by coloured arrows for CHIKV (:), DENV (:) and ZIKV (:).
Virus optimised fluxes are compared to host optimised fluxes through normalisa-
tion against glucose. Optimised fluxes are indicated through circle markers: Host
( ); CHIKV ( ); DENV ( ); ZIKV ( ). Full reaction and metabolite names are
given in Appendix B and C, respectively. CHIKV, Chikungunya virus; DENV,
Dengue virus; ZIKV, Zika virus.
ate citrate (CIT) from oxaloacetate (OAA) using acetyl coenzyme A (ACCOA) as
a cofactor. Complete running of the CAC involves the conversion of CIT through
to isocitrate (ICIT), however, under host control, CIT is used as a co-factor for
the antiport co-transportation of phosphoenolpyruvate (PEP) and malate (MAL)
in the mitochondria-cytosol and cytosol-mitochondria direction, respectively. As
the conversion of CIT to ICIT and –-ketoglutarate (AKG) does not occur, in-
stead, OAA is converted to AKG and aspartate using glutamate as a co-factor.
AKG is then consumed to produce glutamate via glutamate dehydrogenase and or-
nithine transaminase; the latter is associated with the urea cycle. Glutaminolysis
is also used to drive the mitochondrial biosynthesis of glutamate via mitochondrial
glutaminase (GLUNm). The CAC then continues through succinate-CoA (SUC-
COA), which is supplemented by byproducts of fatty acid metabolism and ketone
body metabolism, and succinate (SUCC). CAC then continues through fumarate
(FUM) and malate (MAL), both metabolites are supplemented by FUM and MAL
importation from the cytosol, to produce OAA. OAA is then used to drive CIT,
and AKG/aspartate synthesis at a ratio of 1.87:1. Finally, the remaining OAA is
utilised for PEP production, which is transported out of the mitochondria to the
cytosol and used to drive the lower end of the glycolytic pathway.
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Figure 2.10 (previous page): Citric Acid Cycle metabolic pathway map (A)
with comparison of predicted host- and virus- optimised flux values (loopless FBA)
for (B) CHIKV, (C) DENV, and (D) ZIKV host-virus integrated metabolic mod-
els. Arrows indicate reactions, arrowheads indicate potential directionality (two
arrowheads indicate a bi-directional reaction). Dashed arrows indicate a connect-
ing set of reactions or pathway where flux has not been explicitly indicated. Host
fluxes are indicated through black arrows (:) with directionality indicated by
black arrowhead (grey arrows : and arrow heads indicate no usage of reaction or
directionality). Virus optimisations and directionality are indicated by coloured
arrows for CHIKV (:), DENV (:) and ZIKV (:). Virus optimised fluxes are
compared to host optimised fluxes through normalisation against glucose. Opti-
mised fluxes are indicated through circle markers: Host ( ); CHIKV ( ); DENV
( ); ZIKV ( ). Full reaction and metabolite names are given in Appendix B and
C, respectively. CHIKV, Chikungunya virus; DENV, Dengue virus; ZIKV, Zika
virus.
In contrast to the host optimised system, none of the CHIKV-, DENV- or ZIKV-
optimised systems utilises cytosolic-sourced pyruvate for the running of the CAC;
they all exhibit decoupling of the CAC from the glycolytic pathway and associated
metabolic intermediates. However, CHIKV is the only virus (and indeed the only
optimised system) that has a full complete run through of the CAC from CIT to
OAA (Fig. 2.10A and B). In a similar manner to the host, CHIKV utilises cy-
tosolic CIT for the antiport co-transportation of PEP (which is used to drive the
synthesis of final stage glycolytic intermediates). CIT is also converted via ICIT to
AKG. Glutamate synthesis occurs purely from AKG via the urea cycle reactions
and as a byproduct of polyamine metabolism; there is no activation of glutamate
dehydrogenase. Glutamate is not supplemented via Glutamine degradation (Glu-
taminolysis). Glutamate is utilised in conjunction with OAA for the synthesis
of aspartate (and AKG). Continuing the CAC, SUCCOA is converted through
to SUCC, the latter of which is supplemented by the metabolism of polyamines
which requires the proteogenic amino acid methionine and non-proteogenic amino
acid ornithine. The latter is only produced via the urea cycle, whilst methionine is
extracellularly sourced. SUCC is then converted through to FUM and MAL. MAL
is supplemented with antiport co-transportation from the cytosol, with CIT as a
co-factor. MAL is then used in the replenishment of OAA, but also the synthesis of
mitochondrial pyruvate via malic enzyme (ME1m). This pyruvate is then utilised
to produce CIT from OAA, which is also used for aspartate and AKG production,
at a ratio of 0.045:1. This ratio is much lower than that of the host, indicating a
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higher proportion of CAC flux that is diverted to aspartate (ASPTAm) and AKG
synthesis.
The DENV-optimised system also exhibits CAC decoupling from glycolysis due
to the lack of pyruvate cytosolic importation (Fig. 2.10A and C). However, under
DENV-optimisation the CAC does not run entirely from CIT to OAA. Instead,
CIT has generated from the reversal of intermediate components of the CAC; Isoc-
itrate dehydrogenase (ICDHxm/ICDHyrm), converted AKG to CIT via ICIT. CIT
is then, as is the case with host and virus optimised systems, utilised as a co-factor
in the antiport co-transportation of MAL and PEP. In place of CIT-derived AKG
synthesis, AKG is imported from the cytosol using MAL as a co-factor (reaction
not shown). AKG is then used exclusively to drive the CAC for the synthesis of
CIT and SUCCOA. There, AKG is utilised for glutamate biosynthesis or activa-
tion of the urea cycle. SUCCOA associated reactions are supplemented by flux
from fatty acid metabolism, and SUCCOA is then metabolised to SUCC via con-
version through the additional co-factors derived from ketone body metabolism,
rather than the CAC associated Succinate-CoA ligase (SUCOASm/SUCOAS1m).
The CAC then continues through FUM and MAL, again supplemented by cytoso-
lic importation, and eventually to OAA. OAA is then used exclusively for PEP
synthesis; OAA is not utilised as a co-factor in the interconversion of glutamate
and aspartate. PEP is then transported via antiport to facilitate the synthesis of
cytosolic pyruvate via glycolysis.
Both the ZIKV and DENV optimised systems do not have a su ciently completed
CAC cycle, from CIT to OAA, and both (along with CHIKV) are considered de-
coupled from glycolysis. However, in the ZIKV optimised system there is activation
of the anaplerotic pathways that drive glutaminolysis, identical to the pathways
activated in the host optimised system (Fig. 2.10A and D); the glutamine cytosol-
mitochondria flux is 6-times higher in the ZIKV- (0.49 mmol glucose-1 h-1) than
host- (0.08 mmol glucose-1 h-1) optimised system. This anaplerotic flux is then
used to drive the synthesis of glutamate which ultimately is interconverted to as-
partate (utilising OAA and producing AKG). Similar to DENV, AKG is then used
to drive the synthesis of SUCCOA and the reverse CAC synthesis of CIT. SUC-
COA is supplemented by the metabolism of fatty acids and drives through to the
regeneration of OAA via MAL and FUM, both of which are again supplemented
by cytosolic import. As with CHIKV, OAA is utilised for CIT, aspartate/AKG
and PEP synthesis. However, in the case of the latter, whilst PEP is transported
to the cytosol it is not used for pyruvate synthesis but instead drives the reversal
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of glycolysis.
Amino Acid Biosynthesis
As previously discussed in the glycolysis pathway, under the host optimised system
the glycolytic intermediate 3PG drives both glycolytic and serine biosynthetic flux
at a ratio of 2.82:1 (Fig 2.11A). For the latter, 3PG is converted through to serine.
Serine is a biomass component of the host but is also used for the biosynthesis
of glycine and cysteine, as well as phospholipid metabolism. Specifically, serine
is used for the synthesis of sphingosine and phosphatidylserine, both of which
are utilised in cell membranes and are precursors for the host biomass pseudo-
reaction. The synthesis of cysteine from serine requires homo-cysteine (HCYS),
which is derived from the methionine catabolic product S-adenosyl-L-methionine
(AMET). AMET is converted to the penultimate HCYS precursor S-adenosyl-
L-homocysteine (AHCYS) via cytosolic and mitochondrial (including transport)
methods. Cytosolic AMET to AHCYS metabolism requires the investment of
guanidinoacetate (GUDAC), achieved through the modification of the glycine
amino group, which liberates creatine (CREAT) in the process. The mitochon-
drial conversion requires the serine-derived phospholipid metabolic product phos-
phatidylethanolamine (PE). Ultimately cysteine is synthesised, which results in
the production of the byproduct 2-Oxobutanoate (2OBUT), which is metabolised
and exported to the extracellular compartment.
Serine, Glycine and Cysteine. Unlike the host optimised system, the virus
optimised systems utilise all of the glycolytic intermediate 3PG for the biosyn-
thesis of serine. However, for CHIKV and DENV (Fig 2.11B and C) 3PG is
entirely glucose-derived, whereas in ZIKV (Fig 2.11D) it is produced by reversed
reactions in lower glycolysis, and driven by PEP-derived metabolites. In all virus
conditions, 3PG is converted through to serine, where it is then utilised for the
biosynthesis of glycine and cysteine; only in the case of ZIKV is the phospho-
lipid metabolism pathway active. Compared to the host all three viruses exhibit
a much higher serine-glycine biosynthetic [glucose normalised] flux (GHMT2r): a
nine fold-increase for CHIKV and DENV but a 21 fold-increase for ZIKV. In the
case of ZIKV, glycine represents a much more significant biomass component than
that of CHIKV and DENV (Fig. 2.4) and that of the host (Fig. 2.5).
Cysteine is synthesised from serine, for all three viruses, and as in the case of the
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Figure 2.11 (previous page): Serine, Glycine and Cysteine biosynthesis
metabolic pathway map (A) with comparison of predicted host- and virus- op-
timised flux values (loopless FBA) for (B) CHIKV, (C) DENV, and (D) ZIKV
host-virus integrated metabolic models. Arrows indicate reactions, arrowheads in-
dicate potential directionality (two arrowheads indicate a bi-directional reaction).
Dashed arrows indicate a connecting set of reactions or pathway where flux has
not been explicitly indicated. Host fluxes are indicated through black arrows (:)
with directionality indicated by black arrowhead (grey arrows : and arrow heads
indicate no usage of reaction or directionality). Virus optimisations and direction-
ality are indicated by coloured arrows for CHIKV (:), DENV (:) and ZIKV (:).
Virus optimised fluxes are compared to host optimised fluxes through normalisa-
tion against glucose. Optimised fluxes are indicated through circle markers: Host
( ); CHIKV ( ); DENV ( ); ZIKV ( ). Full reaction and metabolite names are
given in Appendix B and C, respectively. CHIKV, Chikungunya virus; DENV,
Dengue virus; ZIKV, Zika virus.
host also requires the synthesis of the penultimate cysteine precursor HCYS. How-
ever, only CHIKV exhibits a similar state to the host optimised system through the
activation of GUDAC-dependent AHCYS synthesis. However, both CHIKV and
DENV utilise non-mitochondrial routes for AHCYS synthesis, although DENV
exclusively utilises the histidine-based S-adenosyl-L-methionine:histamine N-tele-
methyltransferase (SAMHISTA) reaction, and for CHIKV the histidine-based path-
way carries a substantially larger flux than that of the GUDAC-based pathway,
a ratio of 26.6:1. ZIKV exclusively utilises mitochondrial conversion of AMET
to AHCYS, which requires the usage of serine-derived phospholipids as co-factors
(similar to the host optimised state).
Aspartate and Asparagine. For the host, CHIKV and DENV optimised sys-
tems, aspartate is synthesised from mitochondrial OAA and transported (via glu-
tamate antiport) into the cytosol (Fig 2.12 A, B and C). No mitochondrial aspar-
tate biosynthesis occurs for the DENV-optimised system; aspartate is synthesised
from cytosolic sources of OAA. In the host- and virus-optimised systems, aspar-
tate is utilised for biomass production, nucleotide synthesis and the biosynthesis
of asparagine (ASNS1).
In the case of CHIKV, there is a much higher aspartate and asparagine biosynthetic
flux compared to the host: 14 and 18 fold-increase respectively. Whilst aspartate
and asparagine are used in the CHIKV biomass; asparagine is also used as a
co-factor for the co-transport (via antiport) of extracellular threonine into the
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Figure 2.12 (previous page): Aspartate and Asparagine biosynthesis metabolic
pathway map (A) with comparison of predicted host- and virus- optimised flux
values (loopless FBA) for (B) CHIKV, (C) DENV, and (D) ZIKV host-virus inte-
grated metabolic models. Arrows indicate reactions, arrowheads indicate potential
directionality (two arrowheads indicate a bi-directional reaction). Dashed arrows
indicate a connecting set of reactions or pathway where flux has not been explicitly
indicated. Host fluxes are indicated through black arrows (:) with directionality
indicated by black arrowhead (grey arrows : and arrow heads indicate no usage
of reaction or directionality). Virus optimisations and directionality are indicated
by coloured arrows for CHIKV (:), DENV (:) and ZIKV (:). Virus optimised
fluxes are compared to host optimised fluxes through normalisation against glu-
cose. Optimised fluxes are indicated through circle markers: Host ( ); CHIKV ( );
DENV ( ); ZIKV ( ). Full reaction and metabolite names are given in Appendix
B and C, respectively. CHIKV, Chikungunya virus; DENV, Dengue virus; ZIKV,
Zika virus.
cytosol. ZIKV also exhibits a higher aspartate and asparagine biosynthetic flux
compared to host (13 and eight fold-increase) although there is no activation of
the asparagine-threonine antiport exchange (Fig 2.12A and D). Both CHIKV and
ZIKV utilise aspartate as a source for OAA production, ultimately driving the
cytosolic production of MAL which is then transported to the mitochondria and
used to feed the CAC. Whilst DENV also transports MAL across the mitochondria
for CAC, the source of OAA is not aspartate-derived.
Arginine and Proline
Host, CHIKV and ZIKV utilisation of the urea cycle (Fig 2.13 A, B and D), for
the utilisation of arginine and production of proline, requires the importation of
arginine from the extracellular compartment. In the case of DENV (Fig 2.13 C),
the arginine that is imported is only utilised in the biomass pseudo-reaction; there
is no catabolism of arginine for any other metabolic processes. Host, CHIKV
and ZIKV convert the arginine to ornithine (ORN). Here, ORN is transported to
the mitochondria, but in the case of CHIKV, it is also metabolised to putrescine
(PTRC). Ultimately, PTRC is metabolised further and the byproducts transported
into the mitochondria. Here in the polyamine pathway, they are again further
metabolised to yield glutamate and succinic semialdehyde (SUCSAL); this is used
to feed the CAC via oxidation to succinic acid directly. In the case of CHIKV
and the host, arginine is also utilised for the production of GLUDAC, required for
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cysteine biosynthesis.
The host, CHIKV and ZIKV utilise the mitochondrial ORN synthesised gluta-
mate and glutamate 5-semialdehyde (GLU5SA). In the case of DENV, mitochon-
drial glutamate is phosphorylated to glutamate 5-phosphate and then oxidised to
yield GLU5SA. From here, in all optimisation states, GLU5SA is metabolised to
1-Pyrroline-5-carboxylate (1PYR5C) which is then used for the biosynthesis of pro-
line (which is subsequently transported out of the mitochondria). However, in the
case of ZIKV, there is a split conversion of 1PYR5C to both proline (via P5CRxm)
and glutamate (via P5CDm) with the latter retaining the higher biosynthetic flux
(0.22 vs 0.60 mmol glucose-1 h-1): a 2.7 fold increase.
Glucose utilisation and metabolic resource allocation highlights di erent
demands of virus and host objectives As described in the previous sections,
across all metabolic pathways there is a predicted di erence in the utilisation of
the metabolic network in the host optimised state, when compared to the virus
optimised states. Indeed, there is also a di erence in the utilisation of the metabolic
network between the di erent CHIKV-, DENV- and ZIKV-optimised systems.
These metabolic rearrangement dissimilarities appear to arise from the di erences
in the composition of the respective biomass objective functions, for both host and
viruses.
For example, DENV has a high requirement for methionine (Fig. 2.4b) which is
higher than that of either CHIKV or ZIKV, and consequently is associated with the
smallest predicted reaction fluxes responsible for methionine catabolism (METAT).
CHIKV has the highest requirement for cysteine of all the viruses (Fig. 2.4a),
which is reflected in the predicted fluxes for cysteine biosynthesis (CYSTGL).
Additionally, the CHIKV optimal state is the only state that has activation of
GACMTRc, the reaction responsible for the conversion of methionine into cysteine
synthesis precursors. ZIKV also exhibits similar patterns in the predicted fluxes;
large fluxes are predicted for the reactions within the glycine biosynthetic pathway,
of which ZIKV has a much higher biomass requirement than other viruses (Fig.
2.4c).
In essence, the virus-optimal flux predictions highlight the rearrangement of metabolic
network resources to best suit the current objective that is being optimised for, and
this reflects the di erent compositions of the virus, and the host, biomass objec-
tive functions. However, the real power in this technique comes from comparing
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Figure 2.13 (previous page): Arginine and Proline biosynthesis metabolic
pathway map (A) with comparison of predicted host- and virus- optimised flux
values (loopless FBA) for (B) CHIKV, (C) DENV, and (D) ZIKV host-virus inte-
grated metabolic models. Arrows indicate reactions, arrowheads indicate potential
directionality (two arrowheads indicate a bi-directional reaction). Dashed arrows
indicate a connecting set of reactions or pathway where flux has not been explicitly
indicated. Host fluxes are indicated through black arrows (:) with directionality
indicated by black arrowhead (grey arrows : and arrow heads indicate no usage
of reaction or directionality). Virus optimisations and directionality are indicated
by coloured arrows for CHIKV (:), DENV (:) and ZIKV (:). Virus optimised
fluxes are compared to host optimised fluxes through normalisation against glu-
cose. Optimised fluxes are indicated through circle markers: Host ( ); CHIKV ( );
DENV ( ); ZIKV ( ). Full reaction and metabolite names are given in Appendix
B and C, respectively. CHIKV, Chikungunya virus; DENV, Dengue virus; ZIKV,
Zika virus.
the viruses against each other, and more importantly against the host-optimal
network.
2.3.3 Virus optimal states highlight the di erences between virus, but
also between viruses and host, in metabolic resource allocation
Comparison of the host and virus optimised systems, in the three iHVMs for
CHIKV, DENV and ZIKV has highlighted the di erential usage of metabolic
resources and the associated reaction pathways. Specifically, glucose is utilised
di erentially both between the host and the viruses, but also between individual
viruses.
All viruses exhibit a higher requirement for nucleotide synthesis, ranging from 13-
to 35-times higher flux observed through the de novo nucleotide precursor sup-
plying reaction (PRPPS) when virus-optimised compared to host-optimised. This
flux is achieved by diversion of glycolytic flux, from glycolysis, to the production
of pentose phosphate pathway intermediates for the oxidative (CHIKV and ZIKV)
and non-oxidative (DENV) branches. While CHIKV and DENV commit 44-48%
of the glycolytic-associated flux to the pentose phosphate pathway, ZIKV fully
commits all glucose catabolic flux to the production of the nucleotide biosynthesis
precursors.
De novo biosynthesis of amino acid requires significant metabolic resources, many
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Figure 2.14 (previous page): Summary of the production of biomass precur-
sors via de novo biosynthetic pathways. (a) Cartoon schematic of amino acid
biosynthesis in the human macrophage iAB-AMO-1410 metabolic model (Bord-
bar et al. 2010). Solid arrows depict shortened pathways, dash arrows indicate
direct transport from extracellular sources. Amino acids are grouped by their pre-
cursor molecule and assigned a colour circle. (b) Summary of the biosynthetic
flux values, attributed to each precursor as previously identified, for the host (H),
Chikungunya virus (C), Dengue virus (D), and Zika virus (Z) optimised metabolic
models. Colours are associated with reactions, for summary, as indicated. Or-
ange (PHETHPTOX2), Phenylalanine; green (PRPPS), glucose; red (PGCD),
3-phosphoglycerate; yellow (ALATA L), pyruvate; purple (ASPTA / ASPTAm),
oxaloacetate; blue (P5CRxm), 2-oxobutanoate.
ú Glutamate and glutamine are involved in too many metabolic reactions, includ-
ing interconversions of other amino acids, to accurately summarise the biosynthetic
fluxes.
† Arginine can be synthesised de novo however it is imported from the extracellular
environment in this modelling setup.
of which are derived from glucose (Fig. 2.14) apart from Tyrosine which is syn-
thesised directly from Phenylalanine. Across all three viruses there are large in-
creases in amino acid biosynthetic fluxes, as discussed in the previous section.
This is evident in the increased fluxes seen throughout the glycolytic and CAC
associated reactions. The CAC appears dysfunctional in the DENV- and ZIKV-
optimised systems, with an incomplete metabolism of CAC into OAA; under host-
and CHIKV-optimisation the CAC runs complete from CIT to OAA via the CAC
intermediates. However, in both the host- and ZIKV-optimised systems the CAC is
supplemented by anaplerotic metabolism of glutamine into AKG and OAA (glu-
taminolysis). In the virus-optimised state, cytosolic pyruvate does not directly
enter the CAC (via mitochondrial transport) appearing to decouple the CAC from
glycolysis.
2.4 DISCUSSION
To simulate the metabolic interactions that occur during viral infections, a novel
methodology was created and implemented that represents a virus as a metabolic
pseudo-reaction, utilising the virus structural and composition data obtained from
bioinformatic databases (Geer et al. 2010). These reactions are comprised of nu-
cleotides (RNA), amino acids and the metabolites associated with the energetic
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requirements for the formation of the viruses. Due to a lack of available infor-
mation regarding the ultrastructure and stoichiometric of the lipid envelopes of
CHIKV, DENV and ZIKV, the lipid components of these viruses were omitted from
the pseudo-reactions. With available information, the inclusion of a lipid compo-
nent would improve the overall accuracy of the results. This pseudo-reaction was
successfully integrated into a metabolic reconstruction of a human macrophage
cell (Bordbar et al. 2010) for three virus species: Chikungunya, Dengue and
Zika viruses. These models (MO-CHIKV, MO-DENV and MO-ZIKV, respec-
tively) were analysed using flux balance analysis to predict di erences between
the metabolic state of an uninfected and infected metabolic network.
Comparison of the biomass compositions of the host and virus-associated pseudo-
reactions (Fig. 2.4) highlighted the di erential compositions between them. Whilst
amino acids are utilised by host and viruses in various ways (Fig. 2.5) it is most no-
table that nucleotides represent a much more extensive component of virus biomass
(Fig. 2.6) than that of the host. This is reflected in multiple comparative pre-
dictions of the uninfected and infected models. The requirement for phosphate
import exchange is higher than that of the host for all three viruses (Fig. 2.7)
which is further demonstrated through the increased flux predicted for all viruses
through the pentose phosphate pathway (Fig. 2.9).
Comparison of the usage of the iHVMs in the host- and virus-optimised states
highlighted several key areas of host-metabolism that are altered during the sim-
ulated infection. Di erences in the uptake of metabolites from the in silico media
were highlighted, showing that virus-optimised systems require more exogenous
amino acids (in particular Glutamine) and oxygen than the host. Altered cellular
uptake of extracellular metabolites have been observed experimentally in human
and mammalian cells with ongoing viral infections, and support (in this case) the
idea of di erential oxygen (Palomares et al. 2004, Kussow et al. 1995) and glu-
tamine (Chambers et al. 2010, Sanchez et al. 2015, Newsholme et al. 1986, Fontaine
et al. 2014, Yu et al. 2011a, Carinhas et al. 2017, Goodwin et al. 2015) usage by
virus-infected cells.
Comparison of the individual central metabolic, de novo nucleotide and amino acid
biosynthesis highlighted the di erent metabolic strategies of the virus-optimised
systems, both compared to the host but also to other viruses. Regardless of the
virus being optimised, all virus-optimisations resulted in an increased flux through
glycolysis-associated reactions and pathways, such as the pentose phosphate path-
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way and serine biosynthetic reactions. This glycolytic metabolic regulation does
not solely occur at the initial steps of glycolysis, but occurs throughout the gly-
colytic pathway. Under the control of CHIKV and DENV, there is an activa-
tion of MGSA reactions which convert DHAP to pyruvate. This can indicate
that phosphate has become a limiting factor in the metabolic system and thus
glyceraldehyde-3-phosphate dehydrogenase cannot maintain a high-enough flux
for necessary pyruvate supply(Matsuoka & Shimizu 2013). This highlights pre-
dicted virus-specific regulation of multiple metabolic network points, supporting
experimental observations in cases of DENV infection (Fontaine et al. 2015, Fischl
& Bartenschlager 2011). Under virus control, there is also activation of multiple
gluconeogensis associated reactions, and in the case of ZIKV the entire lower part
of glycolysis is reversed. This switching of the glycolytic pathway, from glycolysis
to gluconeogensis has been observed in multiple viral infections and is attributed
to the virus biosynthetic requirements (Deng et al. 2011, Jhuang et al. 2015)
Overall, this analysis successfully develops, describes and compares the metabolic
processes of a virus-controlled metabolic network. The di erences in metabolic
resource allocation can be directly attributed to the biosynthetic needs of the
viruses, and appear to increase associated biosynthetic-fluxes far above that of the
hosts. The link between the increase in metabolic output and observable disease
is still tenuous, and will require further research, however this modelling platform




Single-Reaction Perturbations of the
Chikungunya, Dengue and Zika virus Integrated
Metabolic Models
3.1 INTRODUCTION
Virus infections can be viewed as an interaction between the virus and its hosts
metabolic network, causing a rearrangement of metabolic resources to facilitate
virus production (Maynard et al. 2010, Sanchez & Laguno  2015, Munger et al.
2008). This entanglement between host metabolism and virus production opens up
the possibility of perturbing the re-arrangement of host metabolic resources in or-
der to disrupt viral production (Ikeda & Kato 2007, Karupiah & Harris 1995).
Chapter 2 resulted in the creation of three iHVMS for CHIKV, DENV and ZIKV.
Subsequent metabolic analysis of these models highlighted the di erential usage
of reactions and metabolites between host- and virus-optimised systems, and in-
deed between the CHIKV-, DENV- and ZIKV-optimised systems themselves. To
explore the possibility of metabolic-based antiviral therapeutics, these stoichio-
metric models and their optimisation through FBA can provide an ideal starting
point to demonstrate and predict points of importance in the virus-controlled net-
work.
Here, we develop and apply an FBA-based approach to analyse the iHVMs for
Manuscript associated with this chapter is currently under submission.
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CHIKV, DENV and ZIKV (MO-CHIKV, MO-DENV and MO-ZIKV respectively).
Analysis of these models, in terms of perturbing their metabolic flux distribution
when optimised for the virus objective function (VBOF), highlights reactions that
can be constrained in order to limit virus production. While other host-virus
metabolic modelling studies have focused on using the models as a tool to further
understand the interplay between virus infection and host metabolic alterations
(Jain & Srivastava 2009, Birch et al. 2012), here we expand upon this and actively
search for metabolic antiviral targets. We show that our novel methodology recov-
ers most of the known targets of existing RNA-virus antiviral drugs while high-
lighting a set of currently unexplored reactions. These reactions are able to limit
viral production, either broadly for all three viruses or for a specific virus.
The resulting output from these predictions is a set of reactions combined with
suggested inhibitory chemical compounds, identified from the DrugBank (Wishart
et al. 2008) database, for CHIKV, DENV and ZIKV. Sensitivity analysis of the
antiviral drug targets was conducted through alterations to the host model media
assumptions (in silico extracellular metabolite alterations) and through evaluation
of over 10,000 computationally generated mutant viruses (for CHIKV, DENV and
ZIKV).
3.2 METHODS
3.2.1 Integrated Host-Virus Metabolic Model Selection and Creation
Three virus species were selected, as previously defined in §2.2.1, Table 2.1: Chikun-
gunya virus (CHIKV), dengue virus (DENV) and zika virus (ZIKV). VBOFs and
integrated host-virus metabolic models were created for each individual virus as
described previously in §2.2.2.
3.2.2 Single Reaction Perturbations of Integrated Host-Virus Metabolic
Models
Exploration of potential antiviral targets, in the form of constrained reactions,
require the definition of new linear optimisation problems that can be applied to
the integrated host-virus metabolic models. The previous flux balance analysis
optimisation problem (§1.7, Eq. 1.9) is expanded to test two conditions for model
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Figure 3.1: Toy model of flux balance analysis optimisation problems for (A)
single-reaction knockouts and (B) single-reaction host-derived enforcements. Toy
networks show metabolites (M) as nodes and reactions as edges, with associated
reaction flux (V) marked. Flux ranges are shown for the enforced reactions, where
the minimum (e≠) and maximum (e+) enforcement bounds are highlighted.
reactions: knockouts and host-derived enforcements. Toy model examples for both
single reaction knockouts and single reaction host-derived enforcements are shown
in Fig. 3.1.
Single Reaction Knockouts
Knockout analysis considered the e ect of systematically setting individual re-
action fluxes to zero, and then attempting to maximise the VBOF. This results
in a knockout optima for the VBOF (Zko), which can then be compared against
the original VBOF optima (Zwt). This is performed systematically, for a single
reaction, over all non-objective function reactions in the metabolic model (Eq.
3.1).
maximise Zko = cT · v
subject to S · v = 0
lb < v < ub
0 < vi < 0
(3.1)
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where indexation i is over all reactions v in the model systematically and the
associated lower (lb) and upper (ub) bounds are simultaneously set to zero. This
model is then optimised for VBOF, yielding the virus knockout optima (Zko). A
reaction knockout is defined as e ective if Zko < Zwt, indicated that knockout of
the targeted reaction does result in reduced virus optima. This reduction in virus
optima signifies a decrease in the amount of viral biomass that can be produced,
which is used as a proxy for decreased virus particle production.
Single Reaction Host-Derived Enforcements
Host-derived enforcements consider the e ect of maintaining specific reaction fluxes
as they were in a host-optimised state, whilst attempting to optimise the model
for a VBOF. The bounds for reactions are systematically set so that the lower and
upper flux bounds relate to a specific flux range, e. The range is derived from the
corresponding minimum (F ≠) and maximum (F +) flux values, for the individual
reaction, obtained from the FVA solution for the host (H) and virus (V ) optimal
solutions. The range (e) is bounded by minimum (e≠) and maximum (e+) flux
values, which are calculated from conditional arguments (Eq 3.2, 3.3 and 3.4; Fig.
3.1).
if F +H > F +V , F ≠F Ø F ≠V








+ = F +H
(3.2)
if F ≠H < F ≠V , F +F Æ F +V
then e≠ = F ≠H
e




H ≠ F ≠V
2
B (3.3)
if F ≠H > F ≠V , F +F < F +V
then e≠ = F ≠H
e
+ = F +H
(3.4)
These calculated flux ranges for each individual reaction are then applied as an
additional constraint to the integrated host-virus metabolic model, through alter-
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ation of the linear optimisation problem, which is subsequently optimised for the
VBOF. Similar to the knockout condition, a new linear optimisation problem is
constructed for the single reaction host-derived enforcement (Eq. 3.5).
maximise Ze = cT · v
subject to S · v = 0
lb < v < ub
e
≠




where indexation i is over all reactions v in the model systematically and the
associated lower and upper bounds are set to the corresponding flux minimum
and maximum values, as calculated earlier. This model is then optimised for the
VBOF, yielding the virus host-derived enforcement optima Ze. A reaction host-
derived enforcement is considered ’e ective’, in terms of its potential as an antiviral
target, if Ze < Zwt.
3.2.3 Generation of alternative virus biomass objective functions and
statistical analyses
To evaluate the sensitivity of the results of the single-reaction analysis to possible
changes in virus sequences, a mutation-based approach was chosen. This approach
allows the consideration of how specific the predicted results of the analysis are
to individual viruses (original, wild-type viruses), or could simply have arisen
due to the biomass function(s) sharing identical biomass precursors (i.e. amino
acids and nucleotides) independent of individual metabolite stoichiometries. A
range of VBOFs were generated that were created from mutated forms of the
associated virus nucleotide and subsequent protein sequences in order to achieve
a compositional gradient away from the known viruses. To this end, two di erent
groups of mutations were implemented: limited nucleotide variations and extensive
nucleotide with structural variation.
Limited Nucleotide Variations
To evaluate impact of small deviations from the original VBOFs, variants of the
original virus genomes were generated through nucleotide substitution (Fig. 3.2),
where the number of nucleotides altered through point mutations were 1, 2, 3, 4,
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5 or 10 substitutions. For the subsequent VBOF generation from these variant
genomes, the genome and protein copy numbers were kept as in the original (for
the respective virus genera).
Figure 3.2: Schematic for the point mutation of the virus genomes, for the
point mutation sensitivity analysis of host-derived flux enforced reactions. Unique
nucleotide sites are selected from the original wild-type genome for a given number
of point mutation sites (1, 2, 3, 4, 5 or 10)
To evaluate more variant VBOFs, another 1000 genomes were generated for each
virus that were created from the original genome with a random number (between 0
and the total length of the genome) of nucleotide substitutions and using randomly
drawn structural and non-structural polyprotein copy numbers per virus particle.
This approach is denoted as the ”Virus-Like Particle” (VLP) approach, due to
the constraints on the length of the genome and the inclusion of the original
polyprotein structures.
Extensive Nucleotide with Structural Component Variations
Finally, and in an attempt to generate a set of VBOFs that are far removed from
the original ones in terms of compositional gradient, both in terms of genome se-
quence and the structural and non-structural protein numbers, random VBOFs
were directly generated. This is implemented by drawing 1000 sets of individ-
ual stoichiometries of biomass components from a uniform distribution on [a, b],
where a and b are (1) ±99% of the original stoichiometric coe cients of a given
virus, or (2) are ±99% of the average of all original stoichiometric coe cients of a
given virus. These approaches to generating variant virus genomes yield a set of
sequences (and associated VBOFs) that are increasingly removed from the original
virus VBOFs.
For each randomised VBOF created, the host-derived flux enforcement analysis
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is repeated (with a recalculation of the bounds used for the individual enforce-
ment), and the reactions that perturb virus optima the most when constrained are
identified. This whole analysis resulted in 8000 randomised VBOFs and FBA sim-
ulations, the results of which are summarised as percentage impact of individual
host reactions on virus optima for di erent sets of VBOFs.
To compare results of flux enforcement analysis to that obtained from using ran-
domised biomass functions, a one-way ANOVA and Tukey’s honest significance test
were used for each individual virus (which includes the point mutations) against
the randomised virus groups (VLP and random).
3.2.4 Measuring impact of alternative host model assumptions on single-
reaction analyses
The host macrophage model uses specific metabolite uptake fluxes, which are
mostly based on experimental observations (Bordbar et al. 2010), but which can
directly influence FBA-based results. To evaluate the potential impact of altered
model uptake bounds, virus optimisation was reanalysed using alternative metabo-
lite uptake fluxes in the host model in a systematic fashion. First, metabolites are
identified that are supplied (via exchange reactions) to the metabolic model with
non-arbitrary lower bounds (lb), where 0 > lb > ≠ inf, as previously defined
in §2.5 Table 2.8. Each of the identified reactions are then systematically con-
strained, such that the lb is reduced from the original model values (Bordbar et al.
2010) (in steps of 10%) until the lb = 0, e ectively knocking-out the respective
exchange reaction. For each altered (additionally constrained) model, the host-
derived enforcement analysis is repeated, with re-calculation of the viable host
reaction bounds and optimisation of VBOF, done for each of the three viruses
(CHIKV, DENV, ZIKV).
3.3 RESULTS
Results presented encompass predictions of potential antiviral targets through two
reaction conditions: knockouts and host-derived enforcements. All analyses were
conducted for CHIKV, DENV and ZIKV in their respective iHVMs and are pre-
sented as ”broad targets” (all viruses a ected) and ”specific targets” (one or two
viruses are a ected). E ectiveness is defined as when the target reaction results
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in a virus optima that is less than the unconstrained virus optima.
As highlighted in chapter 2 the host-optimal and virus-optimal flux distributions
can di er, therefore we hypothesis that the iHVM can be constrained in a way to
limit viral production. Here, such constraints are applied in two di erent ways:
reaction knockouts (Eq. 3.1) and host-derived enforcements (Eq 3.5).
E ective targets, able to reduce the virus optima (as previously defined), are
cross-checked against the DrugBank database (Wishart et al. 2008) for compounds
that are verified or predicted to inhibit the aforementioned reaction. This cross-
reference check is completed using the reaction-associated enzyme commission
(EC) number, which links enzymes to specific reactions (Schomburg 2004). These
compounds can then be utilised for experimental validation.
3.3.1 Single Reaction Knockouts Highlight Metabolic Overlap of Host
and Virus Optimal States
The single reaction knockout analysis predicts that there are individual reactions
that are able to completely inhibit virus biomass optimisation; essentially, the virus
is unable utilise some biomass precursors for it’s own production, under the a ects
of the additional constraints in place from the single reaction knockout analysis.
.
In total, there were 41 reactions that were predicted to be e ective against all
three viruses: CHIKV, DENV and ZIKV. These reactions, including numbers of
potential drug candidates for antiviral therapeutic use, are listed in Table 3.1 (full
results available in Appendix D). All targets presented result in a reduced virus
optima (in all cases) of zero, e ectively meaning that no viral biomass is produced
under that particular reaction constraint condition. The one exception to this
is an additional reaction that was predicted to be e ective against ZIKV, and
reducing the associated optima to 92% of the original, wild-type optima: ATPS4m,
a mitochondrial reaction that is involved in oxidative phosphorylation.
However, whilst these predicted reactions provide potential antiviral targets against
CHIKV, DENV and ZIKV, they also reduce the viability of the host metabolic
network. Under the additional constraints imposed by the single reaction knock-
out analysis, any reaction that reduces the virus optima to zero also inadvertently
reduces the host optima to zero. Essentially, there does not exist a single reaction
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knockout that can be e ective at reducing virus optima, whilst simultaneously per-













Table 3.1: Summary of 41 reactions that are predicted to have an antiviral e ect whilst under a single reaction knockout
condition. Number of drug candidates are identified from the DrugBank (Wishart et al. 2008) database if matched with an
UniProt Identifier (derived from the EC Number). The knockout targets listed are predicted to be e ective against all three
viruses: Chikungunya, Dengue and Zika. In all cases the virus knockout optima was reduced to 0. EC Number, Enzyme
Commission Number (Schomburg 2004).
Reaction Information
Number of Drug Candidates
Model Reaction ID Model Subsystem EC Number
ADSL1 Nucleotides 4.3.2.2 0
ADSL2 IMP Biosynthesis 4.3.2.2 0
ADSS Nucleotides 6.3.4.4 7
AHC Methionine Metabolism 3.3.1.1 4
AICART IMP Biosynthesis 2.1.2.3 9
AIRCr IMP Biosynthesis 4.1.1.21 1
ALATA L Glutamate metabolism 2.6.1.2 4
ASNS1 Alanine and Aspartate Metabolism 6.3.5.4 4
ASPCTr Pyrimidine Biosynthesis 2.1.3.2 2
CBPS Pyrimidine Biosynthesis 6.3.5.5 2
CTPS1 Nucleotides 6.3.4.2 1
CYOR-u10m Oxidative Phosphorylation 1.10.2.2 9
CYSTGL Cysteine Metabolism 4.4.1.1 5
CYSTS Methionine Metabolism 4.2.1.22 4
DHORD9 Pyrimidine Biosynthesis















Table 3.1 – continued from previous page
Model Reaction ID Model Subsystem EC Number Number of Drug Candidates
DHORTS Pyrimidine Biosynthesis 3.5.2.3 2
G5SADrm Arginine and Proline Metabolism
GARFT IMP Biosynthesis 2.1.2.2 3
GHMT2r Glycine, Serine, and Threonine
Metabolism
2.1.2.1 7
GK1 Nucleotides 2.7.4.8 1
GLUPRT IMP Biosynthesis 2.4.2.14 2
GMPS2 Nucleotides 6.3.5.2 1
IMPC IMP Biosynthesis 3.5.4.10 9
IMPD Nucleotides 1.1.1.205 7
METAT Methionine Metabolism 2.5.1.6 3
O2t Transport, Extracellular
OMPDC Pyrimidine Biosynthesis 4.1.1.23 1
ORPT Pyrimidine Biosynthesis 2.4.2.10 1
P5CRxm Arginine and Proline Metabolism 1.5.1.2 2
PGCD Glycine, Serine, and Threonine
Metabolism
1.1.1.95 1
PHETHPTOX2 Tyr, Phe, Trp Biosynthesis 1.14.16.1 9
PRAGSr IMP Biosynthesis 6.3.4.13 3
PRAIS IMP Biosynthesis 6.3.3.1 3















Table 3.1 – continued from previous page
Model Reaction ID Model Subsystem EC Number Number of Drug Candidates
PRASCS IMP Biosynthesis 6.3.2.6 1
PRFGS IMP Biosynthesis 6.3.5.3 1
PROtm Transport, Mitochondrial
PRPPS Pentose Phosphate Pathway 2.7.6.1 0
PSERT Glycine, Serine, and Threonine
Metabolism
2.6.1.52 2
PSP L Glycine, Serine, and Threonine
Metabolism
3.1.3.3 1
RPI Pentose Phosphate Pathway 5.3.1.6 1
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Overall, this knockout-driven analysis highlights that, whilst a number of reactions
can be fully inhibited and completely stop the virus from being able to produce
biomass within the constrained metabolic network, there are no reactions that
are capable of reducing the virus optima whilst simultaneously maintaining any
aspect of host viability. In order to explore potential antiviral-yielding metabolic
constraints, that maintain host viability (i.e. the host optima is non-zero), a novel
methodology was developed that requires the enforcement of a host optimal state
on the metabolic network.
3.3.2 Host-Derived Enforcements Provide Potential Antiviral E ect
Following from the knockout results, the host-derived enforcement analysis was
developed. This analysis ensures that host viability is entirely preserved (i.e. the
host optima does not decrease from the original unconstrained host optima), while
virus optima is reduced below wild-type levels. This is achieved through mainte-
nance of host metabolic resource allocation through reaction flux manipulation,
specifically alteration of the lower and upper reaction bounds (Eq 3.5).
The enforcement analysis predicted several potential antiviral targets, many of
which were also identified in the knockout analysis. These antiviral targets span a
variety of subsystems, and are shown to have an e ect on all three viruses to some
degree (Fig. 3.3). There was also another set of antiviral targets predicted, that
are virus-specific in terms of their e ects; not all virus optima are reduced when
additional host-derived constraints are applied to the reaction (Fig. 3.5).
There are a subset of reactions that were not predicted as antiviral targets in host-
enforcement analysis, when they previously had been highlighted in the knockout
analysis. This suggests that some reactions cannot be constrained in such a way to
simultaneously be an e ective antiviral whilst negating damage to the host. Whilst
these identified reactions are potential antiviral targets, in the sense that altering
their fluxes can limit virus production within the host, they do not contribute to
the set of host-viable antiviral targets, as discussed above.
A set of these reactions overlap with known antiviral drug targets, identified
through literature analysis. There are currently 10 antivirals specific to RNA
viruses which target a total of 5 unique metabolic enzymes (Table 3.2). Of these
5 drug targets (and the associated drugs) one has been experimentally verified
to be e ective against CHIKV (Inositol-5’-monophosphate dehydrogenase; IMPD)
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(Khan et al. 2011) and another against DENV (dihydroorotate dehydrogenase;
DHORD9) (Wang et al. 2011). While the other three targets have been verified
to be e ective against some RNA viruses(Leyssen et al. 2008), they have yet to be













Table 3.2: List of antiviral compounds identified, which interact with host metabolic reactions that a ect RNA virus production
(Littler & Oberg 2005, Leyssen et al. 2008). CTP Synthase is encoded for by two genes, CTPS1 and CTPS2 (Sahoo et al. 2012),
and both are a ected by the associated antiviral compounds (only one gene is shown). All antiviral compounds, and their
associated target reactions, were identified from literature search. EC; Enzyme Commission (Schomburg 2004)
.
Compound Target Reaction Model Reaction ID EC Number
Cyclopentylcytosine
Cytidine triphosphate synthetase CTPS1 6.3.4.2
Cyclopentenylcytosine
DD264
Dihydroorotate dehydrogenase DHORD9 1.3.5.2NITD-982
A3
Ribavirin
Inosine 5-monophosphate dehydrogenase IMPD 1.1.1.205
VX-497
Pyrazofurin
Orotidine 5-phosphate decarboxylase OMPDC 4.1.1.23
6-azauridine
C-c3Ado
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These enforcement reactions are not universal in the viruses that they e ect; they
can be split into the broad (Fig. 3.3) and specific (Fig. 3.5) target results.
Reactions are identified as being e ective against all three viruses under the host-
derived enforcement condition (Fig 3.3), with more instances of greater ZIKV
optima reduction that than of DENV, which both are more e ectively perturbed
than CHIKV (Fig 3.3A), due to a greater number of reactions able to reduce the
virus optima to below 80% for DENV and ZIKV than CHIKV. Varying e ective-
ness, in terms of the ability of a reaction to be targeted and reduce virus optima,
varies across viruses and subsystems. Of all 46 reactions predicted to be e ective
broad antiviral targets, only one reaction is able to reduce the optima of all three
viruses to below 60%: guanylate kinase (GMP:ATP); GK1. This phosphortrans-
ferase catalyses the following reaction:
ATP + GMP ≠≠ÔÓ ≠ ADP + GDP
and is a critical step in the synthesis of guanosine containing nucleotides. A
selection of reactions, in addition to GK1, that form the main branched pathways
of de novo nucleotide biosynthesis are shown in Fig. 3.4. Of all identified broad-
targeting reactions, the majority (24) fall within these pathways.
From this analysis, 13 subsystems are highlighted as having reactions that can
be constrained in such a way to act as potential antiviral targets (Fig 3.3B). The
subsystem with the most e ective reaction targets is the IMP biosynthesis subsys-
tem, responsible for the metabolism of inosine nucleosides to synthesise adenosine
and guanine ribonucleotide bases. In fact, the top three subsystems (including
the aforementioned) relate to de novo nucleotide biosynthesis, with the second
and third most e ective subsystems relating to general nucleotide and pyrimi-
dine biosynthesis. Note that whilst reactions are uniquely assigned to subsystems
(they cannot be assigned to more than one), many subsystems are directly ad-
jacent to one another in terms of reaction progression (i.e. the ”Nucleotides”
subsystem feeds and is fed directly by the ”IMP Biosynthesis” and ”Pyrimi-
dine Biosynthesis” pathways due to the metabolic network topology). In gen-
eral, nucleotide-associated metabolism represents 4 of the 13 identified subsystems,
with the remaining being associated with amino acid metabolism (3/13), co-factor
metabolism (2/13), and other miscellaneous transport and side-reactions.
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Figure 3.3: Summary of the broad targets (all viruses a ected) predicted by
single-reaction host-derived enforcement analysis. (A) Heat map of the percentage
original unconstrained virus optima, for single reactions, under the host-derived en-
forcement condition and grouped numerically by subsystem (key in bottom right).
(B) Proportion breakdown of the number of reactions identified for each numeri-
cally labelled subsystem.
(continued on next page...)
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Figure 3.3 (previous page): (C) Number of reactions that are identified as
being e ective under host-derived enforcement conditions, and the associated en-
zyme commission (EC) classification assigned to them (N/A denotes no associated
EC record for a given reaction). Full list of reaction names can be found in Table
3.3. CHIKV, Chikungunya Virus; DENV, Dengue Virus; ZIKV, Zika virus.
The majority of reactions identified do not have an associated EC number, which
identifies the class / type of enzyme that is associated with the reaction (Fig 3.3
C), denoted as N/A. Of the rest of the reaction targets identified, the majority
belong to one of three enzyme classes: transferases (EC2); lyases (EC4); and ligases
(EC6). These three reaction classes are largely responsible for the transformation,
catabolism and anabolism (respectively) of metabolic compounds. The majority of
these ECs and associated reactions, as discussed, occur in the nucleotide-containing
pathways.
Another set of reactions predicted, where those that specifically e ect one or two
viruses, and as such are known as ”specific targets”. From the host-derived en-
forcement analysis a total of 58 reactions were predicted to be in this set (Fig
3.5 A). The majority of the reactions predicted reduce virus optima, of one of the
three viruses, to 90-100% of the original wild-type virus optima (i.e. a reduction
of ¡ 10%). Whilst there are reactions predicted to be e ective against all three
viruses, the breakdown is not evenly weighted between them; there are 17, 4 and
53 CHIKV, DENV and ZIKV specific targets (respectively). Some of these tar-
gets are not virus exclusive, and are also identified in another viruses e ective set
(Fig 3.5 B). CHIKV and ZIKV share the largest overlap (12 reactions e ective
against them both) and ZIKV has the highest number of ZIKV-exclusively e ec-
tive reactions (37). Observation of the reaction subsystem breakdown (Fig 3.5
C) highlights the di erential e ective subsystem distribution for the three viruses.
The most e ective subsystems against CHIKV, DENV and ZIKV (respectively)
were: valine, leucine and isoleucine metabolism; tryptophan metabolism; extracel-
lular transport. Analysis of the EC numbers of the reactions highlight a di erent
distribution of the largest number of e ective reactions in terms of enzyme classes:
EC1 oxidoreductases (CHIKV); EC2 transferases (ZIKV). In the case of DENV
the distribution is spread evenly (due to the low number of DENV-specific e ective
reactions) across the EC1, EC2 and EC4 classes.
For both broad- and specific-reaction targets (Tables 3.3 and 3.4), a set of potential
drug candidates are identified from the DrugBank (Wishart et al. 2008) compound
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CTPS1 / CTPS2 ♦•
Figure 3.4: Single-reaction host-derived enforcement targets predicted as be-
ing e ective against Chikungunya (CHIKV), Dengue (DENV) and Zika (ZIKV)
viruses. Existing antiviral targets ( ) and reactions with drugs predicted from this
analysis ( ) are shown. Full reaction names are given in Appendix B.
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Figure 3.5: Summary of the specific targets (one or two viruses e ected) pre-
dicted by single-reaction host derived enforcement analysis. (A) Heat map of
the percentage original unconstrained virus optima, for single reactions, under the
host-derived enforcement condition and grouped numerically by subsystem ...
(continued on next page...)
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Figure 3.5 (previous page): ... (key in middle right). (B) Venn diagram
showing the overlap between specific reaction targets, in terms of the viruses they
e ect. (D) Proportion breakdown of the number of reactions that are identified
specifically for each virus, subdivided for each colour-coded subsystem. D Number
of reactions that are identified as being e ective under host-derived enforcement
conditions, and the associated enzyme commission (EC) classification assigned to
them (N/A denotes no associated EC record for a given reaction). Full list of
reaction names can be found in Table 3.4. CHIKV, Chikungunya Virus; DENV,
Dengue Virus; ZIKV, Zika virus.
database, indicated by a ”Yes” in the respective table. A full list of identified
chemical compounds, identified as e ective drugs for the associated reaction target,













Table 3.3: Reactions predicted to have an antiviral e ect whilst under a single reaction host-derived enforcement condition.
Drug candidates are listed from the DrugBank (Wishart et al. 2008) database if matched with an UniProt Identifier (derived
from the EC Number). Enforcement targets are predicted to be e ective against Chikungunya (CHIKV), Dengue (DENV) and
Zika (ZIKV) viruses. Full results available in Appendix D. EC Number, Enzyme Commission Number (Schomburg 2004).
Reaction Information % Original Optima
Drugs Identified
Model Reaction ID Model Subsystem EC Number CHIKV DENV ZIKV
2HBO Propanoate Metabolism 1.1.1.27 98 88 89 Yes
2HBt2 Transport, Extracellular 98 88 89 No
2MCITt Transport, Extracellular 98 88 89 No
ADSL1 Nucleotides 4.3.2.2 89 71 69 No
ADSL2 IMP Biosynthesis 4.3.2.2 86 71 67 No
ADSS Nucleotides 6.3.4.4 89 71 69 Yes
AICART IMP Biosynthesis 2.1.2.3 86 71 67 Yes
AIRCr IMP Biosynthesis 4.1.1.21 86 71 67 Yes
ASPCTr Pyrimidine Biosynthesis 2.1.3.2 85 70 67 Yes
CBPS Pyrimidine Biosynthesis 6.3.5.5 85 70 67 Yes
CTPS1 Nucleotides 6.3.4.2 74 65 61 Yes
CYSAMO Taurine and hypotaurine metabolism 93 93 92 No
CYSTA Cysteine Metabolism 2.6.1.3 93 93 92 Yes
CYSTGL Cysteine Metabolism 4.4.1.1 85 81 85 Yes
CYSTS Methionine Metabolism 4.2.1.22 85 81 85 Yes
DHORD9 Pyrimidine Biosynthesis 85 70 67 No















Table 3.3 – continued from previous page
Model Reaction ID Model Subsystem EC Number CHIKV DENV ZIKV Drugs Identified
DHORTS Pyrimidine Biosynthesis 3.5.2.3 85 70 67 Yes
GARFT IMP Biosynthesis 2.1.2.2 86 71 67 Yes
GK1 Nucleotides 2.7.4.8 50 50 50 Yes
GLUPRT IMP Biosynthesis 2.4.2.14 86 71 67 Yes
GMPS2 Nucleotides 6.3.5.2 83 71 66 Yes
H2CO3D Miscellaneous 4.2.1.1 85 70 67 Yes
H2CO3D2 Miscellaneous 85 70 67 No
HYPTROX Taurine and hypotaurine metabolism 93 93 92 No
IMPC IMP Biosynthesis 3.5.4.10 86 71 67 Yes
IMPD Nucleotides 1.1.1.205 83 71 66 Yes
MCITS Propanoate Metabolism 4.1.3.31 98 88 89 No
MCLACCYSR Cysteine Metabolism 93 93 92 No
MCLOR Cysteine Metabolism 1.1.1.27 93 93 92 Yes
MERCPLACCYSt Transport, Extracellular 93 93 92 No
OBDHc Glycine, Serine, and Threonine
Metabolism
1.2.7.2 98 88 89 No
OMPDC Pyrimidine Biosynthesis 4.1.1.23 85 70 67 Yes
ORPT Pyrimidine Biosynthesis 2.4.2.10 85 70 67 Yes
PAN4PP CoA Catabolism 93 93 92 No
PNTEH CoA Catabolism 93 93 92 No















Table 3.3 – continued from previous page
Model Reaction ID Model Subsystem EC Number CHIKV DENV ZIKV Drugs Identified
PNTK CoA Biosynthesis 2.7.1.33 93 93 92 No
PPCDC CoA Biosynthesis 4.1.1.36 93 93 92 Yes
PPNCL3 CoA Biosynthesis 6.3.2.5 93 93 92 No
PRAGSr IMP Biosynthesis 6.3.4.13 86 71 67 Yes
PRAIS IMP Biosynthesis 6.3.3.1 86 71 67 Yes
PRASCS IMP Biosynthesis 6.3.2.6 86 71 67 Yes
PRFGS IMP Biosynthesis 6.3.5.3 86 71 67 Yes
PRPPS Pentose Phosphate Pathway 2.7.6.1 85 71 67 No
RPI Pentose Phosphate Pathway 5.3.1.6 85 71 67 Yes
TAURt4(2)r Transport, Extracellular 93 93 92 No
THRD L Glycine, Serine, and Threonine
Metabolism
4.3.1.19 95 91 91 Yes















Table 3.4: Reactions predicted to have an antiviral e ect whilst under a single reaction host-derived enforcement condition, but
only against Chikungunya (CHIKV), Dengue (DENV) and Zika (ZIKV) viruses in a specific manner (i.e. Chikungunya only).
Drug candidates are listed from the DrugBank (Wishart et al. 2008) database if matched with an UniProt Identifier (derived
from the EC Number). Full results available in D. EC Number, Enzyme Commission Number (Schomburg 2004).
Reaction Information % Original Optima
Drugs Identified
Model Reaction ID Model Subsystem EC Number CHIKV DENV ZIKV
3AIBTm Valine, Leucine, and Isoleucine
Metabolism
2.6.1.22 97 100 97 Yes
3AIBt Transport, Extracellular 97 100 97 No
3AIBtm Valine, Leucine, and Isoleucine
Metabolism
2.6.1.22 97 100 97 Yes
3HBCOAHLm Valine, Leucine, and Isoleucine
Metabolism
3.1.2.4 97 100 97 Yes
5HLTDL Tryptophan metabolism 4.1.1.28 100 91 84 Yes
5HTRPVESSEC Transport, Extracellular 100 91 84 No
ACOAD9m Valine, Leucine, and Isoleucine
Metabolism
1.3.99.12 97 100 97 No
ADEt Transport, Extracellular 100 100 96 No
ADKd Nucleotides 2.7.4.3 100 100 98 Yes
AHC Methionine Metabolism 3.3.1.1 85 100 100 Yes
ARGN Urea cycle/amino group metabolism 3.5.3.1 100 100 97 Yes
ARGNm Urea cycle/amino group metabolism 3.5.3.1 100 100 97 Yes















Table 3.4 – continued from previous page
Model Reaction ID Model Subsystem EC Number CHIKV DENV ZIKV Drugs Identified
ARGtm Transport, Mitochondrial 100 100 97 No
CAMPt Transport, Extracellular 100 100 96 No
CBPSam Glutamate metabolism 6.3.4.16 100 100 96 Yes
CGMPt Transport, Extracellular 100 100 97 No
CREATt4(2)r Transport, Extracellular 100 100 97 No
DATPtn Transport, Nuclear 100 100 98 No
DCYTt Transport, Extracellular 100 100 96 No
DGSNt Transport, Extracellular 100 100 96 No
DGTPtn Transport, Nuclear 100 100 96 No
DHFR Folate Metabolism 1.5.1.3 100 100 99 Yes
DINt Transport, Extracellular 100 100 97 No
DURIPP Nucleotides 100 100 99 No
ECOAH12m Valine, Leucine, and Isoleucine
Metabolism
4.2.1.17 97 100 97 Yes
GACMTRc Urea cycle/amino group metabolism 2.1.1.2 100 100 97 Yes
GHMT2r Glycine, Serine, and Threonine
Metabolism
2.1.2.1 100 87 79 Yes
GLYAMDTRc Urea cycle/amino group metabolism 2.1.4.1 100 100 97 Yes
GUAt Transport, Extracellular 100 100 96 No















Table 3.4 – continued from previous page
Model Reaction ID Model Subsystem EC Number CHIKV DENV ZIKV Drugs Identified
HIBDm Valine, Leucine, and Isoleucine
Metabolism
1.1.1.31 97 100 97 Yes
HYXNt Transport, Extracellular 100 100 96 No
ILEtec Transport, Extracellular 0 100 100 No
METAT Methionine Metabolism 2.5.1.6 85 100 100 Yes
MMMm Valine, Leucine, and Isoleucine
Metabolism
5.4.99.2 97 100 97 Yes
MMTSADm Valine, Leucine, and Isoleucine
Metabolism
1.2.1.18 97 100 97 Yes
NDPK5m Nucleotides 2.7.4.6 100 100 97 Yes
OCBTm Urea cycle/amino group metabolism 2.1.3.3 100 100 96 Yes
OIVD2m Valine, Leucine, and Isoleucine
Metabolism
1.2.1.25 97 100 97 No
P5CRxm Arginine and Proline Metabolism 1.5.1.2 100 100 95 Yes
PGCD Glycine, Serine, and Threonine
Metabolism
1.1.1.95 100 100 95 Yes
PHETHPTOX2 Tyr, Phe, Trp Biosynthesis 1.14.16.1 94 100 100 Yes
PROtm Transport, Mitochondrial 100 100 95 No
PSERT Glycine, Serine, and Threonine
Metabolism
2.6.1.52 100 100 95 Yes















Table 3.4 – continued from previous page
Model Reaction ID Model Subsystem EC Number CHIKV DENV ZIKV Drugs Identified
PSP L Glycine, Serine, and Threonine
Metabolism
3.1.3.3 100 100 95 Yes
PUNP3 Purine Catabolism 2.4.2.1 100 100 97 Yes
PUNP4 Purine Catabolism 2.4.2.1 100 100 96 Yes
PUNP5 Purine Catabolism 2.4.2.1 100 100 97 Yes
PUNP6 Purine Catabolism 2.4.2.1 100 100 97 Yes
PYNP2r Pyrimidine Catabolism 2.4.2.2 100 100 96 No
THBPT4ACAMDASE Tetrahydrobiopterin 4.2.1.96 94 100 100 Yes
THYMt Transport, Extracellular 100 100 99 No
TMDPP Pyrimidine Catabolism 2.4.2.4 100 100 99 Yes
TMDS Nucleotides 2.1.1.45 100 100 99 Yes
TRPHYDRO2 Tryptophan metabolism 1.14.16.4 100 91 84 Yes
URAt Transport, Extracellular 100 100 96 No
UREAtm Urea cycle/amino group metabolism 100 100 97 No
VALTAm Valine, Leucine, and Isoleucine
Metabolism
2.6.1.42 97 100 97 Yes
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3.3.3 E ect of virus mutations and model alterations on predicted an-
tiviral targets
The results presented so far in this chapter have supported the idea of using the
iHVMs for identifying host-based antiviral targets. However, any analysis based
on stoichiometric metabolic flux optimisation, as done so here, can be dependent
on details of model implementation and assumptions regarding the biomass com-
position of the modelled organism (Schuetz et al. 2012).
For example, whilst the host metabolic model and the biomass function that it
incorporates are verified against experimental data (Thiele & Palsson 2010) the
model still assumes a specific media composition and uptake fluxes. Variation in
the media and associated exchange fluxes, responsible for supplying the network
with the necessary metabolic resources, may alter the antiviral e ect that is pre-
dicted. In the same vein, alterations of the organisms biomass composition (in
this case, alterations of the virus biomass) may result in altered e ectiveness of
predicted antiviral targets. This can be likened to the e ect of virus mutation
on subverting current antiviral theraputics, such as those seen in cases of HIV
resistance (Littler & Oberg 2005, Perelson & Ribeiro 2013). Therefore, being able
to preemptively model such situations, and identify antiviral targets that still re-
main viable (i.e. able to reduce the virus optima) would potentially prove useful
in selecting appropriate targets for experimental studies.
To test the robustness of the predictions in this chapter, the e ects of in silico
media alterations (host-centred) and virus genome mutations (virus-centred) are
conducted.
Impact of altered metabolic model in Silico media constraints
To test if the host-derived reaction predictions are robust against key assumptions
in the model, the e ects of variations in the media composition are analysed for
the host model in the context of the antiviral target prediction. For each virus
(CHIKV, DENV and ZIKV) the host-derived enforcements were reanalysed for
1000 alternative media uptake fluxes for 20 di erent media metabolites (Table
3.5).
For all viruses, altering the media can a ect the perturbation achieved by the
host-derived flux enforced reaction. However, for many of the reactions, the media
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Table 3.5: In silico media components for the human macrophage metabolic
model (Bordbar et al. 2010).
In silico Media Component Model Metabolite ID
Arginine arg L e
Butyrate but e
Glucose glc e
Glutamine gln L e
Bicarbonate hco3 e
Histidine his L e
Isoleucine ile L e
Leucine leu L e
Lysine lys L e
Methionine met L e
Oxygen o2 e
Steric Acid ocdca e
Oleic Acid ocdcea e
Phenylalanine phe L e
Phosphate pi e
Pyruvate pyr e
Threonine thr L e
Tryptophan trp L e
Myristic Acid ttdca e
Valine val L e
alterations do not completely reverse the perturbation e ect. Specifically, alter-
ation of the media uptake fluxes does not restore the enforced virus optima back to
the wild-type unconstrained optima. Summary of in silico media alteration results
are shown in Appendix E.
Creation of mutated virus biomass objective functions
The e ect of mutations of the viral genome(s) on the host-derived antiviral targets
are further assessed through three mutation analyses: limited nucleotide variations
(LNVs); virus-like particle mutations; and extensive nucleotide with structural
component variations (ENVs).
For the LNVs, a total of 6000 mutant genomes were created each for CHIKV,
DENV and ZIKV. These 6000 mutant genomes are comprised of 6 distinct groups,
each which has a di erent number of point mutations randomly interspaced in the
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nucleotide sequence of the genome: 1, 2, 3, 4, 5 or 10 nucleotide mutations at a
single time. The resulting genomes were translated into the appropriate polypro-
tein for each virus, and new mutant VBOFs were created. These were individually
analysed under the same host-derived enforcement methodology to assess the im-
pact that point mutations may have on predicted antiviral targets. To assess
whether the results for the point mutated viruses di er qualitatively or quantita-
tively, the average and standard deviation of the enforced optima (of the point
mutated VBOFs) were analysed (Appendix E). In each case, for CHIKV, DENV
and ZIKV, the set of reactions predicted to be e ective against the point mutated
VBOFs is qualitatively identical to that of the wild-type VBOFs. Quantitatively,
the reaction-associated reduction of the wild-type VBOF lies within a single stan-
dard deviation of the average e ect across all point mutations, for that viruses. In
other words, the results are centred tightly around the original enforcement result
for the wild-type VBOF.
To further assess the impact that virus mutation may have on the predicted an-
tiviral targets, and to assess whether the results for the wild-type VBOF are
statistically significant, a further set of mutants were created: Virus-Like Parti-
cles (VLPs) and ENV VBOFs. A visualisation of the variation in stoichiometric
coe cients, for the LNV, VLP and ENV conditions, are shown for each virus in
Appendix E.
A series of one-way analysis of variances (ANOVAs) on these mutants, compared
to the wild-type and point mutation VBOFs, were conducted for each reaction in
the model and the associated predictions.
For each virus, across most e ective reactions (that is a reduction from the wild-
type optima), it was identified that the biomass reduction associated with the pre-
dicted reactions is statistically significant when compared to their e ects for the
virus-like and ENV biomass functions. In essence, most of the antiviral targets pre-
dicted using this methodology are unique, both in terms of the quantitative e ect
on the virus (i.e. the reduction of virus optima) when compared across di erent
virus species, but also when compared against randomly generated populations
(which can be considered as virus-like and non-virus like entities). A summary
of these statistics is available in Table. 3.6. This was calculated from looking
at the variance between the viruses of the mutant category, against the original,
wild-type viruses. There are a couple of exceptions only in the case of ZIKV,
where the reactions mediated by cystathionine g-lyase (CYSTGL) and cystathio-
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nine beta-synthase (CYSTS) did not show any significance in their e ect under
flux enforcement.
Table 3.6: Summary of Tukey test for Chikungunya (CHIKV), Dengue (DENV)
and Zika (ZIKV) viruses. Comparisons were made between the aggregated group
(WT+PM) of wild-type (WT) and limited nucleotide variation (LNV) viruses
against the extensive nucleotide with structural component variations (ENV) and
the WT and LNV of the other virus species. Frequency of single-reaction host-
derived enforcements are stated, for the statistically significant (p < 0.05) and
insignificant (p Ø 0.05) results.












CHIKV ENV 75 16
DENV WT+LNV 75 75
ZIKV WT+LNV 75 16
DENV WT+LNV




ZIKV WT+LNV 59 6
ZIKV WT+LNV




DENV WT+LNV 141 24
Further analysis with a post hoc Tukey test showed that most of the reactions
identified as broad-targets in the host-derived enforcement analysis also showed
significant di erences in the magnitude of their e ects among the three di erent
viruses. In other words, while the reactions we highlight are not necessarily unique
when comparing amongst CHIKV, DENV and ZIKV, their quantitative e ects on
virus production is significantly di erent for each species. Combined with the
fact that our randomisation process maintained the key features of stoichiometric
di erences among the host and virus-like biomass functions, we highlight that the
flux-perturbing e ects of the identified reactions emerge from the core metabolic
stoichiometric di erences between host and the viruses.
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3.4 DISCUSSION
In this chapter, a computational approach is presented that combines applica-
tion of FBA (and variants) and FVA, with the development of integrated host-
virus metabolic models, for antiviral prediction. This approach recovers known
metabolic (reaction targeting) antiviral targets within an integrated human macrophage
metabolic model, and predicts new potential targets against three viruses: CHIKV,
DENV and ZIKV.
The predictions here are formed primarily of reactions that are involving nu-
cleotides and amino acids. Further developing upon the previous chapter study
§2.3.1, this host-derived enforcement analysis highlights the importance of the dif-
ferences in host and virus metabolite usage and thus composition. As shown, many
of the reactions predicted to be e ective against any of the three viruses involve
the metabolism of nucleotides. This can be explained by the relative ratios of
the host- (macrophage) and virus-associated biomass objective functions (Table
3.7).
Table 3.7: Comparison of the amino acid (AA) and nucleotide (NTPS) biomass
objective compositions and subsequent ratio of nucleotides to amino acids. Human
macrophage, iAB-AMO-1410; Chikungunya virus, CHIKV; Dengue virus, DENV;
Zika virus, ZIKV.
Biomass Function Proportion of biomassNTPS % AA% NTPS:AA
iAB-AMO-1410 3.78 86.45 0.04
CHIKV 7.26 92.74 0.08
DENV 13.11 86.89 0.15
ZIKV 12.87 87.03 0.15
Comparing the biomass objective functions in this way highlights the consider-
ably higher proportion of nucleotide-associated biomass in the viruses than the
host macrophage. This increased requirement for nucleotides propagates into the
antiviral predictions; the host has a lower nucleotide level to satisfy than the
virus, making nucleotide-producing and consuming reactions viable antiviral tar-
gets. This is also mirrored in the overlap with the metabolic-targeting antivirals
identified from literature search (Leyssen et al. 2008, Khan et al. 2011, Ho mann
et al. 2011), whereby they almost exclusively target nucleotide associated reac-
tions. These sequential, non-branching pathways simultaneously highlight why
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nucleotide biosynthesis is a useful antiviral but non-viable host target. Both the
host and the virus require these for their own production, and whilst the host
utilises a smaller proportion of nucleotides (relative to its overall biomass), the
topology of the nucleotide biosynthesis network does not allow for significant re-
dundancies.
Unlike amino acid metabolites, where the reactions and pathways formed are in-
trinsically branched and their topology demonstrates multiple routes between pre-
cursors and the end amino acids, nucleotides do not exhibit the same type of
network topology. Instead, the nucleotide metabolites are biosynthesised via a
series of single-reaction chains, resulting in a chain of reactions that has reduce
robustness, in terms of alternative network routes if a reaction were to be inhib-
ited / altered, when compared to amino acids (Ravasz et al. 2002, Guimerà &
Nunes Amaral 2005). This is save for a small set of salvage pathways which still
require either externally supplied nucleotide precursors or catabolism of existing
nucleotides. Subsequently, this issue surrounding the e ects of network topology
and the overlap of biomass precursors (between host and virus) highlights the ad-
vantages of the host-derived enforcement therapeutic approach over the reaction
knockout approach, in terms of host viability and successful antiviral therapeutic
delivery (Littler & Oberg 2005).
Both the single-reaction knockout and host-derived enforcement analysis highlight
nucleotide associated reactions. However, the knockouts result in the reduction
of host optima as well as the virus optima (in both cases the optima is reduced
to zero). Not only does this demonstrate the level of entanglement between host
and virus (and indeed the dependency of the virus on the host) but also the
infeasibility of single-reaction knockouts as a viable antiviral therapeutic approach;
this antiviral treatment strategy would result in large-scale host and virus damage
which may perturb host viability and successful antiviral treatment. Host-derived
enforcements predict antiviral reaction targets that can be perturbed to reduce
virus optima whilst having minimal or no e ect on the ability of the host to
optimise. This approach appears advantageous, as it is able to directly combat the
virus’ production ability whilst allowing the host to remain viable until conclusion
of the infection or identification and eradication/support by the host immune
system.
The results of this analysis are in line with an integrated perspective that views
the virus as an additional metabolic burden on the host cells, that could be met
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or avoided by tinkering of host metabolic fluxes. The observed overlap between
predicted reactions and known antiviral drugs gives confidence to this integrated
modelling approach and highlights its potential as a prediction tool to guide ex-
perimental design. In addition, the model and virus sensitivity analysis gives
confidence that this approach is highlighting antiviral targets that are not only
virus-species specific, but also specific to virus organisms themselves (as opposed
to all organisms containing the same viral biomass precursors). This can be es-
pecially useful in the case of new and emerging viruses for which limited clinical
and experimental data may be available to inform drug target identification using
existing compound databases (Wishart et al. 2008, Schomburg 2004).
The integrated stoichiometric metabolic modelling approach focuses on metabolic
changes as a driver of virus production and does not consider factors associated
with virus-host cell recognition, viral entry, lipid envelope production, and release
(Timm & Yin 2012). Furthermore, the application of the linear optimisation on
stoichiometric models (i.e. FBA and FVA) strictly assumes that host metabolism
is at steady state, and thus prohibits analysis of the dynamics of cellular physiology.
Such dynamics could be taken into account to a certain extent by imposing di erent
flux constraints, which could be derived from proximal experimental data (Birch
et al. 2012), through the development of simplified metabolic temporal models
(Molenaar et al. 2009, Weiße et al. 2015), or by combining dynamics with linear
optimisation on stoichiometric models (Birch et al. 2014, Mahadevan et al. 2002).
Additionally, the extent of the missing information, such as genes, enzymes or
reactions, in genome-scale stoichiometric models creates limitations on how much
of the metabolic processes can be covered (Aurich & Thiele 2016).
Future e orts to improving model curation and standardisation (Zomorrodi &
Segrè 2016) would open up the possibility of extensive analysis of host-virus pair-
ings from a metabolic stance. Such modelling e orts would immensely benefit
from a collection of appropriate, relevant experiment datasets. In particular, ex-
perimental analysis of cellular metabolic fluxes, as well as the determination of cel-
lular uptake rates and metabolite requirements, can allow direct evaluation of the
model. The presented findings already suggest that integrated host-virus models
can highlight metabolic changes in the host and predict principal host metabolic
processes that are linked to host-virus compositional mismatches and that can
be used to combat virus production without altering host functions (Grantham
1974). In particular, analysis of extended flux enforcement strategies such as
flux limitations on double reaction combinations might identify virus-specific drug
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combinations (Littler & Oberg 2005). Combined with the future development of
additional host-virus integrated models covering many cell and virus types can




Double-Reaction Perturbations of the
Chikungunya, Dengue and Zika Virus Integrated
Metabolic Models
4.1 INTRODUCTION
The previous chapter explored the e ectiveness of single-reaction targeting as
means of predicting potential antiviral therapeutics. In particular, a novel method-
ology was developed, ”host-derived enforcements”, that apply an additional con-
straint to the metabolic system that maintains host-optimality whilst perturbing
virus production. We highlighted many targets that were mostly confined to the
de novo nucleotide biosynthetic pathways. CHIKV, DENV and ZIKV were all
a ected by these reactions, albeit quantitatively di erent, and the average result
was a small reduction in virus optima: approximately 70-80% of the wild-type
optima.
Given the interplay between the virus and host-metabolic network (Sanchez et al.
2015) and the relative lack of metabolic-based antivirals for RNA viruses outside
of nucleotide biosynthesis (Leyssen et al. 2008), a multi-reaction approach (in the
context of host metabolism) could provide fruitful antiviral theraputics. Realising
this systems-level understanding of host-viral metabolic interactions and how to
e ectively perturb virus production requires the development of a computational
approach that not only e ectively predicts multi-reaction antiviral therapies, but
explores the impact on host-virus metabolic resource allocation. Previous exper-
imental and clinical studies have highlighted the e ectiveness of both multiple
target and multiple drug antiviral approaches in respiratory virus (Hayden 1996)
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and Hepatitis C viral infections (Poordad et al. 2013).
Metabolic systems are highly complex, branched networks that contain multiple
pathways, compartments and subsystems (Schuster et al. 2000, Hatzimanikatis
et al. 2005). Although simplified in their representation, metabolic networks dis-
play a level of redundancy in the production of biomass components (Wang &
Zhang 2009). This redundancy, from an evolutionary and survivability aspect,
ensures that an organism can still produce the required biomass components even
when the metabolic network is subject to damage or distress (Almaas et al. 2005).
It is this property of metabolic networks that potentially makes multiple-reaction
targeting a more optimal solution for antiviral development: since biomass metabo-
lites can be created using more than one pathway, the corresponding antiviral treat-
ment would too require more than one control point (in this case reactions).
To better explore the possibility of multiple metabolic perturbations as an antiviral
therapeutic, here we develop an extension to our preexisting methodology and
constrain two control points [reactions] of the metabolic network against CHIKV,
DENV and ZIKV.
4.2 METHODS
4.2.1 Integrated Host-Virus Metabolic Model Selection and Creation
Three virus species were selected, as previously defined in §2.2.1, Table 2.1: Chikun-
gunya virus (CHIKV), dengue virus (DENV) and zika virus (ZIKV). VBOFs and
integrated host-virus metabolic models were created for each individual virus as
described previously in §2.2.2.
4.2.2 Double Reaction Perturbations of Integrated Host-Virus Metabolic
Models
As explored in previous chapters 2 and 3, reaction perturbations represent a po-
tential avenue for the discovery of antiviral targets. however, these have only been
considered in terms of a single reaction. In an expansion to this methodology,
combinations of two model reactions, called ’double perturbations’, are explored
under two conditions: double reaction knockouts and double reaction host-derived
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enforcements. Toy models / schematics for both conditions are shown in Fig.











































Figure 4.1: Toy model of flux balance analysis optimisation problems for (A)
double-reaction knockouts and (B) double-reaction host-derived enforcements.
Toy networks show metabolites (M) as nodes and reactions as edges, with associ-
ated reaction flux (V) marked. Flux ranges are shown for the enforced reactions,
where the minimum (e≠) and maximum (e+) enforcement bounds are highlighted.
Double Reaction Knockout Analysis
Knockout analysis considers the e ect of systematically setting individual reac-
tion fluxes to zero, and then attempting to maximise the integrated host-virus
metabolic model for virus production, previously described as a single-reaction
linear optimisation problem in §3.2.2. Here, double-reaction knockouts are consid-
ered, to see if there are combinations of reactions that, when their flux bounds are
set to zero, can di erentially a ect virus optima. To implement this, an additional
inequality is added to the single-reaction knockout linear optimisation problem
(Eq. 3.1), yielding the double-reaction knockout linear optimisation problem (Eq.
4.1).
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maximise Zko = cT · v
subject to S · v = 0
lb < v < ub
0 < vi < 0
0 < vj < 0
(4.1)
where indexation i and j are over all reactions v in the model systematically and
the associated lower (lb) and upper (ub) bounds are simultaneously set to zero.
Note that under this condition, reaction i ”= j, as this is equal to a single-reaction
knockout. This model is then optimised for VBOF, yielding the virus knockout
optima (Zko). A reaction knockout is considered ’e ective’, in terms of its potential
as an antiviral target, if Zko < Zwt.
Double Reaction Host-Derived Enforcement Analysis
As previously described in §3.2.2, an integrated host-virus metabolic model can
be additionally constrained in such a way that host-viable flux ranges are enforced
whilst the model is optimised for virus production. Similar to the reaction knock-
out condition, and additional inequality is added to the single-reaction host-derived
enforcement linear optimisation problem (Eq. 3.5), yielding the double-reaction
host-derived enforcement linear optimisation problem (Eq. 4.2).
maximise Ze = cT · v
subject to S · v = 0
lb < v < ub
e
≠









where indexation i and j are over all reactions v in the model systematically and
the associated lower (lb) and upper (ub) bounds are set to the calculated lower (ei)
and upper (ej) enforcement values. Note that under this condition, reaction i ”= j,
as this is equal to a single-reaction enforcement. This model is then optimised for
VBOF, yielding the virus knockout optima (Ze). A reaction knockout is considered
’e ective’, in terms of its potential as an antiviral target, if Zko < Zwt.
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4.2.3 Epistatic interactions
The epistatic interactions between the single-reaction (previous study) and double-
reaction host-derived enforcement targets were compared to assess whether reac-
tions, when paired, act in a synergistic manner (that is, the e ect they have on the
virus host-enforced optima Ze is more than would be expected from their e ects
in the single-reaction perturbations). For this method, we quantify a negative
epistatic e ect as a desired epistatic e ect: the combination of these reactions re-
duces the virus optima more than would be predicted and therefore is highlighted
as a beneficial (antiviral) target.
The epistatic interactions (Á) between pairs of reactions are calculated by:
Á = fAB ≠ fAfB (4.3)
where AB are the double-reaction enforcement virus optima, and A and B are
the single-reaction enforcement virus optima for the reactions A,B in the double-
enforcement condition. If both reactions are identical (A = B) then Á cannot be
calculated and (for the purposes of the results) recorded as ’NaN’.
4.3 RESULTS
4.3.1 Double-Reaction Enforcements Highlight Multiple Metabolic Net-
work Targeting Points
In order to assess the impact that combining multiple reaction pairs, under the
conditions of knockouts and host-derived enforcements, may have on virus produc-
tion, a double-reaction methodology was created and implemented for the iHVMs
of CHIKV, DENV and ZIKV associated metabolic models.
The integrated HVMs identified multiple pairs of reactions that, compared to each
reaction in the single-enforcement condition from the previous study, result in a
synergistic e ect that results in a more substantial than expected decrease in virus
optima. In this way, we define a ”beneficial” synergy (concerning antiviral e ect)
as a negative value. Many of these reaction pairs when grouped by subsystems
are e ective in the context of amino acid metabolism. For CHIKV and DENV,
combinations of nucleotide associated reactions do not lead to the synergistic ef-
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fects that are seen with the combination of amino acid associated reactions. An
exception of this is the case of ZIKV, where a mixture of nucleotide and amino acid
reactions cause increased perturbation to the ZIKV optima, beyond what would
be expected from a combination of the single reaction perturbations.
4.3.2 Double Host-Enforcements: Chikungunya Virus
From the subset of reactions that are e ective against CHIKV in the double-
reaction condition, we highlight reactions that exhibit a synergistic e ect when
paired together. As shown in Fig. 4.2, there a few sets of reaction pairs that
exhibit a large negative value of synergy (Á Æ ≠0.6). This indicates that when these
reactions are paired together, the e ect on the virus (in terms of optima reduction)
is greater than what would be predicted from the single-reaction perturbations
alone. The absolute values of these double-reaction host-derived enforcements, in
terms of reduction of virus optima (compared to wild-type), are shown for CHIKV
in Fig. 4.3.
Reactions that have a positive synergy, indicating that pairing of the reactions
does not reduce the virus optima to a level that would be predicted from the
single-reaction results, are also highlighted. The majority of these reactions are
associated with the interactions of both the Nucleotides and Pentose Phosphate
Pathway subsystems, with other metabolic reaction subsystems.
Reactions are attributed to a model subsystem, and these can also be further
categorised based upon the major metabolic junction (defined in the context of
a single metabolite) that these subsystems are associated with. In the case of
these CHIKV-associated negative synergy reactions, they broadly fall into two
categories: cysteine related and threonine related.
Concerning cysteine, we observe that restricting the anabolic reactions and increas-
ing the catabolic reactions reduces its availability for virus production. Cysteine
is considered a non-essential amino acid and is synthesised (along with glycine and
serine) from glycolytic intermediates. In that sense, we can target both sides of
metabolism (anabolic and catabolic) to perturb the virus production.
These identified reactions predict that downregulating the supply of precursors
for cysteine biosynthesis such as Cystathionine (CYST-L), while simultaneously
increasing the flux of cysteine-consuming reactions, result in a decrease of CHIKV
optima. The combination of these reactions pairs causes cysteine to become a
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Coenzyme A Metabolism
Cysteine Metabolism






Taurine and Hypotaurine Metabolism
Tetrahydrobiopterin Metabolism
Transport, Extracellular
Figure 4.2: Exhaustive comparison of Chikungunya virus double-reaction host-
derived enforcement epistatic interactions, grouped by subsystem. Colour bar
indicates the epistatic interaction value; greater antiviral e ect (blue) to lesser
antiviral e ect (red) than would have been predicted from the single-reaction en-
forcements alone. Reaction IDs are shown on the x- and y-axis, combining to form
a double-reaction pair. Pairings of identical reactions are highlighted by an un-
filled square. Subsystems are labeled on the y-axis. Reaction IDs with full names
are given in the original model publication (Bordbar et al. 2010).
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Coenzyme A Metabolism
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Figure 4.3: Exhaustive comparison of Chikungunya virus double-reaction host-
derived enforcement reactions, grouped by subsystem. Colour bar indicates the
proportion of original wild-type virus optima when two reactions simultaneously
undergo host-derived enforcement; greater optima reducing e ect (dark blue; virus
optima is 0% of wild-type) to lesser antiviral e ect (white; virus optima is 100%
of wild-type). Reaction IDs are shown on the x- and y-axis, combining to form a
double-reaction pair. Where pairings of reactions are identical, the value shown
corresponds to the e ect of that reaction under the single-reaction host-derived
enforcement analysis. Subsystems are labeled on the y-axis. Reaction IDs with
full names are given in the original model publication (Bordbar et al. 2010).
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limited resource which the virus requires for optimal production (Fig. 4.4). As
has been shown with the comparison between host and viral usage of amino acids,
CHIKV has an almost 2-fold increased requirement for cysteine when compared to
the host (Appendix F). This mismatch of usage potentially allows for a reduction
in the availability of cysteine, something that the host can tolerate (and remain
optimal) but CHIKV cannot. Ultimately, the combination of pairs upregulated
(+) and downregulated (-) reactions appears to show the greatest antiviral e ect,
as is discussed throughout these results.
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Figure 4.4 (previous page): Chikungunya virus double-reaction host-derived
enforcements that are associated with cysteine (CYS-L) metabolism. Synergistic
reaction pairs are formed between any ( ) and ( ) reactions, when simultaneously
enforced. Reactions can be upregulated (+) or downregulated (-). Black arrows (:)
denote reaction directionality, and coloured arrows indicated the directionality of
primary (:) and secondary (:) reaction pair members if reaction is bidirectional.
Virus-associated biomass precursors are highlighted in green. Model compartment
boundaries are indicated by dashed line (- - -). Reaction and metabolite abbrevi-
ations are expanded in the original model publication (Bordbar et al. 2010).
There are also reactions highlighted that are associated with the catabolism of
2-Oxobutanoate (2OBUT). In this case, pairs of reactions that catabolise 2OBUT
are upregulated and thus increase the demand on 2OBUT (Fig. 4.5). 2OBUT is a
product in the biosynthesis of cysteine, but also from the catabolism of threonine.
Threonine is identified as an amino acid that is used almost 3-fold more in CHIKV
composition than the host.
Similar to the case with cysteine, the pairing of reactions that are associated
with the catabolism of 2OBUT cause a perturbation on the virus optima. Specif-
ically, by upregulating the catabolism of 2OBUT to 2-Hydroxybutyrate (2HB)
and Propanoyl-Coa (PPCOA) simultaneously, a demand is created within the
metabolic network for 2OBUT synthesis. This can be satisfied either through in-
creased cysteine biosynthesis, which may be of potential benefit to CHIKV due to
its high biomass requirement for cysteine or through increased catabolism of thre-
onine. In the latter case, while this would increase the supply of 2OBUT, it would
decrease the availability of threonine to the virus optimised network. As this has
been identified as a significant component of the CHIKV biomass, this results in
an overall decrease of virus production within this constrained network.
Regarding threonine, we observe that increasing the catabolic reactions reduces
the availability of threonine for virus production. Unlike cysteine, threonine is
an essential amino acid and cannot be synthesised de novo. These examples, in
particular those that are associated with amino acids that are biosynthesised de
novo, highlight how the combined constraining of the in- and ef-fluxes of amino acid
associated metabolites can create highly e ective, synergistic perturbations that
can reduce the ability of CHIKV to optimise within the [constrained] metabolic
network.
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Figure 4.5: Chikungunya virus double-reaction enforcements associated with
threonine metabolism. Synergistic reaction pairs are formed between any ( ) and
( ) reactions, when simultaneously enforced. Reactions can be upregulated (+) or
downregulated (-). Black arrows (:) denote reaction directionality, and coloured
arrows indicated the directionality of primary (:) and secondary (:) reaction
pair members if reaction is bidirectional. Virus-associated biomass precursors are
highlighted in green. Model compartment boundaries are indicated by dashed line
(- - -). Reaction and metabolite abbreviations are expanded in the original model
publication (Bordbar et al. 2010).
Sean Aller 132
4 | Double-Reaction Perturbations of Host-Virus Metabolic Models
4.3.3 Double Host-Enforcements: Dengue Virus.
From the subset of reactions that are e ective against DENV in the double-reaction
conditions, we highlight a similar set of synergistic reactions to that found in
CHIKV (Fig. 4.6). The absolute values of these double-reaction host-derived
enforcements, in terms of reduction of virus optima (compared to wild-type), are
shown for DENV in Fig. 4.7.
Coenzyme A Metabolism
Cysteine Metabolism





Taurine and Hypotaurine Metabolism
Transport, Extracellular
Figure 4.6: Exhaustive comparison of Dengue virus double-reaction host-derived
enforcement epistatic interactions, grouped by subsystem. Colour bar indicates
the epistatic interaction value; greater antiviral e ect (blue) to lesser antiviral
e ect (red) than would have been predicted from the single-reaction enforcements
alone. Reaction IDs are shown on the x- and y-axis, combining to form a double-
reaction pair. Pairings of identical reactions are highlighted by an unfilled square.
Subsystems are labeled on the y-axis. Reaction and metabolite abbreviations are
expanded in the original model publication (Bordbar et al. 2010).
Notable exceptions are that for DENV we no longer find that cysteine anabolism
is a viable target, that is, limiting the supply of cysteine biosynthesis precursors no
longer causes a reduction in DENV optima. From the comparison between host
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Figure 4.7: Exhaustive comparison of Dengue virus double-reaction host-derived
enforcement reactions, grouped by subsystem. Colour bar indicates the proportion
of original wild-type virus optima when two reactions simultaneously undergo host-
derived enforcement; greater optima reducing e ect (dark blue; virus optima is 0%
of wild-type) to lesser antiviral e ect (white; virus optima is 100% of wild-type).
Reaction IDs are shown on the x- and y-axis, combining to form a double-reaction
pair. Where pairings of reactions are identical, the value shown corresponds to the
e ect of that reaction under the single-reaction host-derived enforcement analysis.
Subsystems are labeled on the y-axis. Reaction IDs with full names are given in
the original model publication (Bordbar et al. 2010).
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and virus compositions, it is clear that cysteine is proportionally equal in both
the host and virus biomass objectives (Appendix B and C). In this sense, this
means cysteine cannot be a target for cross-constraining. However, we observe
that methionine is utilised roughly 2-fold more in the DENV biomass than the
host’s biomass function, and thus, displays several synergistic pairs that can be
constrained.
Methionine, an essential amino acid, is involved in the biosynthesis of other cellu-
lar proteins as well as being a component of both viral and host biomass objective
functions. The methionine derivative S-adenosyl methionine (AMET) is also in-
volved in cysteine biosynthesis. Methionine supply is therefore dependent on the
anabolic activity of cysteine. We identify reactions with the highest levels of syn-
ergy are associated with the cysteine and cysteine-linked coenzyme A metabolic
pathways, that are associated with the metabolism of Methionine and its metabolic
derivatives. Whereas in CHIKV, the most e ective identified reaction pairs were a
combination of an upregulated and downregulated reaction, in the case of DENV
we highlight only pairs of upregulated reactions.
Specifically, pairings of CYSTA and PPNCL3 (both beginnings of sequential chains
of reactions) when simultaneously upregulated results in decreased DENV optima
(Fig. 4.8). The proposed mechanism for this is that through the upregulation,
there is an increased demand for cysteine synthesis. This, in turn, requires that
methionine (considered critical in the virus biomass composition due to its rela-
tively high proportional usage) be catabolised into the derivatives required for cys-
teine synthesis. Ultimately this limits the amount of methionine available for virus
biomass production, thus reducing the virus optima. In other words, there appears
to be a trade-o  between methionine and cysteine, which is ”tipped against” the
virus through the appropriate metabolic constraints.
The pairing of 2obut associated reactions is similar to CHIKV. Threonine is also
identified as an amino acid that is present in a higher proportion of DENV biomass
than in the host. Therefore, the proposed mechanism is the same as that of
CHIKV, in that threonine becomes a limiting resource for virus biomass produc-
tion.
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Figure 4.8: Dengue virus double-reaction enforcements associated with cysteine
and methionine metabolism. Synergistic reaction pairs are formed between any ( )
and ( ) reactions, when simultaneously enforced. Reactions can be upregulated
(+) or downregulated (-). Black arrows (:) denote reaction directionality, and
coloured arrows indicated the directionality of primary (:) and secondary (:)
reaction pair members if reaction is bidirectional.
(continued on next page...)
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Figure 4.8 (previous page): Virus-associated biomass precursors are high-
lighted in green. Model compartment boundaries are indicated by dashed line (-
- -). Reaction and metabolite abbreviations are expanded in the original model
publication (Bordbar et al. 2010).
4.3.4 Double Host-Enforcements: Zika Virus.
The double-enforcement conditions for ZIKV, which are e ective in reducing virus
optima and show synergistic e ects, do not follow the same pattern as in CHIKV
and DENV (Fig. 4.9). Absolute values of these double-reaction host-derived
enforcements, in terms of reduction of virus optima (compared to wild-type), are
shown for in Fig. 4.10.x As previously discussed, in these cases only reactions that
are immediately associated with amino acids (or their metabolism) were directly
identified. These identified amino acids are also highlighted as being di erentially
utilised between the viruses and the host biomass functions.
However, in the case of ZIKV, we find that the double-reaction enforcements that
have the most substantial synergistic e ect include both nucleotide and amino acid
associated reactions. Broadly, we categorise the double-enforcement conditions
into three groups: amino acid only; nucleotide and amino acid interplay; and
nucleotide only.
As has been discussed previously for the CHIKV and DENV results, the di erences
in host and virus biomass composition play a substantial role in the predicted
antiviral targets; this is particularly interesting for the ZIKV antiviral targets
due to the prediction of nucleotide associated antiviral targets. ZIKV has a high
requirement for glycine, an essential amino acid in the biosynthesis of nucleotides.
While DENV also has a higher-than-host usage of glycine (CHIKV is similar to
host) its requirement for serine and cysteine, two amino acids that are also derived
from the same glycolytic intermediate as glycine, are lower / the same as the host
(respectively). ZIKV, however, has a higher demand for serine than DENV, so the
increased demand of multiple amino acids from the same precursor has potential
downstream e ects on both amino acid and nucleotide biosynthesis reactions.
Nucleotide associated reactions, therefore, represent an e ective (and synergistic)
target for ZIKV when compared to CHIKV and DENV. In particular, we find
that a combination of purine and pyrimidine catabolic reactions cause a decrease
in the virus optima. More specifically, by increasing the production of deoxyguano-
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Valine, Leucine and Isoleucine Metabolism
Figure 4.9: Exhaustive comparison of Zika virus double-reaction host-derived
enforcement epistatic interactions, grouped by subsystem. Colour bar indicates
the epistatic interaction value; greater antiviral e ect (blue) to lesser antiviral
e ect (red) than would have been predicted from the single-reaction enforcements
alone. Reaction IDs are shown on the x- and y-axis, combining to form a double-
reaction pair. Pairings of identical reactions are highlighted by an unfilled square.
Subsystems are labeled on the y-axis. Reaction and metabolite abbreviations are
expanded in the original model publication (Bordbar et al. 2010).
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Figure 4.10: Exhaustive comparison of Zika virus double-reaction host-derived
enforcement reactions, grouped by subsystem. Colour bar indicates the proportion
of original wild-type virus optima when two reactions simultaneously undergo host-
derived enforcement; greater optima reducing e ect (dark blue; virus optima is 0%
of wild-type) to lesser antiviral e ect (white; virus optima is 100% of wild-type).
Reaction IDs are shown on the x- and y-axis, combining to form a double-reaction
pair. Where pairings of reactions are identical, the value shown corresponds to the
e ect of that reaction under the single-reaction host-derived enforcement analysis.
Subsystems are labeled on the y-axis. Reaction IDs with full names are given in
the original model publication (Bordbar et al. 2010).
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sine and deoxyuridine from guanine and uridine (respectively), the supply of the
associated RNA nucleotides which are required for virus biomass production is lim-
ited. This is achieved through the simultaneous upregulation of purine-nucleoside
phosphorylases (deoxyguanosine-associated) with pyrimidine-nucleoside phospho-
rylases (uracil- and deoxyuracil-associated) causing a constraint on the precursors
and intermediates required for RNA nucleotide synthesis and incorporation into
the virus biomass (Fig. 4.11). In essence, as has been predicted for the other
viruses, a combination of simultaneously regulating the in- and ef-flux of nucleotide






















Figure 4.11: Zika virus double-reaction enforcements associated with pyrimidine
and purine metabolism. Synergistic reaction pairs are formed between any ( ) and
( ) reactions, when simultaneously enforced. Reactions can be upregulated (+) or
downregulated (-). Black arrows (:) denote reaction directionality, and coloured
arrows indicated the directionality of primary (:) and secondary (:) reaction
pair members if reaction is bidirectional. Virus-associated biomass precursors are
highlighted in green. Model compartment boundaries are indicated by dashed line
(- - -). Reaction and metabolite abbreviations are expanded in the original model
publication (Bordbar et al. 2010).
Some nucleotide-amino acid associated reaction pairs were also identified as ef-
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fective against ZIKV. Specifically, the combination of serine and serine-precursor
synthesis reactions with purine catabolism reactions results in decreased virus op-
tima (Fig. 4.12). While ZIKV proportionally uses less serine than that of the
host, its requirement for glycine is much higher. The serine synthesis reactions
provide the penultimate precursor to glycine and therefore may represent a good
target for down-regulation in addition to the role of glycine in the biosynthesis of
purine nucleotides. Interestingly, these combinations of nucleotide and amino acid
reactions, as shown, have not appeared in the double-reaction analysis for CHIKV
and DENV. Potentially, we are seeing the e ects of trade-o  between a the in-
creased demand of glycine and nucleotides in the ZIKV optimised system, that is
not present in the CHIKV and DENV optimised ones (due to the respective virus
biomass compositions). This particular trade o  between serine/cysteine/glycine
and nucleotide biosynthesis, as shown through the prediction of serine-associated
and a purine-associated reactions, therefore goes some way in explaining why this
e ect is not observed in the other viruses. To put it simply, ZIKV requires a
higher amount of glycine (compared to the host and the other viruses) that is
utilised for de novo nucleotide biosynthesis and therefore presents a ZIKV-unique
antiviral perturbation that e ectively reduces the virus’ ability to optimise in the
constrained system.
Hypoxanthine, as part of the purine catabolic pathway, can be used to synthesise
inosine monophosphate (IMP), the precursor to both guanine and adenosine-based
RNA nucleotides. By upregulating the reactions that consume hypoxanthine a
limitation is created on the amount that can be utilised for RNA purine nucleotide
anabolism. The upregulation of hypoxanthine to inosine and deoxyinosine (as
well as direct transport out of the cell) restricts purine salvage pathways and
thus creates a network where IMP cannot be synthesised entirely in this manner.
Combined with the downregulation of serine producing reactions, not only limiting
a biomass component itself but also results in a limit on the amount of glycine
available, which when combined with a disruption of the purine catabolic pathway,
causes a decrease in overall virus biomass production.
As with CHIKV and DENV, reaction pairs that involve only amino acids are
predicted as antiviral targets. In the case of ZIKV, the primary amino acids high-
lighted by this double reaction enforcement involve the amino acids arginine and
proline (Fig. 4.13), both of which make up proportionally less of the ZIKV biomass
that the host. This is reflected in the fact that the reactions identified all involve
upregulation of arginine and proline producing pathways. More specifically, we
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Figure 4.12: Zika virus double-reaction enforcements associated with serine-
glycine metabolism and purine catabolism. Synergistic reaction pairs are formed
between any ( ) and ( ) reactions, when simultaneously enforced. Reactions can
be upregulated (+) or downregulated (-). Black arrows (:) denote reaction di-
rectionality, and coloured arrows indicated the directionality of primary (:) and
secondary (:) reaction pair members if reaction is bidirectional. Virus-associated
biomass precursors are highlighted in green. Model compartment boundaries are
indicated by dashed line (- - -). Reaction and metabolite abbreviations are ex-
panded in the original model publication (Bordbar et al. 2010).
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identify reaction pairs that are found in the urea cycle. Combinations of cytosolic
arginase (ARGN) with either the cytosol-to-mitochondrial arginine transport re-
action (ARGtm), mitochondrial arginase (ARGNm) or mitochondrial-to-cytosolic
urea transport reaction (UREAtm) result in decrease ZIKV optima. In essence,
these combinations cause a reduction in the availability of cytosolic arginine (the
virus can only use amino acids that are cytosolic) and increase the availability of
both cytosolic and mitochondrial ornithine (ORN), an important non-proteogenic
amino acid used in proline biosynthesis. This represents a case where instead of
limiting amino acid precursors, their overproduction causes a detrimental e ect on
virus production. In part, this is due to the limited metabolic resources available
to the network, therefore by forcing the over-production of amino acids that form
a lesser component of the viral biomass, the metabolic resources are consumed as






















Figure 4.13: Zika virus double-reaction enforcements associated with arginine
and proline metabolism. Reaction pairs are formed between any primary ( ) and
secondary ( ) reactions, when simultaneously enforced. Reactions can be upregu-
lated (+) or downregulated (-). Black arrows (:) denote reaction directionality,
and coloured arrows indicated the directionality of primary (:) and secondary
(:) reaction pair members if reaction is bidirectional. Virus-associated biomass
precursors are highlighted in green. Model compartment boundaries are indicated
by dashed line (- - -). Reaction and metabolite abbreviations are expanded in the
original model publication (Bordbar et al. 2010).
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Summary. Double-reaction host-derived enforcements highlight a number of po-
tentially novel antiviral targets for CHIKV, DENV and ZIKV. Broadly, these an-
tiviral targets can be classified as amino acid or nucleotide targeting, based upon
the metabolic pathways they fall into. CHIKV and DENV are susceptible to the
most amino acid associated reactions, targeted towards the amino acids that con-
tribute proportionally more to their overall biomass. ZIKV, whilst a ected by
amino acid targeting reactions, also is predict to be a ected by nucleotide alter-
ing reaction pairs. Regardless of the types of reactions predicted to be e ective
in a pair, it is the case that pairs of up- and down-regulated reactions are the
most e ective, and yielded the greatest synergistic e ect, of any host-derived en-
forcement pair. For many of these reactions, it was possible to identify existing
inhibitory compounds from the DrugBank database (Wishart et al. 2008) that can
potentially be experimentally explored as antiviral targets. Full tables of double-
reaction enforcements targets for each virus, along with drug targets, are presented
in Appendix F.
4.4 DISCUSSION
Here we present a novel computational methodology for predicting multiple control
points (reactions) in an ”infected” host-virus metabolic model. Building upon the
previous chapter, where potential antiviral network perturbations were considered
exhaustively in a single-reaction manner, we simulate the host-derived enforcement
of reaction pairs in the model for all unique reaction combinations. This resulted
in the simulation of 5757921 reaction pairs for each virus, totalling to 17273763
overall.
Compared to the single-reaction results, the double-reaction knockouts result in
a greater number of virus optima reducing reactions. Due to the high number
of completely reducing targets, an in-text table has not been included in this
section (see Appendix F). However, as with the single-reaction knockout analysis,
all targets are accompanied (if applicable) with a potential drug candidate(s) for
the reaction(s). Similar to the single-reaction knockout results, the e ect against
the virus production simultaneously e ects the host viability. Therefore, the single-
reaction enforcement analysis was repeated in this double-reaction manner.
The double-reaction enforcements result in a larger number of potential antiviral
reaction-combinations. Some of the reactions highlighted in this analysis as being
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e ective as a potential antiviral were up- or down-regulated. Whilst upregulated
reactions may indeed provide some antiviral e ect, they are potentially more dif-
ficult to achieve than a downregulated [inhibited] reaction, mainly due to a lack
of viable drugs / compounds that achieve upregulation. It is most likely that the
enzyme/gene itself would need to be upregulated in order to achieve this e ect.
We also acknowledge that whilst reactions that are labelled as compartment trans-
porters (i.e. cytosol to mitochondria), such as hypoxanthine transport (HYXNt)
shown in Fig. 4.12, may represent viable targets, they also typically lack identi-
fied drugs/compounds (in a similar manner to the upregulated reactions). This is
due to a lack of information regarding the exact protein complex that is respon-
sible for the transport, or due to the transportation being via a process such as
di usion.
Where possible, drug candidates have been identified and recorded for the reac-
tions. However, some of these drugs are small molecules (i.e. NADH, GMP) and as
such may not be suitable for antiviral therapeutic treatment. In some cases, drug
candidates were not available at all. For both of these instances, two possibilities
can be considered:
1. Searching other databases (i.e. BRENDA) for other potential inhibitors
2. Using short interfering RNAs (siRNAs) to inhibit the enzyme (using the
EC number as an identifier for the gene-protein linked to that reaction) and
therefore act as the novel antiviral therapeutic.
Overall, ZIKV shows the broadest range of e ects (in terms of the virus optima
reduction) but also the largest reduction in any case. CHIKV and DENV are both
predicted to be a ected by the double-reaction enforcements also, but not to the




The aim of this PhD project was to develop an in silico modelling approach,
using applications of flux balance analysis, to explore the metabolic interactions
between a human macrophage host and three viruses: Chikungunya, Dengue and
Zika viruses. To accomplish this the biomass composition, in terms of metabolic
resources and energy requirements, had to be established for each virus being
modelled. Additionally, these representations of the virus biomass (the biomass
objective function) had to be integrated into a suitable host model, in this case a
human macrophage metabolic network. Once these had been established and cre-
ated, flux balance analysis was used to predict the di erences in a host-optimised
and virus-optimised network, the latter serving as a proxy for complete virus con-
trol. This method was then further built upon to identify sets of reactions (both
in terms of a single set or sets of reaction pairs) that can be perturbed in such a
way that elicit an antiviral e ect, whilst attempting to preserve the host viability.
This section will contain the findings of this thesis, and will be summarised in a
number of key areas. These will be: the di erences in host- and virus-optimised
metabolic systems, predictions of single- and double-reaction antiviral targets, the
role of viral biomass composition in the e ectiveness of antiviral targets, and the
implications that this has on antiviral development. Finally, future directions for
this project will be discussed.
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5.1 UNDERSTANDING THE INTERACTIONS BETWEEN HOST
AND VIRUS: A METABOLIC VIEWPOINT
During this PhD study, one of the main aims was to use in silico methodologies
to predict and explore the interactions between host organism’s metabolic net-
works and viruses that infect and utilise the associated metabolic resources. The
interplay between viruses and hosts, in terms of metabolic perturbations and re-
arrangements, has been established and experimentally verified (Miyake-Stoner &
O’Shea 2014, Rodrigues et al. 2013, Delgado et al. 2010, Sanchez & Laguno  2015,
Maynard et al. 2010). However, whilst these metabolic interactions have been char-
acterised for some viruses, there still remains a lack of understanding in terms of
the specific reaction modulation that occurs during these metabolic interactions.
These studies are also particularly resource intensive, requiring the selection of a
suitable viral host, development of assays and in some cases the amendment or
development of specific methodologies, all of which can require significant amounts
of time to implement (Gautam et al. 2017, Geisbert & Jahrling 2004, Morse et al.
2012). In an e ort to alleviate some of these hurdles, the development of in silico
systems proved potentially useful and insightful (Aurich & Thiele 2016, Kerkhoven
et al. 2014). To this end, this project expanded upon previous attempts to model
the interactions between host organisms and viruses. Previous studies had ex-
plored the metabolic interactions between bacteria and phages (Birch et al. 2012,
Jain & Srivastava 2009), and the interactions between human hosts and bacte-
rial pathogens (Bordbar et al. 2010), but these same techniques had not yet been
applied to a human host and viral pathogen.
In chapter 2, a method for the description of a virus as a metabolic component
of a host metabolic network was developed and used to integrate three viruses -
Chikungunya, Dengue and Zika viruses - into a human macrophage host metabolic
network (Bordbar et al. 2010). The idea behind this method, that viruses can be
considered as an extra metabolic ’demand’ on a host, is the driving force behind
the majority of the research proposed in this thesis (Maynard et al. 2010, Mah-
moudabadi et al. 2017). These models were then used to predict the di erences
in a host- and virus-optimised metabolic network, an abstraction that is used as
a proxy for complete host- and viral-control of the metabolic network. Whilst the
latter may not represent an actual biological state - one could argue that a virus
can never completely control a metabolic system as this would inadvertently kill
the host - the di erences between the two states can inform metabolic interactions
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that observed outside of the in silico environment (Heinken & Thiele 2015).
Flux predictions, for the host macrophage metabolic network, were completed for
host- and virus-optimised systems. In general, the di erences between the host-
and virus-optimal states centred around the increased diversion of glycolytic fluxes,
in the virus-optimal state, to amino acid and nucleotide de novo biosynthetic
pathways (§2.3.2). These diversions related to the increased biomass-associated
demands for amino acids and RNA nucleotides of the viral biomass in compar-
ison to the host. This diversion of glycolytic flux, and indeed diversion of flux
towards these biosynthetic pathways, lines up with previous research and studies
that have identified the di erences in metabolic regulation between uninfected and
virus-infected cells (El-Bacha et al. 2004, Delgado et al. 2010, Carinhas et al. 2017,
Enav et al. 2014). In particular, it is interesting to look at the di erences between
the individual viruses themselves. Whilst CHIKV and DENV are predicted to
optimised the metabolic network so that glycolytic intermediates drive both the
synthesis of nucleotide precursors, but also amino acids (serine, glycine and cys-
teine) and pyruvate, in the ZIKV optimised system there is a complete dissociation
of glycolysis from serine-biosynthesis, pyruvate synthesis and indeed the feeding of
the citric acid cycle (§2.3.2 and §2.3.3). Instead, under the control of ZIKV, the
citric acid cycle is predominantly fed via glutamine catabolism, an e ect that has
been noted in other virus infected cells, mainly by the Vaccinia virus (Fontaine
et al. 2014).
These results provide an insight into the specific reaction alterations that may
occur during the transition from uninfected to virus-infected, in terms of the viral-
mediate rearrangement of metabolic resources. However, these results need to be
further explored with in vitro metabolic flux analysis studies in order to further
promote both the understanding of the metabolic network perturbations during
infection, but also to inform the model design and further improve the accuracy
of the in silico predictions. Currently, there is a lack of data regarding the charac-
terisation of intracellular fluxes, which hampers the development of this technique
(Blank 2017). Future research will require the characterisation of these fluxes, in
order to fully realise the systems biology cycle and spur the development of more
accurate and elaborate metabolic models. However, the research conducted in this
thesis provides a potential foundation, in terms of techniques used and the types
of analyses performed, to initiate such an endeavour.
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5.2 MODEL PREDICTIONS BETWEEN HOST- AND
VIRUS-OPTIMAL METABOLIC STATES MATCHES
METABOLITE-BASED OBSERVATIONS FROM INFECTED CELLS
As previously discussed, the model predictions arise from a thought-experiment in
which we compare fluxes from the host metabolic system optimised for either host
or virus objective functions. While a full shift of host metabolism to supporting
viral production is unlikely, this comparison can still provide insights into how
metabolic fluxes in a host might shift with subsequent viral infection. To see if the
model predictions match with biological observations, a comparison was attempted
between the general flux results, presented in chapter 2, with experimental data
collected from controlled virus infection experiments involving the three viruses
(CHIKV, DENV and ZIKV). Unfortunately, exploration of the literature failed to
yield any studies that have directly measured metabolic flux changes across the
course of a viral infection, for these viruses. There were, however, few datasets
that considered changes in the cell medium or the serum upon infection, and
subsequently found notable overlaps with this data and the flux predictions from
this thesis project. For example, the model predictions for the upregulation of
glycine, serine and threonine metabolic sub-processes (§2.3.2) in the CHIKV- and
DENV-optimised models matches with previous metabolic studies of the serum of
CHIKV and DENV infected humans (Shrinet et al. 2016).
There was also an attempt to compare the predictions with gene expression data
from several infection experiments, presenting expression levels before and after
infection. Unfortunately, none of these studies was conducted on the modelled
host, the human macrophage cell, but instead used other human cell lines, and
as a result there was no strong overall correlation between expression changes in
metabolic genes and model-based flux changes (in line with the previously observed
lack of correlation between enzyme expression and metabolic flux changes (Guo &
Feng 2016)).
5.3 CREATING A SYSTEMS BIOLOGY PLATFORM FOR VIRAL
METABOLIC MODELLING
Currently, multiple methods and computational applications exist for constraint-
based metabolic modelling (Chindelevitch et al. 2014, Hoppe et al. 2011, Orth et al.
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2010), although the most common application is the COBRA toolbox and asso-
ciated code-specific extensions (Ebrahim et al. 2013). Whilst this toolbox is able
to facilitate the creation, curation and analysis of metabolic models, it is unable
to construct organism specific mathematical constructs (such as biomass objective
functions). Therefore, part of this thesis project aimed to create an additional soft-
ware layer for the COBRA toolbox, that would specifically be built for the creation
and analysis of virus-infected metabolic models; this in-house software is called Vi-
raNet, and its use and code is detailed in §2.2.7 and Appendix A.5, respectively.
The full python-based program is also available through the OSS Lab Research
Group computational resources website (http://osslab.lifesci.warwick.ac.uk/?pid=resources).
The goal of creating this automated software, which requires minimal user input to
create a host-virus integrated metabolic model, was to establish a systems biology
platform that could spur further research into the metabolic analysis of host-virus
interactions, as has previously been done for other combinations of organisms and
indeed other systems biology based endeavours (Heinken & Thiele 2015, Munger
et al. 2008, Kitano 2002).
5.4 PREDICTING ANTIVIRAL TARGETS: ISSUES OF
METABOLIC ENTANGLEMENT
The overlap between a host and a virus, in terms of their composition and metabolic
demands, are substantial: both organisms utilise a variety of amino acids and nu-
cleotides to function, which therefore presents an issue when it comes to metabolite-
based antiviral design (Maynard et al. 2010). As discussed throughout chapters
2-4, the overlap of biomass precursor metabolites between the human macrophage
host and CHIKV, DENV, and ZIKV biomass objective functions, presented an is-
sue in the prediction of e ective antiviral targets. Initially, this project began with
exploring the e ect of knocking out a single reaction (by reducing the flux bounds
of that reaction to zero, e ectively removing it from the metabolic network) on
the ability of the virus to optimise (§3.3.1). The results appeared promising; a
number of reactions under the knockout constraint would render the virus (via
the associated objective function reaction) unable to optimise within this con-
strained metabolic network. However, subsequent experiments predicted that the
host biomass objective function was also unable to be optimised for, and as a result
the targets also reduced host viability. These results highlighted the key point dis-
cussed earlier; because the host and virus overlap in terms of biomass precursors,
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complete inhibition of an associated reaction (for those precursors) will ultimately
end up a ecting both the host and the virus (Ikeda & Kato 2007, Miyake-Stoner
& O’Shea 2014). This trail of thought was what spurred the development of the
host-derived enforcement reaction analysis (§3.2 and §3.3.2).
In essence, the host-derived enforcement analysis looked at how reactions could
be partially perturbed (as opposed to entirely knocked-out) through up- or down-
regulation, in order to decrease the predicted virus optima whilst simultaneously
ensuring that the host optima did not deviate from the original prediction. This
maintenance, or enforcement, of host viability enables the prediction of a set of an-
tiviral targets that in theory maximise perturbation of the virus whilst minimising
damage to the host. This premise contrasts with current metabolism-orientated
[RNA] antiviral targets, most of which exclusively target de novo nucleotide biosyn-
thesis (Leyssen et al. 2008, Khan et al. 2011, Jain et al. 2001, Wang et al. 2011,
Chung 2015). Whilst these antivirals have been experimentally validated and
shown to reduce the overall titre of infectious virus released from infected cells,
they are also attributed to an increase in cell death relative to non-infected cells.
This trade-o  was found in chapter 3, whereby single-reaction knockouts in nu-
cleotide biosynthetic pathways disabled the ability of the virus, but also the host,
to optimise and use the metabolic network. Chapter 3 resolved this issue of host
damage through the use of host-derived enforcements, and predicted small re-
ductions in virus optima (between 2 and 15%). Whilst this proved promising,
in terms of creating a method that confers host viability whilst perturbing the
virus, the results can be criticised for only producing negligible e ects against the
viruses. Thus, in an attempt to further explore and expand upon this method,
double-reactions were considered under the constraint of host derived enforcements
(§4.3.1 - 4.3.4) for antiviral against CHIKV, DENV and ZIKV.
The double-reactions proved to be more successful, in terms of (a) the number
of antiviral targets they predicted were e ective and (b) the reduction of virus
optima associated with those reaction pairings. What is particularly interest-
ing, is whilst single-reaction antiviral targets were mainly predicted to a ect the
nucleotide biosynthetic pathways, the double-reaction pathways (in the cases of
CHIKV and DENV) predominantly a ected the amino acid biosynthetic path-
ways. In the case of ZIKV, both amino acid and nucleotide pathway targets
yielded e ective results. What is interesting is why this result has come about,
particularly in the light of metabolic network topology.
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The de novo nucleotide biosynthetic pathways, specifically purine and pyrimidine
pathways, are non-branched and are a series of single input and single outputs, un-
til the terminal branching event which results in the production of uracil-cytidine
or adenosine-guanine nucleotides, respectively. Therefore, single-reaction pertur-
bations are able to easily a ect these synthesis pathways, as only one point of this
network has to be perturbed in order to elicit a downstream e ect. Vice versa, in
the case of amino acids the de novo synthesis pathways are highly branched, with
many interconnecting input and output reactions and multiple points of redun-
dancy (several pathways to and from compounds) . This creates a situation where
a single reaction is unable to perturb the amino acid biosynthesis enough to elicit
an antiviral e ect, but two reactions simultaneously perturbed are able to. This
also helps explain why double-reactions are unable to produce a more substantial
e ect in the nucleotide biosynthetic pathways, as the single-reaction-chain pertur-
bations a ect all downstream reactions with equal e ect. The largest issue faced,
therefore, is how exactly to select pairs of reactions to yield the antiviral e ect,
the main result of which this thesis presents.
5.5 FUTURE DIRECTIONS
This thesis concludes with a set of reaction predictions, both for single- and double-
reactions, that are e ective against CHIKV, DENV and ZIKV. The most obvious
future direction from this project is the experimental validation of the antiviral
targets predicted in this project. At the time of writing, two collaborators are
currently developing and implementing research projects that will experimentally
validate the predicted targets, using drug compounds identified from the DrugBank
database (Wishart et al. 2008) or through the use of small interfering RNAs (siR-
NAs), which specifically target the enzyme that catalyses the associated antiviral
reaction target. These external collaborators, the Defence Science and Technology
Laboratories (DSTL, UK) and University of Western Australia (UWA, Australia)
will be initially focusing on CHIKV and ZIKV, respectively. The outputs of this
thesis have inspired and informed these research projects, which upon completion
will be further expanded to include DENV and other viruses that have as of yet
not been computationally modelled.
This thesis also raises questions surrounding the influence of host-virus biomass
composition mismatch as a potential avenue for further research. Throughout
this thesis, the influence that stoichiometry has on antiviral targets, and indeed
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flux predicts, has been clear: di ering requirements for the amount of biomass
precursors causes appropriate changes in the metabolic network. The interplay
between the di erent precursors (nucleotides and amino acids) is therefore a logical
next step, in order to determine how this may a ect both the observed infection
and antiviral predictions. Current literature and experimental evidence suggests
that there are downstream e ects of di erent virus compositions during infection,
and that these di erences play a role in how the virus interacts with the host cell
(Mahmoudabadi et al. 2017). There are also observable di erences in the amino
acid and nucleotide levels within a cell (Dittmar et al. 2006, Martini et al. 2004,
Bergström et al. 1974), and experiments have been conducted that show the impact
this has on protein production (Raiford et al. 2008, Kaleta et al. 2013, Akashi &
Gojobori 2002) but also that viruses can and have evolved to adapt to the host
intracellular metabolic resources (Taubenberger & Kash 2010). Understanding this
interplay between free metabolite resource concentrations and virus production
and adaptation will aid in the discovery of e ective antiviral targets.
5.6 FINAL CONCLUSIONS
Ultimately, this thesis concludes that the stoichiometric di erences between host
and virus drive the magnitude of the antiviral e ect, predicted by the host-derived
enforcements, for CHIKV, DENV and ZIKV. Nucleotide targets provide a more
generic (in terms of the viruses they e ect) antiviral e ect that is successful against
CHIKV, DENV and ZIKV. The amino acid targets, under the condition of double-
reaction constraints, appear to o er more specificity in terms of their antiviral
potential against di erent viruses. In the case of CHIKV, DENV and ZIKV, many
of the reactions predicted to be e ective against CHIKV were also e ective against
DENV. However, ZIKV had a number of reaction pairings that were not present,
or had a smaller e ect, in the other two viruses. This mainly revolved around the
linkage between amino acids and nucleotides, specifically in the case of glycine (of
which ZIKV has a substantially higher biomass demand than CHIKV or DENV)
which is utilised as a nucleotide precursor. These biomass compositional di erences
seem to be what is driving the antiviral e ects predicted, where trade-o s between
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King, Z. A., Dräger, A., Ebrahim, A., Sonnenschein, N., Lewis, N. E. & Pals-
son, B. Ø. (2015), ‘Escher: A Web Application for Building, Sharing, and Em-
bedding Data-Rich Visualizations of Biological Pathways.’, PLoS Comput Biol
11(8), e1004321.
Kitano, H. (2002), ‘Systems Biology: A Brief Overview’, Science 295(5560), 1662–
1664.
Kotte, O., Zaugg, J. B. & Heinemann, M. (2010), ‘Bacterial adaptation through
distributed sensing of metabolic fluxes.’, Molecular Systems Biology 6, 355.
162
Bibliography
Kotzamanis, K., Angulo, A. & Ghazal, P. (2015), ‘Infection homeostasis: impli-
cations for therapeutic and immune programming of metabolism in controlling
infection.’, Med. Microbiol. Immunol. 204(3), 395–407.
Kussow, C. M., Zhou, W., Gryte, D. M. & Hu, W.-S. (1995), ‘Monitoring of mam-
malian cell growth and virus production process using on-line oxygen uptake
rate measurement’, Enzyme and Microbial Technology 17(9), 779–783.
Law, G. L., Korth, M. J., Benecke, A. G. & Katze, M. G. (2013), ‘Systems virol-
ogy: host-directed approaches to viral pathogenesis and drug targeting.’, Nature
Publishing Group 11(7), 455–466.
Le Novère, N., Finney, A., Hucka, M., Bhalla, U. S., Campagne, F., Collado-Vides,
J., Crampin, E. J., Halstead, M., Klipp, E., Mendes, P., Nielsen, P., Sauro, H.,
Shapiro, B., Snoep, J. L., Spence, H. D. & Wanner, B. L. (2005), ‘Minimum
information requested in the annotation of biochemical models (MIRIAM).’,
Nat. Biotechnol. 23(12), 1509–1515.
Lenski, R. E. & Travisano, M. (1994), ‘Dynamics of adaptation and diversification:
a 10,000-generation experiment with bacterial populations.’, Proceedings of the
National Academy of Sciences 91(15), 6808–6814.
Lewis, N. E., Hixson, K. K., Conrad, T. M., Lerman, J. A., Charusanti, P., Pol-
pitiya, A. D., Adkins, J. N., Schramm, G., Purvine, S. O., Lopez-Ferrer, D.,
Weitz, K. K., Eils, R., König, R., Smith, R. D. & Palsson, B. Ø. (2010), ‘Omic
data from evolved E. coli are consistent with computed optimal growth from
genome-scale models.’, Molecular Systems Biology 6, 390–13.
Leyssen, P., De Clercq, E. & Neyts, J. (2008), ‘Molecular strategies to inhibit the
replication of RNA viruses.’, Antiviral Research 78(1), 9–25.
Littler, E. & Oberg, B. (2005), ‘Achievements and challenges in antiviral drug
discovery.’, Antivir. Chem. Chemother. 16(3), 155–168.
Liu, J. K., O’Brien, E. J., Lerman, J. A., Zengler, K., Palsson, B. Ø. & Feist, A. M.
(2014), ‘Reconstruction and modeling protein translocation and compartmen-
talization in Escherichia coli at the genome-scale.’, BMC Syst Biol 8(1), 110.
Lundström, J. O. (1999), ‘Mosquito-borne viruses in western Europe: a review.’,
J Vector Ecol 24(1), 1–39.
163
Bibliography
Luz, K. G. (2016), ‘Dengue, Chikungunya and Zika Virus: Global emergence’,
International Journal of Infectious Diseases 45, 39.
Lwande, O. W., Obanda, V., Bucht, G., Mosomtai, G., Otieno, V., Ahlm, C. &
Evander, M. (2015), ‘Global emergence of Alphaviruses that cause arthritis in
humans.’, Infect Ecol Epidemiol 5, 29853.
Ma, H., Sorokin, A., Mazein, A., Selkov, A., Selkov, E., Demin, O. & Goryanin, I.
(2007), ‘The Edinburgh human metabolic network reconstruction and its func-
tional analysis.’, Molecular Systems Biology 3, 135.
Mahadevan, R., Edwards, J. S. & Doyle III, F. J. (2002), ‘Dynamic Flux Bal-
ance Analysis of Diauxic Growth in Escherichia coli’, Biophysical Journal
83(3), 1331–1340.
Mahadevan, R. & Schilling, C. H. (2003), ‘The e ects of alternate optimal solu-
tions in constraint-based genome-scale metabolic models.’, Metabolic Engineer-
ing 5(4), 264–276.
Mahmoudabadi, G., Milo, R. & Phillips, R. (2017), ‘Energetic cost of building a
virus.’, Proc. Natl. Acad. Sci. U.S.A. 114(22), E4324–E4333.
Marquez, V. E., Lim, M. I., Treanor, S. P., Plowman, J., Priest, M. A., Markovac,
A., Khan, M. S., Kaskar, B. & Driscoll, J. S. (1988), ‘Cyclopentenylcytosine. A
carbocyclic nucleoside with antitumor and antiviral properties.’, J. Med. Chem.
31(9), 1687–1694.
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Appendices
A VIRANET PYTHON CODE




2 # Setup o f workspace
3 import cobra
4 from cobra import Model , Reaction , Metabo l i te
5 from cobra . f l u x a n a l y s i s . l o o p l e s s l o o p l e s s s o l u t i o n
6 import numpy as np
7 import pandas as pd
8 import s t r i n g
9 from v i r ane t import t o o l s




14 # opt imi se
15 # Optimises the HVM f o r host and v i r u s optimal s t a t e s
16 # Inputs :
17 # HVM Integ ra t ed host≠v i r u s model
18 # HostRxn Host o b j e c t i v e r eac t i on , e i t h e r :
19 # ≠ Index value o f r e a c t i o n in Model . r e a c t i o n s
[ i n t ]
20 # ≠ Reaction ID o f the host≠o b j e c t i v e r e a c t i o n
[ s t r ]
21 # s o l v e r [OPTIONAL] Dec lare s o l v e r to use f o r cobrapy :
d e f a u l t i s cg lpk
22 # fbaType [OPTIONAL] Dec lare i f FBA i s normal ’ fba ’ or
l o o p l e s s FBA ’ l o o p l e s s ’
23 #
24 # Outputs :
25 # objIdx Index value f o r the o b j e c t i v e r e a c t i o n s
26 # hostF Host≠o b j e c t i v e optima value
27 # hostX Vector o f non≠o b j e c t i v e r e a c t i o n f l u x e s f o r host≠
opt imised
28 # virusF Virus≠o b j e c t i v e optima value
29 # virusX Vector o f non≠o b j e c t i v e r e a c t i o n f l u x e s f o r v i rus
≠opt imised
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30 #
31 de f opt imi se (HVM, HostRxn , s o l v e r=’ cg lpk ’ , fbaType=’ fba ’ ) :
32 ” Optimise HVM”
33 # [ 1 ] I n i t i a l Setup
34 # I d e n t i f y the host o b j e c t i v e r e a c t i o n
35 t ry :
36 i n tTes t = i n t ( HostRxn )
37 hostIdx = HostRxn
38 except :
39 f o r i i in range ( l en (HVM. r e a c t i o n s ) ) :
40 i f HostRxn in s t r (HVM. r e a c t i o n s [ i i ] ) :
41 hostIdx = i i
42 v i ru s Idx = len (HVM. r e a c t i o n s ) ≠ 1 # ViraNet ( c ) appends
v i r u s r e a c t i o n to end in genHVM. py
43 objIdx = [ hostIdx , v i ru s Idx ]
44 # [ 2 ] State Opt imisat ions
45 # I d e n t i f y the r e a c t i o n s
46 hostObj = HVM. r e a c t i o n s [ hostIdx ]
47 virusObj = HVM. r e a c t i o n s [ v i ru s Idx ]
48 # Record the bounds
49 hostLb = HVM. r e a c t i o n s [ hostIdx ] . lower bound
50 hostUb = HVM. r e a c t i o n s [ hostIdx ] . upper bound
51 virusLb = HVM. r e a c t i o n s [ v i ru s Idx ] . lower bound
52 virusUb = HVM. r e a c t i o n s [ v i ru s Idx ] . upper bound
53 # Host opt im i sa t i on
54 HVM. change ob j e c t i v e ( hostObj )
55 # Zero≠bound v i r u s r e a c t i o n
56 HVM. r e a c t i o n s [ v i ru s Idx ] . lower bound = 0
57 HVM. r e a c t i o n s [ v i ru s Idx ] . upper bound = 0
58 # > Condi t iona l FBA statement
59 i f ’ fbaType ’ == ’ fba ’ :
60 # Record Optima
61 hos tSo l = HVM. opt imize ( o b j e c t i v e s e n s e=’ maximize ’ , s o l v e r=
s o l v e r )
62 hostX = hostSo l . x # Host≠optimal f l u x
vec to r
63 hostF = hos tSo l . f # Optima value f o r host
o b j e c t i v e
64 e l i f ’ fbaType ’ == ’ l o o p l e s s ’
65 # Record Optima
66 HVM. s o l v e r = ’ cp lex ’
67 HVM. o b j e c t i v e = hostObj . id
68 hos tSo l = l o o p l e s s s o l u t i o n (HVM)
69 hostX = hostSo l . x # Host≠optimal f l u x
vec to r
70 hostFrame = pd . DataFrame ({ ’ r e a c t i o n ’ : l i s t (HVM. r e a c t i o n s .
l i s t a t t r ( ’ id ’ ) ) , ’ f l u x ’ : hostX })
71 hostFrame = hostFrame . s o r t v a l u e s ( by=’ r e a c t i o n ’ )
72 hostF = hostFrame [ ’ f l u x ’ ] [ hostFrame [ ’ r e a c t i o n ’ ] . i s i n ( [
hostObj . id ] ) ] # Optima value host o b j e c t i v e
73 # Return v i r u s r e a c t i o n to c o r r e c t bounds
74 HVM. r e a c t i o n s [ v i ru s Idx ] . lower bound = virusLb
75 HVM. r e a c t i o n s [ v i ru s Idx ] . upper bound = virusUb
76 # Virus opt im i sa t i on
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77 # Check that v i r u s o b j e c t i v e i s c o r r e c t and generated from ’
gene ra t i on . py ’
78 i f ’ prodrxn VN ’ in virusObj . id :
79 # Zero≠bound host r e a c t i o n
80 HVM. r e a c t i o n s [ hostIdx ] . lower bound = 0
81 HVM. r e a c t i o n s [ hostIdx ] . upper bound = 0
82 # > Condi t iona l FBA statement
83 i f ’ fbaType ’ == ’ fba ’ :
84 HVM. change ob j e c t i v e ( v irusObj )
85 # Record Optima
86 v i r u s S o l = HVM. opt imize ( o b j e c t i v e s e n s e=’ maximize ’ , s o l v e r
=s o l v e r )
87 virusX = v i r u s S o l . x # Virus≠optimal f l u x
vec to r
88 virusF = v i r u s S o l . f # Optima value f o r
v i r u s o b j e c t i v e
89 e l i f ’ fbaType ’ == ’ l o o p l e s s ’
90 # Record Optima
91 HVM. s o l v e r = ’ cp lex ’
92 HVM. o b j e c t i v e = virusObj . id
93 v i r u s S o l = l o o p l e s s s o l u t i o n (HVM)
94 virusX = v i r u s S o l . x # virus ≠optimal
f l u x vec to r
95 virusFrame = pd . DataFrame ({ ’ r e a c t i o n ’ : l i s t (HVM.
r e a c t i o n s . l i s t a t t r ( ’ id ’ ) ) , ’ f l u x ’ : virusX })
96 virusFrame = virusFrame . s o r t v a l u e s ( by=’ r e a c t i o n ’ )
97 virusF = virusFrame [ ’ f l u x ’ ] [ virusFrame [ ’ r e a c t i o n ’ ] .
i s i n ( [ v i rusObj . id ] ) ] # Optima value v i r u s o b j e c t i v e
98 # Record v i r u s optima
99 # Return v i r u s r e a c t i o n to c o r r e c t bounds
100 HVM. r e a c t i o n s [ hostIdx ] . lower bound = hostLb
101 HVM. r e a c t i o n s [ hostIdx ] . upper bound = hostUb
102 e l s e :
103 r a i s e ValueError ( ’ Unsupported ob j e c t i v e , unable to ana lyse :
r e f e r to README’ )
104 # [ 3 ] Outputs




109 # d i f f e r e n t i a l
110 # Compares the host and v i r u s o b j e c t i v e f u n c t i o n s f o r amino ac id and
n u c l e o t i d e
111 # usage
112 # Inputs :
113 # HVM Integ ra t ed host≠v i r u s model
114 # HostRxn Host o b j e c t i v e r eac t i on , e i t h e r :
115 # ≠ Index value o f r e a c t i o n in Model . r e a c t i o n s
[ i n t ]
116 # ≠ Reaction ID o f the host≠o b j e c t i v e r e a c t i o n
[ s t r ]
117 #
118 # Outputs :
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119 # rel d i fAA , Re la t i v e d i f f e r e n t i a l comparison o f amino ac id
and n u c l e o t i d e
120 # re l d i fNT usage in the host and v i r u s o b j e c t i v e f u n c t i o n s
121 # [ Re la t i v e comparison : amino ac id s are only
cons ide red with in
122 # the amino ac id f r a c t i o n ; n u c l e o t i d e s are only
cons ide red
123 # within the n u c l e o t i d e f r a c t i o n ]
124 # abs difAA , Absolute d i f f e r e n t i a l comparison o f amino ac id
and n u c l e o t i d e
125 # abs difNT usage in the host and v i r u s o b j e c t i v e f u n c t i o n s
126 # [ Absolute comparison : amino ac id s and n u c l e o t i d e s
are
127 # cons ide red aga in s t a l l macromolecular f r a c t i o n s ]
128 #
129 de f d i f f e r e n t i a l (HVM, HostRxn ) :
130 ” D i f f e r e n t i a l usage o f amino ac id s and n u c l e o t i d e s ”
131 # [ 1 ] I n i t i a l Setup
132 # I d e n t i f y the host o b j e c t i v e r e a c t i o n
133 t ry :
134 i n tTes t = i n t ( HostRxn )
135 hostIdx = HostRxn
136 except :
137 f o r i i in range ( l en (HVM. r e a c t i o n s ) ) :
138 i f HostRxn in s t r (HVM. r e a c t i o n s [ i i ] ) :
139 hostIdx = i i
140 v i ru s Idx = len (HVM. r e a c t i o n s ) ≠ 1 # ViraNet ( c ) appends
v i r u s r e a c t i o n to end in genHVM. py
141 objIdx = [ hostIdx , v i ru s Idx ]
142 hostID = HVM. r e a c t i o n s [ hostIdx ] . id
143 virusID = HVM. r e a c t i o n s [ v i ru s Idx ] . id
144 # Condit ion : ensure v i r u s r e a c t i o n i s v i r u s o b j e c t i v e
145 i f ’ prodrxn VN ’ not in v irusID :
146 r a i s e ValueError ( ’ Unsupported ob j e c t i v e , unable to ana lyse :
r e f e r to README’ )
147 # Convert model i n to an array
148 m = HVM. to ar ray based mode l ( )
149 # Create data frame
150 mFrame = pd . DataFrame (
151 data = m. S . todense ( ) ,
152 columns = m. r e a c t i o n s . l i s t a t t r ( ” id ” ) ,
153 index = m. metabo l i t e s . l i s t a t t r ( ” id ” )
154 )
155 # [ 2 ] D i f f e r e n t i a l usage a n a l y s i s
156 # Str ip the host and v i r u s o b j e c t i v e func t i on s t o i c h i o m e t r i c
c o e f f i c i e n t s
157 hostS = mFrame [ hostID ]
158 v i rusS = mFrame [ v i rusID ]
159 # Storage v a r i a b l e c r e a t i o n
160 hostAA = np . z e ro s ( ( 2 0 , 1 ) )
161 hostNT = np . z e ro s ( ( 4 , 1 ) )
162 virusAA = np . z e r o s ( ( 20 , 1 ) )
163 virusNT = np . z e ro s ( ( 4 , 1 ) )
164 # Loop and c o l l e c t the s t o i c h i o m e t r i c c o e f f i c i e n t s
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165 # Amino ac id s
166 f o r i i in range ( l en ( aaMets ) ) :
167 hostAA [ i i ] = np . abso lu t e ( hostS [ metDict [ aaMets [ i i ] ] ] )
168 virusAA [ i i ] = np . abso lu t e ( v i rusS [ metDict [ aaMets [ i i ] ] ] )
169 # Nuc l eo t ide s
170 f o r i i in range ( l en ( ntpsMets ) ) :
171 i f ( hostS [ metDict [ ’ ctp ’ ] ] ) > 0 :
172 hostNT [ i i ] = np . abso lu te ( hostS [ metDict [ ntpsMets [ i i ] ] ] )
173 e l s e :
174 oldMet = metDict [ ntpsMets [ i i ] ]
175 tempMet = oldMet . r e p l a c e ( ’ tp ’ , ’mp ’ )
176 hostNT [ i i ] = np . abso lu te ( hostS [ tempMet ] )
177 i f ntpsMets [ i i ] i s not ” atp ” :
178 virusNT [ i i ] = np . abso lu t e ( v i rusS [ metDict [ ntpsMets [ i i ] ] ] )
179 e l s e :
180 virusNT [ i i ] = np . abso lu t e ( v i rusS [ metDict [ ntpsMets [ i i ] ] ] )
≠ np . abso lu te ( v i rusS [ metDict [ ’ adp ’ ] ] )
181 # [ 3 ] Create output
182 # Dict ionary to hold metabo l i t e s with corre spond ing va lue s
183 r e l d i f = d i c t ( )
184 a b s d i f = d i c t ( )
185 # Rela t i v e d i f f e r e n c e
186 f o r i i in range ( l en ( aaMets ) ) :
187 rd i fH = hostAA [ i i ] / np . sum( hostAA )
188 rd i fV = virusAA [ i i ] / np . sum( virusAA )
189 rd i fX = ( rd i fV / rd i fH ) ≠ 1
190 rd i fX = rdi fX . t o l i s t ( )
191 rd i fX = rdi fX [ 0 ]
192 r e l d i f [ aaMets [ i i ] ] = rd i fX
193 f o r i i in range ( l en ( ntpsMets ) ) :
194 rd i fH = hostNT [ i i ] / np . sum( hostNT )
195 rd i fV = virusNT [ i i ] / np . sum( virusNT )
196 rd i fX = ( rd i fV / rd i fH ) ≠ 1
197 rd i fX = rdi fX . t o l i s t ( )
198 rd i fX = rdi fX [ 0 ]
199 r e l d i f [ ntpsMets [ i i ] ] = rd i fX
200 # Absolute d i f f e r e n c e
201 f o r i i in range ( l en ( aaMets ) ) :
202 adifH = hostAA [ i i ] / np . sum( hostS )
203 adifV = virusAA [ i i ] / np . sum( v i rusS )
204 adifX = ( adifV / adifH ) ≠ 1
205 adifX = adifX . t o l i s t ( )
206 adifX = adifX [ 0 ]
207 a b s d i f [ aaMets [ i i ] ] = adifX
208 f o r i i in range ( l en ( ntpsMets ) ) :
209 adifH = hostNT [ i i ] / np . sum( hostS )
210 adifV = virusNT [ i i ] / np . sum( v i rusS )
211 adifX = ( adifV / adifH ) ≠ 1
212 adifX = adifX . t o l i s t ( )
213 adifX = adifX [ 0 ]
214 a b s d i f [ ntpsMets [ i i ] ] = adifX
215 # Return va lue s
216 re turn ( r e l d i f , a b s d i f )
217 #######
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221 # Compares the f l u x d i s t r i b u t i o n o f a host≠optimal s t a t e with that o f
a v i rus ≠
222 # optimal s t a t e
223 # Inputs :
224 # objIdx Index value f o r the o b j e c t i v e r e a c t i o n s
225 # hostX Vector o f non≠o b j e c t i v e r e a c t i o n f l u x e s f o r host≠
opt imised
226 # virusX Vector o f non≠o b j e c t i v e r e a c t i o n f l u x e s f o r v i rus
≠opt imised
227 #
228 # Outputs :
229 # hvmComp Comparison o f HOS and VOS f l u x va lue s ( as % t o t a l
f l u x )
230 # hvmStat Reaction s t a t s f o r HOS and VOS s t a t e s :
231 # ≠ Upregulated
232 # ≠ Downregulated
233 # ≠ Activated
234 # ≠ I nac t i va t ed
235 # ≠ Reversed
236
237 de f compare ( objIdx , hostX , virusX ) :
238 ”Host≠Virus Comparison”
239 # [ 1 ] I n i t i a l Setup
240 # Numpy Conversion
241 hostX = np . array ( hostX )
242 virusX = np . array ( virusX )
243 # Remove the o b j e c t i v e r e a c t i o n s from both f l u x ve c t o r s
244 hostXd = np . d e l e t e ( hostX , objIdx )
245 virusXd = np . d e l e t e ( virusX , objIdx )
246 # Convert f l u x ve c t o r s to abso lu t e and normal i s e to summation o f
vec to r
247 pHOS = ( hostXd / sum(np . abso lu t e ( hostX ) ) ) ú 100
248 pVOS = ( virusXd / sum(np . abso lu t e ( virusX ) ) ) ú 100
249 # Convert to s u i t a b l e numpy array
250 pHOS = np . array (pHOS)
251 pVOS = np . array (pVOS)
252 # [ 2 ] Reaction S t a t i s t i c s
253 # Var iab l e s f o r c a l c u l a t i o n s
254 t o l = 1 .05 #
Regulated t o l e r a n c e
255 e = 1e≠06 #
Threshold f o r ’ on ’
256 ne = e ú ≠1 #
Negative th r e sho ld
257 i n f = np . i n f
258 # Reaction s t a t e s : Upregulated ; Downregulated ; Act ivated ;
Inac t i va t ed ; Reversed
259 urRxns = 0
260 drRxns = 0
261 avRxns = 0
262 iaRxns = 0
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263 reRxns = 0
264 # I n i t i a t e loop
265 f o r i i in range ( l en (pHOS) ) :
266 # Upregulated
267 i f (pVOS[ i i ] > e ) and (pHOS[ i i ] > e ) and ( (pVOS[ i i ] / pHOS[ i i
] ) > t o l ) and ( (pVOS[ i i ] / pHOS[ i i ] ) < i n f ) :
268 urRxns += 1
269 e l i f (pVOS[ i i ] < ne ) and (pHOS[ i i ] < ne ) and ( (pVOS[ i i ] /
pHOS[ i i ] ) > t o l ) and ( (pVOS[ i i ] / pHOS[ i i ] ) < i n f ) :
270 urRxns += 1
271 # Downregulated
272 i f (pVOS[ i i ] > e ) and (pHOS[ i i ] > e ) and ( (pHOS[ i i ] / pVOS[ i i
] ) > t o l ) and ( (pHOS[ i i ] / pVOS[ i i ] ) < i n f ) :
273 drRxns += 1
274 e l i f (pVOS[ i i ] < ne ) and (pHOS[ i i ] < ne ) and ( (pHOS[ i i ] /
pVOS[ i i ] ) > t o l ) and ( (pHOS[ i i ] / pVOS[ i i ] ) < i n f ) :
275 drRxns += 1
276 # Activated
277 i f ( np . abso lu t e (pVOS[ i i ] ) > e ) and (np . abso lu t e (pHOS[ i i ] ) < e
) :
278 avRxns += 1
279 # Inac t i va t ed
280 i f ( np . abso lu t e (pVOS[ i i ] ) < e ) and (np . abso lu t e (pHOS[ i i ] ) > e
) :
281 iaRxns += 1
282 # Reversed
283 i f (pVOS[ i i ] > e and pHOS[ i i ] < ne ) or (pVOS[ i i ] < ne and
pHOS[ i i ] > e ) :
284 reRxns +=1
285 # [ 3 ] Outputs
286 # hvmComp
287 hvmComp = np . vstack ( (pHOS,pVOS) )
288 hvmComp = hvmComp. t ranspose ( )
289 # hvmStat
290 hvmStat = [ urRxns , drRxns , avRxns , iaRxns , reRxns ]
291




296 # v a r a b i l i t y
297 # Optimises the HVM f o r host and v i r u s optimal s t a t e s , us ing f l u x
v a r i a b i l i t y
298 # a n a l y s i s
299 # Inputs :
300 # HVM Integ ra t ed host≠v i r u s model
301 # HostRxn Host o b j e c t i v e r eac t i on , e i t h e r :
302 # ≠ Index value o f r e a c t i o n in Model . r e a c t i o n s
[ i n t ]
303 # ≠ Reaction ID o f the host≠o b j e c t i v e r e a c t i o n
[ s t r ]
304 # Optional Inputs
305 # s o l v e r Dec lare s o l v e r to use f o r cobrapy : d e f a u l t i s
cg lpk
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306 #
307 # Outputs :
308 # hostFVA Vector o f non≠o b j e c t i v e r e a c t i o n f l u x e s f o r host≠
opt imised [ maximum | minimum ]
309 # virusFVA Vector o f non≠o b j e c t i v e r e a c t i o n f l u x e s f o r v i rus
≠opt imised [ maximum | minimum ]
310 #
311 de f v a r i a b i l i t y (HVM, HostRxn , s o l v e r=’ cg lpk ’ ) :
312 ” V a r i a b i l i t y o f HVM”
313 # [ 1 ] I n i t i a l Setup
314 # I d e n t i f y the host o b j e c t i v e r e a c t i o n
315 t ry :
316 i n tTes t = i n t ( HostRxn )
317 hostIdx = HostRxn
318 except :
319 f o r i i in range ( l en (HVM. r e a c t i o n s ) ) :
320 i f HostRxn in s t r (HVM. r e a c t i o n s [ i i ] ) :
321 hostIdx = i i
322 v i ru s Idx = len (HVM. r e a c t i o n s ) ≠ 1 # ViraNet ( c ) appends
v i r u s r e a c t i o n to end in genHVM. py
323 objIdx = [ hostIdx , v i ru s Idx ]
324 # [ 2 ] State Opt imisat ions
325 ######
326 # Host opt im i sa t i on #
327 hostObj = HVM. r e a c t i o n s [ hostIdx ]
328 HVM. change ob j e c t i v e ( hostObj )
329 # Ensure no f l u x can go through the v i r u s r e a c t i o n
330 # Store the bounds
331 virusLb = HVM. r e a c t i o n s [ v i ru s Idx ] . lower bound
332 virusUb = HVM. r e a c t i o n s [ v i ru s Idx ] . upper bound
333 HVM. r e a c t i o n s [ v i ru s Idx ] . lower bound = 0
334 HVM. r e a c t i o n s [ v i ru s Idx ] . upper bound = 0
335 # FVA
336 varHost = cobra . f l u x a n a l y s i s . f l u x v a r i a b i l i t y a n a l y s i s (HVM,
s o l v e r=s o l v e r )
337 # Return v i r u s o b j e c t i v e bounds
338 HVM. r e a c t i o n s [ v i ru s Idx ] . lower bound = virusLb
339 HVM. r e a c t i o n s [ v i ru s Idx ] . upper bound = virusUb
340 ######
341 # Virus opt im i sa t i on #
342 virusObj = HVM. r e a c t i o n s [ v i ru s Idx ]
343 # Check that v i r u s o b j e c t i v e i s c o r r e c t and generated from ’
gene ra t i on . py ’
344 i f ’ prodrxn VN ’ in virusObj . id :
345 HVM. change ob j e c t i v e ( v irusObj )
346 # Ensure no f l u x can go through the host r e a c t i o n
347 # Store the bounds
348 hostLb = HVM. r e a c t i o n s [ hostIdx ] . lower bound
349 hostUb = HVM. r e a c t i o n s [ hostIdx ] . upper bound
350 HVM. r e a c t i o n s [ hostIdx ] . lower bound = 0
351 HVM. r e a c t i o n s [ hostIdx ] . upper bound = 0
352 # FVA
353 varVirus = cobra . f l u x a n a l y s i s . f l u x v a r i a b i l i t y a n a l y s i s (
HVM, s o l v e r=s o l v e r )
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354 # Return host o b j e c t i v e bounds
355 HVM. r e a c t i o n s [ hostIdx ] . lower bound = hostLb
356 HVM. r e a c t i o n s [ hostIdx ] . upper bound = hostUb
357 e l s e :
358 r a i s e ValueError ( ’ Unsupported ob j e c t i v e , unable to ana lyse :
r e f e r to README’ )
359 ######
360 # [ 3 ] Outputs
361 # Create o f data frames
362 hostFVA = pd . DataFrame . f r om d i c t ( varHost )
363 hostFVA = hostFVA . t ranspose ( )
364 virusFVA = pd . DataFrame . f r om d i c t ( varVirus )
365 virusFVA = virusFVA . t ranspose ( )
366 # Return






373 # Analys i s o f the e f f e c t o f a s i n g l e ≠r e a c t i o n knockout on v i r u s
product ion
374 # Inputs :
375 # HVM Integ ra t ed host≠v i r u s model
376 # s o l v e r [OPTIONAL] Dec lare s o l v e r to use f o r cobrapy :
d e f a u l t i s cg lpk
377 #
378 # Outputs :
379 # koVirus Vector o f v i r u s optima va lue s f o r s i n g l e ≠r e a c t i o n
knockout
380
381 de f knockout (HVM, HostRxn , s o l v e r=’ cg lpk ’ ) :
382 ” Reaction Knockouts ”
383 # [ 1 ] I n i t i a l Setup
384 # I d e n t i f y the host o b j e c t i v e r e a c t i o n
385 t ry :
386 i n tTes t = i n t ( HostRxn )
387 hostIdx = HostRxn
388 except :
389 f o r i i in range ( l en (HVM. r e a c t i o n s ) ) :
390 i f HostRxn in s t r (HVM. r e a c t i o n s [ i i ] ) :
391 hostIdx = i i
392 # Ensure v i r u s i s o b j e c t i v e
393 HVM. change ob j e c t i v e (HVM. r e a c t i o n s [ ≠1])
394 # Var iab le c r e a t i o n to hold v i r u s optima
395 koVirus = np . z e ro s ( ( l en (HVM. r e a c t i o n s ) ,1 ) )
396 # [ 2 ] Knockout Ana lys i s
397 # Record the host bounds
398 hostLb = HVM. r e a c t i o n s [ hostIdx ] . lower bound
399 hostUb = HVM. r e a c t i o n s [ hostIdx ] . upper bound
400 # I n i t i a t e loop
401 f o r i i in range ( l en (HVM. r e a c t i o n s ) ) :
402 # Store the bounds o f the r e a c t i o n [ i i ]
403 rxnLb = HVM. r e a c t i o n s [ i i ] . lower bound
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404 rxnUb = HVM. r e a c t i o n s [ i i ] . upper bound
405 # Alter bounds to zero
406 HVM. r e a c t i o n s [ i i ] . lower bound = 0
407 HVM. r e a c t i o n s [ i i ] . upper bound = 0
408 # Ensure the host o b j e c t i v e i s s e t to zero bounds
409 HVM. r e a c t i o n s [ hostIdx ] . lower bound = 0
410 HVM. r e a c t i o n s [ hostIdx ] . upper bound = 0
411 # Record and s t o r e the v i r u s optima
412 vSol = HVM. opt imize ( o b j e c t i v e s e n s e=’ maximize ’ , s o l v e r=s o l v e r )
413 koVirus [ i i ] = vSol . f
414 # Return r e a c t i o n [ i i ] to i t ’ s o r i g i n a l bounds
415 HVM. r e a c t i o n s [ i i ] . lower bound = rxnLb
416 HVM. r e a c t i o n s [ i i ] . upper bound = rxnUb
417 # Return host bounds to o r i g i n a l
418 HVM. r e a c t i o n s [ hostIdx ] . lower bound = hostLb
419 HVM. r e a c t i o n s [ hostIdx ] . upper bound = hostUb
420 # [ 3 ] Outputs





426 # Analys i s o f the e f f e c t o f a s i n g l e ≠r e a c t i o n host≠der ived c o n s t r a i n t
en fo rced
427 # f o r a v i rus ≠opt imised system
428 # Inputs :
429 # HVM Integ ra t ed host≠v i r u s model
430 # hostX Vector o f non≠o b j e c t i v e r e a c t i o n f l u x e s f o r host≠
opt imised
431 # Optional Inputs
432 # s o l v e r Dec lare s o l v e r to use f o r cobrapy : d e f a u l t i s
cg lpk
433 # use fva Use the Host FBA r e s u l t ( Fa l se ) or use the FVA
range as
434 # the a d d i t i o n a l c o n s t r a i n t ( True )
435 # userange Use the Host FVA r e s u l t s f o r enforcement ana ly s i s
, e i t h e r the
436 # median FVA value f o r both bounds ( Fa l se ) or the
min / max FVA
437 # as the r e a c t i o n bounds ( True )
438 # HostRxn Host o b j e c t i v e r eac t i on , e i t h e r :
439 # ≠ Index value o f r e a c t i o n in Model . r e a c t i o n s
[ i n t ]
440 # ≠ Reaction ID o f the host≠o b j e c t i v e r e a c t i o n
[ s t r ]
441 # Outputs :
442 # enfVirus Vector o f v i r u s optima va lue s with a d d i t i o n a l
host≠c o n s t r a i n t
443 # Optional Outputs :
444 # maxEnfBound Maximum enf bound
445 # minEnfBound Minimum enf bound
446
447 de f en f o r c e (HVM, hostX , HostRxn , s o l v e r=’ cg lpk ’ , use fva=False , userange=
False ) :
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448 ”Host≠der ived Enforcement ”
449 # [ 1 ] I n i t i a l Setup
450 # I d e n t i f y v i r u s r e a c t i o n
451 v i ru s Idx = len (HVM. r e a c t i o n s ) ≠ 1 # ViraNet ( c ) appends
v i r u s r e a c t i o n to end in genHVM. py
452 virusObj = HVM. r e a c t i o n s [ v i ru s Idx ]
453 # FVA Condi t iona l
454 i f u se fva == False :
455 # Ensure v i r u s i s o b j e c t i v e
456 HVM. change ob j e c t i v e (HVM. r e a c t i o n s [ ≠1])
457 # Numpy Conversion
458 hostX = np . array ( hostX )
459 e l i f u se fva == True :
460 # Ensure host i s o b j e c t i v e
461 # I d e n t i f y the host o b j e c t i v e r e a c t i o n
462 t ry :
463 i n tTes t = i n t ( HostRxn )
464 hostIdx = HostRxn
465 except :
466 f o r i i in range ( l en (HVM. r e a c t i o n s ) ) :
467 i f HostRxn in s t r (HVM. r e a c t i o n s [ i i ] ) :
468 hostIdx = i i
469 hostObj = HVM. r e a c t i o n s [ hostIdx ]
470 HVM. change ob j e c t i v e ( hostObj )
471 # Record the bounds
472 hostLb = HVM. r e a c t i o n s [ hostIdx ] . lower bound
473 hostUb = HVM. r e a c t i o n s [ hostIdx ] . upper bound
474 virusLb = HVM. r e a c t i o n s [ v i ru s Idx ] . lower bound
475 virusUb = HVM. r e a c t i o n s [ v i ru s Idx ] . upper bound
476 # Host opt im i sa t i on
477 HVM. change ob j e c t i v e ( hostObj )
478 # Zero≠bound v i r u s r e a c t i o n
479 HVM. r e a c t i o n s [ v i ru s Idx ] . lower bound = 0
480 HVM. r e a c t i o n s [ v i ru s Idx ] . upper bound = 0
481 # Perform f l u x v a r a b i l i t y a n a l y s i s
482 varHost = cobra . f l u x a n a l y s i s . f l u x v a r i a b i l i t y a n a l y s i s (
HVM, s o l v e r=s o l v e r )
483 # Return v i r u s r e a c t i o n to c o r r e c t bounds
484 HVM. r e a c t i o n s [ v i ru s Idx ] . lower bound = virusLb
485 HVM. r e a c t i o n s [ v i ru s Idx ] . upper bound = virusUb
486 # Var iab le c r e a t i o n to hold v i r u s optima
487 HVM. change ob j e c t i v e ( v irusObj )
488 en fVi rus = np . z e r o s ( ( l en ( hostX ) ,1 ) )
489 # [ 2 ] Enforcement Ana lys i s
490 # I n i t i a t e loop
491 #####################################
492 # USEFVA #
493 # False c o n d i t i o n a l
494 i f u se fva == False :
495 # Record the host bounds
496 hostLb = HVM. r e a c t i o n s [ hostIdx ] . lower bound
497 hostUb = HVM. r e a c t i o n s [ hostIdx ] . upper bound
498 # I n i t i a t e loop
499 f o r i i in range ( l en (HVM. r e a c t i o n s ) ) :
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500 # Store the bounds o f the r e a c t i o n [ i i ]
501 rxnLb = HVM. r e a c t i o n s [ i i ] . lower bound
502 rxnUb = HVM. r e a c t i o n s [ i i ] . upper bound
503 # Ensure the host o b j e c t i v e i s s e t to zero bounds
504 HVM. r e a c t i o n s [ hostIdx ] . lower bound = 0
505 HVM. r e a c t i o n s [ hostIdx ] . upper bound = 0
506 # Alter reacton [ i i ] bounds to match host≠der ived f l u x :
hostX [ i i ]
507 HVM. r e a c t i o n s [ i i ] . lower bound = hostX [ i i ]
508 HVM. r e a c t i o n s [ i i ] . upper bound = hostX [ i i ]
509 # Record and s t o r e the v i r u s optima
510 vSol = HVM. opt imize ( o b j e c t i v e s e n s e=’ maximize ’ , s o l v e r=
s o l v e r )
511 en fVi rus [ i i ] = vSol . f
512 # Return r e a c t i o n [ i i ] to i t ’ s o r i g i n a l bounds
513 HVM. r e a c t i o n s [ i i ] . lower bound = rxnLb
514 HVM. r e a c t i o n s [ i i ] . upper bound = rxnUb
515 # Return host bounds to o r i g i n a l
516 HVM. r e a c t i o n s [ hostIdx ] . lower bound = hostLb
517 HVM. r e a c t i o n s [ hostIdx ] . upper bound = hostUb
518 # True c o n d i t i o n a l
519 e l i f u se fva == True :
520 # Record the host bounds
521 hostLb = HVM. r e a c t i o n s [ hostIdx ] . lower bound
522 hostUb = HVM. r e a c t i o n s [ hostIdx ] . upper bound
523 #####################################
524 # USERANGE #
525 # Condi t iona l : Median o f FVA range
526 i f userange == False :
527 f o r i i in range ( l en (HVM. r e a c t i o n s ) ) :
528 # Store the bounds o f the r e a c t i o n [ i i ]
529 rxnLb = HVM. r e a c t i o n s [ i i ] . lower bound
530 rxnUb = HVM. r e a c t i o n s [ i i ] . upper bound
531 # Alter reacton [ i i ] bounds to match median host≠
der ived f l u x from FVA: varHost [ i i ]
532 maxFVA = varHost [HVM. r e a c t i o n s [ i i ] . id ] [ ’maximum ’
]
533 minFVA = varHost [HVM. r e a c t i o n s [ i i ] . id ] [ ’minimum ’
]
534 medianFVA = maxFVA ≠ ( (maxFVA ≠ minFVA) / 2)
535 HVM. r e a c t i o n s [ i i ] . lower bound = medianFVA
536 HVM. r e a c t i o n s [ i i ] . upper bound = medianFVA
537 # Ensure the host o b j e c t i v e i s s e t to zero bounds
538 HVM. r e a c t i o n s [ hostIdx ] . lower bound = 0
539 HVM. r e a c t i o n s [ hostIdx ] . upper bound = 0
540 # Record and s t o r e the v i r u s optima
541 vSol = HVM. opt imize ( o b j e c t i v e s e n s e=’ maximize ’ , s o l v e r
=s o l v e r )
542 en fVi rus [ i i ] = vSol . f
543 # Return r e a c t i o n [ i i ] to i t ’ s o r i g i n a l bounds
544 HVM. r e a c t i o n s [ i i ] . lower bound = rxnLb
545 HVM. r e a c t i o n s [ i i ] . upper bound = rxnUb
546 # Condi t iona l : Max / min bounds from FVA f o r r e a c t i o n
547 e l i f userange == True :
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548 # Pass f l u x v a r i a b i l i t y a n a l y s i s r e s u l t s to t o o l s .
rangeCa lcu la to r
549 ( enfVirus , maxEnfBound , minEnfBound ) = t o o l s .
rangeCa lcu la to r (HVM, hostIdx , v i rus Idx , s o l v e r )
550 # Return host bounds to o r i g i n a l
551 HVM. r e a c t i o n s [ hostIdx ] . lower bound = hostLb
552 HVM. r e a c t i o n s [ hostIdx ] . upper bound = hostUb
553 #####################################
554 #####################################
555 # [ 3 ] Outputs
556 re turn ( enfVirus , maxEnfBound , minEnfBound )
557 #######
Listing 1: Viranet Sub-Package: analysis.py
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A.2 generation.py
1 #######
2 # genera t i on . py gene ra t e s the v i r u s biomass o b j e c t i v e func t i on (VBOF)
, and the
3 # host≠v i r u s i n t e g r a t e d model (HVM) f o r a g iven v i r u s genome f i l e (
virusGB ) and
4 # a given host metabo l i c model ( hostModel ) f i l e ( . mat , . xml )
5 #######
6 # Setup o f workspace
7 import cobra
8 from cobra import Model , Reaction , Metabo l i te
9 import numpy as np
10 from v i r ane t . i n f o import metDict , ntpsDict , aaDict ,
miscDict , ntpsMets , aaMets , N A, k atp , k ppi
11 import re
12
13 # D e f i n i t i o n s
14 # Virus l o c a t i o n s
15 # This i n d i c a t e the 6 s t a r t i n g amino ac id s o f the non≠s t r u c t u r a l
po lypro t e in
16 # f o r the supported f l a v i v u r s e s . These are used to determine the
s e p e r a t i o n
17 # of s t r u c t u r a l and non≠s t r u c t u r a l p o l yp r o t e i n s
18 DENVloc = ’DSGCVV’
19 ZIKVloc = ’DVGCSV’
20 # Metabol i te d e f i n i t i o n s f o r f i n a l o b j e c t i v e r e a c t i o n c r e a t i o n
21 # This c r e a t e s a mapping between the python≠cobrapy and the ViraNet
func t i on
22 atp c = Metabol i te ( metDict [ ’ atp ’ ] )
23 c tp c = Metabol i te ( metDict [ ’ ctp ’ ] )
24 gtp c = Metabol i te ( metDict [ ’ gtp ’ ] )
25 utp c = Metabol i te ( metDict [ ’ utp ’ ] )
26 a l a c = Metabol i te ( metDict [ ’A ’ ] )
27 a rg c = Metabol i te ( metDict [ ’R ’ ] )
28 asn c = Metabol i te ( metDict [ ’N ’ ] )
29 asp c = Metabol i te ( metDict [ ’D ’ ] )
30 cy s c = Metabol i te ( metDict [ ’C ’ ] )
31 g l n c = Metabol i te ( metDict [ ’Q ’ ] )
32 g l u c = Metabol i te ( metDict [ ’E ’ ] )
33 g l y c = Metabol i te ( metDict [ ’G’ ] )
34 h i s c = Metabol i te ( metDict [ ’H ’ ] )
35 i l e c = Metabol i te ( metDict [ ’ I ’ ] )
36 l e u c = Metabol i te ( metDict [ ’L ’ ] )
37 l y s c = Metabol i te ( metDict [ ’K ’ ] )
38 met c = Metabol i te ( metDict [ ’M’ ] )
39 phe c = Metabol i te ( metDict [ ’F ’ ] )
40 pro c = Metabol i te ( metDict [ ’P ’ ] )
41 s e r c = Metabol i te ( metDict [ ’S ’ ] )
42 t h r c = Metabol i te ( metDict [ ’T ’ ] )
43 t r p c = Metabol i te ( metDict [ ’W’ ] )
44 t y r c = Metabol i te ( metDict [ ’Y ’ ] )
45 v a l c = Metabol i te ( metDict [ ’V ’ ] )
46 adp c = Metabol i te ( metDict [ ’ adp ’ ] )
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47 h2o c = Metabol i te ( metDict [ ’ h2o ’ ] )
48 h c = Metabol i te ( metDict [ ’h ’ ] )
49 p i c = Metabol i te ( metDict [ ’ Pi ’ ] )
50 pp i c = Metabol i te ( metDict [ ’ PPi ’ ] )
51 #######
52 # Generation o f the v i r u s biomass o b j e c t i v e func t i on
53 # Inputs :
54 # VirusGB User≠supp l i ed GenBank f i l e (NCBI) f o r d e s i r e d v i r u s [ . gb ,
. txt ]
55
56 # Outputs :
57 # VBOF Virus biomass o b j e c t i v e func t i on f o r d e s i r e d v i r u s
58
59 de f VBOF( VirusGB ) :
60 ”Generate VBOF”
61
62 # [ 1 ] I n i t i a l Setup
63 # Open v i r u s f i l e and parse contents
64 with open ( VirusGB , ’ rU ’ ) as v f :
65 v i r u s F i l e = vf . r e a d l i n e s ( )
66 f o r i i in range ( l en ( v i r u s F i l e ) ) :
67 v i r u s F i l e [ i i ] = v i r u s F i l e [ i i ] . r s t r i p ( ’ \n ’ )
68 # I d e n t i f y v i r u s genera and d e f i n e virusMethod
69 # virusMethod denotes the method o f VBOF genera t i on to use , based
upon the
70 # v i r u s genera
71 virusData = s t r ( v i r u s F i l e )
72 i f ” a lphav i ru s ” . lower ( ) in virusData . lower ( ) :
73 virusMethod = 1
74 e l i f ” f l a v i v i r u s ” . lower ( ) in virusData . lower ( ) :
75 virusMethod = 2
76 e l s e :
77 r a i s e ValueError ( ’ Unsupported v i rus , unable to c r e a t e VBOF:
r e f e r to README’ )
78 # VBOF Parameters : virusMethod dependent
79 # Alphavirus
80 i f virusMethod == 1 :
81 # Copy number f o r v i r a l genome [ Cg ]
# Source : Strauss , J . H. , & Strauss , E . G. (1994) .
82 Cg = 1
83 # Copy number f o r v i r a l s t r u c t u r a l po lyp ro t e in [ Csp ]
# Source : Strauss , J . H. , & Strauss , E . G. (1994) .
84 Csp = 240
85 # Copy number f o r v i r a l nons t ruc tu ra l po lypro t e in [ Cnp ]
# Source : Strauss , J . H. , & Strauss , E . G. (1994) .
86 Cnp = 1
87 # F l a v i v i r u s
88 e l i f virusMethod == 2 :
89 # Copy number f o r v i r a l genome [ Cg ]
# Source : Mukhopadhyay , S . , Kuhn , R. J . , & Rossmann , M.
G. (2005) .
90 Cg = 1
91 # Copy number f o r v i r a l s t r u c t u r a l po lyp ro t e in [ Csp ]
# Source : Mukhopadhyay , S . , Kuhn , R. J . , & Rossmann , M.
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G. (2005) .
92 Csp = 180
93 # Copy number f o r v i r a l nons t ruc tu ra l po lypro t e in [ Cnp ]
# Source : Mukhopadhyay , S . , Kuhn , R. J . , & Rossmann , M.
G. (2005) .
94 Cnp = 1
95 # Virus Name
96 # FUTURE UPDATE: D e f i n i t i o n v ia b lat imore c l a s s i f i c a t i o n and
genera / s p e c i e s
97 i f ” chikungunya ” . lower ( ) in virusData . lower ( ) :
98 virusName = ”CHIKV”
99 v i r u s F u l l = ”Chikungunya Virus ”
100 e l i f ” s e m l i k i ” . lower ( ) in virusData . lower ( ) :
101 virusName = ”SFV”
102 v i r u s F u l l = ” Seml ik i Forest Virus ”
103 e l i f ” s i n d b i s ” . lower ( ) in virusData . lower ( ) :
104 virusName = ”SINV”
105 v i r u s F u l l = ” S indb i s Virus ”
106 e l i f ” dengue ” . lower ( ) in virusData . lower ( ) :
107 virusName = ”DENV”
108 v i r u s F u l l = ”Dengue Virus ”
109 f lavMeth = 1
# I n d i c a t o r f o r nons t ruc tu ra l s t a r t
110 e l i f ” z ika ” . lower ( ) in virusData . lower ( ) :
111 virusName = ”ZIKV”
112 v i r u s F u l l = ” Zika Virus ”
113 f lavMeth = 2
# Which Virus Locat ion paramter to use
114 e l i f ” ea s t e rn ” . lower ( ) in virusData . lower ( ) :
115 virusName = ”EEEV”
116 v i r u s F u l l = ” Eastern Equine E n c e p h a l i t i s Virus ”
117 e l i f ” western ” . lower ( ) in virusData . lower ( ) :
118 virusName = ”WEEV”
119 v i r u s F u l l = ”Western Equine E n c e p h a l i t i s Virus ”
120 e l i f ” venezue lan ” . lower ( ) in virusData . lower ( ) :
121 virusName = ”VEEV”
122 v i r u s F u l l = ” Venezuelan Equine E n c e p h a l i t i s Virus ”
123 e l s e :
124 r a i s e ValueError ( ’ Unsupported v i rus , unable to c r e a t e VBOF:
r e f e r to README’ )
125
126 # [ 2 ] Sequence I d e n t i f i c a t i o n
127 # Genome Sequence : i n i t i a l s t ep i s to i d e n t i f y s t a r t /end
p o s i t i o n s in the v i r u s f i l e
128 startG = [ j j f o r j j , s in enumerate ( v i r u s F i l e ) i f ’ORIGIN ’ in s ]
129 endG = [ j j f o r j j , s in enumerate ( v i r u s F i l e ) i f ’ // ’ in s ]
130 startG = i n t ( ’ ’ . j o i n (map( s t r , startG ) ) )
131 endG = i n t ( ’ ’ . j o i n (map( s t r , endG) ) )
132 startG = startG + 1
133 # Store genome sequence
134 regex = re . compi le ( ’ [ ˆ a≠zA≠Z ] ’ )
135 virusGenome = s t r ( ’ ’ . j o i n ( v i r u s F i l e [ startG : endG ] ) )
136 virusGenome = regex . sub ( ’ ’ , virusGenome )
137 # Polyprote in sequences : s p l i t i n to s t r u c t u r a l and nons t ruc tu ra l
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138 # This s tep i s v i r u s genera dependent ( supported v i r u s e s only ,
s e e README)
139 # Alphavirus
140 i f virusMethod == 1 :
141 # S t r u c t u r a l po lyp ro t e in i d e n t i f i c a t i o n
142 tempS1 = [ j j f o r j j , s in enumerate ( v i r u s F i l e ) i f ’ /
product=”s t r u c t u r a l po lyp ro t e in ” ’ in s ]
143 tempStruct = v i r u s F i l e [ tempS1 [ 0 ] : ]
144 tempS2 = [ j j f o r j j , s in enumerate ( tempStruct ) i f ’
/ t r a n s l a t i o n ’ in s ]
145 tempStruct = tempStruct [ tempS2 [ 0 ] : ]
146 tempS3 = [ j j f o r j j , s in enumerate ( tempStruct ) i f ’
gene ’ in s ]
147 tempStruct = tempStruct [ : tempS3 [ 0 ] ]
148 # Clean≠up and Store
149 structReg = re . compile ( ’ / t r a n s l a t i o n=’ )
150 v i r u s S t r u c t = s t r ( tempStruct )
151 v i r u s S t r u c t = structReg . sub ( ’ ’ , v i r u s S t r u c t )
152 v i r u s S t r u c t = regex . sub ( ’ ’ , v i r u s S t r u c t )
153 # Nonstructura l po lypro t e in i d e n t i f i c a t i o n
154 tempN1 = [ j j f o r j j , s in enumerate ( v i r u s F i l e ) i f ’ /
product=”nons t ruc tu ra l po lypro t e in ” ’ in s ]
155 tempNP = v i r u s F i l e [ tempN1 [ 0 ] : ]
156 tempN2 = [ j j f o r j j , s in enumerate (tempNP) i f ’ /
t r a n s l a t i o n ’ in s ]
157 tempNP = tempNP [ tempN2 [ 0 ] : ]
158 tempN3 = [ j j f o r j j , s in enumerate (tempNP) i f ’ gene
’ in s ]
159 tempNP = tempNP [ : tempN3 [ 0 ] ]
160 # Clean≠up and Store
161 npReg = re . compile ( ’ / t r a n s l a t i o n=’ )
162 virusNonStruct = s t r (tempNP)
163 virusNonStruct = npReg . sub ( ’ ’ , v i rusNonStruct )
164 virusNonStruct = regex . sub ( ’ ’ , v i rusNonStruct )
165 # F l a v i v i r u s
166 e l i f virusMethod == 2 :
167 # Polyprote in i d e n t i f i c a t i o n
168 tempP1 = [ j j f o r j j , s in enumerate ( v i r u s F i l e ) i f ’ /
product=” f l a v i v i r u s po lypro t e in ” ’ in s ]
169 tempPol = v i r u s F i l e [ tempP1 [ 0 ] : ]
170 tempP2 = [ j j f o r j j , s in enumerate ( tempPol ) i f ’ /
t r a n s l a t i o n ’ in s ]
171 tempPol = tempPol [ tempP2 [ 0 ] : ]
172 tempP3 = [ j j f o r j j , s in enumerate ( tempPol ) i f ’
gene ’ in s ]
173 tempPol = tempPol [ : tempP3 [0 ] ≠1 ]
174 npReg = re . compile ( ’ / t r a n s l a t i o n=’ )
175 v i rusPo ly = s t r ( tempPol )
176 v i rusPo ly = npReg . sub ( ’ ’ , v i rusPo ly )
177 v i rusPo ly = regex . sub ( ’ ’ , v i rusPo ly )
178 # S t r u c t u r a l and nons t ruc tu ra l po lypro t e in i d e n t i f i c a t i o n
179 # flavMeth c o n d i t i o n a l v a r i a b l e : [ 1 ] Dengue v i r u s ; [ 2 ] Zika
v i r u s
180 i f f lavMeth == 1 :
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181 nsInd = re . search (DENVloc , v i rusPo ly ) . s t a r t ( )
182 virusNonStruct = v i rusPo ly [ nsInd : ]
183 v i r u s S t r u c t = v i rusPo ly [ : nsInd ]
184 e l i f f lavMeth == 2 :
185 nsInd = re . search ( ZIKVloc , v i rusPo ly ) . s t a r t ( )
186 virusNonStruct = v i rusPo ly [ nsInd : ]
187 v i r u s S t r u c t = v i rusPo ly [ : nsInd ]
188 # No supported v i r u s detec ted
189 e l s e :
190 r a i s e ValueError ( ’ Unsupported v i rus , unable to c r e a t e VBOF:
r e f e r to README’ )
191
192 # [ 3 ] Precursor f requency
193 # Genome [ Nuc l eo t ide s ]
194 countA = virusGenome . count ( ’ a ’ )
195 countC = virusGenome . count ( ’ c ’ )
196 countG = virusGenome . count ( ’ g ’ )
197 countU = virusGenome . count ( ’ t ’ ) # Base ’T ’ i s psuedo f o r base
’U ’
198 antiA = countU
199 antiC = countG
200 antiG = countC
201 antiU = countA
202 # S t r u c t u r a l po lyp ro t e in [ Amino Acids ]
203 structCount = np . z e ro s ( ( 20 , 1 ) )
204 f o r i i in range ( l en ( aaMets ) ) :
205 structCount [ i i , 0 ] = v i r u s S t r u c t . count ( aaMets [ i i ] )
206 # Nonstructura l po lypro t e in [ Amino Acids ]
207 nonstructCount = np . z e ro s ( ( 20 , 1 ) )
208 f o r i i in range ( l en ( aaMets ) ) :
209 nonstructCount [ i i , 0 ] = virusNonStruct . count ( aaMets [ i i ] )
210 # Count summation
211 totNTPS = (Cg ú ( countA + countC + countG + countU + antiA +
antiC + antiG + antiU ) )
212 totAA = ( structCount ú Csp) + ( nonstructCount ú Cnp)
213
214 # [ 4 ] VBOF Ca l cu l a t i on s
215 # Nuc l eo t ide s
216 # mol . ntps /mol . v i r u s
217 V a = (Cgú( countA + antiA ) )
218 V c = (Cgú( countC + antiC ) )
219 V g = (Cgú( countG + antiG ) )
220 V u = (Cgú( countU + antiU ) )
221 # g . ntps /mol . v i r u s
222 G a = V a ú ntpsDict [ ” atp ” ]
223 G c = V c ú ntpsDict [ ” ctp ” ]
224 G g = V g ú ntpsDict [ ” gtp ” ]
225 G u = V u ú ntpsDict [ ”utp” ]
226 # Amino Acids
227 # mol . aa/mol . v i r u s
228 V aa = np . z e ro s ( ( 20 , 1 ) )
229 f o r i i in range ( l en ( aaMets ) ) :
230 V aa [ i i , 0 ] = totAA [ i i ]
231 # g . a/mol . v i r u s
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232 G aa = np . z e ro s ( ( 20 , 1 ) )
233 f o r i i in range ( l en ( aaMets ) ) :
234 G aa [ i i , 0 ] = V aa [ i i ] ú aaDict [ aaMets [ i i ] ]
235 # Total genomic and proteomic molar mass
236 M v = ( G a + G c + G g + G u) + G aa . sum ( )
237 # S t o i c h i o m e t r i c c o e f f i c i e n t s
238 # Nuc l eo t ide s [ mmol . ntps /g . v i r u s ]
239 S atp = 1000 ú ( V a/M v)
240 S ctp = 1000 ú ( V c/M v)
241 S gtp = 1000 ú ( V g/M v)
242 S utp = 1000 ú (V u/M v)
243 # Amino ac id s [ mmol . aa/g . v i r u s ]
244 S aa = np . z e r o s ( ( 2 0 , 1 ) )
245 f o r i i in range ( l en ( aaMets ) ) :
246 S aa [ i i ] = 1000 ú ( V aa [ i i ] /M v)
247 # Energy requirements
248 # Genome : Phosphodiester bond format ion products [ Pyrophosphate ]
249 genTemp = ( ( ( countA + countC + countG + countU ) ú k ppi ) ≠ k ppi )
250 genRep = ( ( ( antiA + antiC + antiG + antiU ) ú k ppi ) ≠ k ppi )
251 genTot = genTemp + genRep
252 V ppi = genTot
253 S ppi = 1000 ú ( V ppi/M v)
254 # Protome : Peptide bond format ion [ATP + H2O]
255 # Note : ATP used in t h i s p roce s s i s denoated as ATPe/Ae [ e =
energy ve r s i on ]
256 spAe = ( ( structCount . sum ( ) ú k atp ) ≠ k atp )
257 npAe = ( ( nonstructCount . sum ( ) ú k atp ) ≠ k atp )
258 ppTot = (Csp ú spAe ) + (Cnp ú npAe)
259 V Ae = ppTot
260 S Ae = 1000 ú (V Ae/M v)
261
262 # [ 5 ] VBOF Reaction formatt ing and output
263 # Left≠hand terms : Nuc l eo t ide s
264 # Note : ATP term i s a summation o f genome and energy requi rements
265 S ATP = ( S atp + S Ae ) ú ≠1
266 S CTP = S ctp ú ≠1
267 S GTP = S gtp ú ≠1
268 S UTP = S utp ú ≠1
269 # Left≠hand terms : Amino Acids
270 S AA = S aa ú ≠1
271 S AAf = d i c t ( )
272 f o r i i in range ( l en ( aaMets ) ) :
273 S AAf [ aaMets [ i i ] ] = S AA [ i i , 0 ]
274 # Left≠hand terms : Energy Requirements
275 S H2O = S Ae ú ≠1
276 # Right≠hand terms : Energy Requirements
277 S ADP = S Ae
278 S Pi = S Ae
279 S H = S Ae
280 S PPi = S ppi
281 # Create r e a c t i o n output
282 react ion name = virusName + ’ prodrxn VN ’
283 v i r u s r e a c t i o n = Reaction ( react ion name )
284 v i r u s r e a c t i o n . name = v i r u s F u l l + ’ product ion r e a c t i o n ( c rea ted :
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ViraNet ( c ) ) ’
285 v i r u s r e a c t i o n . subsystem = ’ Virus Production ’
286 v i r u s r e a c t i o n . lower bound = 0
287 v i r u s r e a c t i o n . upper bound = 1000
288 v i r u s r e a c t i o n . o b j e c t i v e c o e f f i c i e n t = 0
289 v i r u s r e a c t i o n . add metabo l i t e s ( ({
290 atp c : S ATP ,
291 c tp c : S CTP ,
292 gtp c : S GTP,
293 utp c : S UTP ,
294 a l a c : S AAf [ ’A ’ ] ,
295 a rg c : S AAf [ ’R ’ ] ,
296 asn c : S AAf [ ’N ’ ] ,
297 asp c : S AAf [ ’D ’ ] ,
298 cy s c : S AAf [ ’C ’ ] ,
299 g l n c : S AAf [ ’Q ’ ] ,
300 g l u c : S AAf [ ’E ’ ] ,
301 g l y c : S AAf [ ’G’ ] ,
302 h i s c : S AAf [ ’H ’ ] ,
303 i l e c : S AAf [ ’ I ’ ] ,
304 l e u c : S AAf [ ’L ’ ] ,
305 l y s c : S AAf [ ’K ’ ] ,
306 met c : S AAf [ ’M’ ] ,
307 phe c : S AAf [ ’F ’ ] ,
308 pro c : S AAf [ ’P ’ ] ,
309 s e r c : S AAf [ ’S ’ ] ,
310 t h r c : S AAf [ ’T ’ ] ,
311 t r p c : S AAf [ ’W’ ] ,
312 t y r c : S AAf [ ’Y ’ ] ,
313 v a l c : S AAf [ ’V ’ ] ,
314 h2o c : S H2O ,
315 adp c : S ADP,
316 p i c : S Pi ,
317 h c : S H ,
318 pp i c : S PPi }) )
319
320 # DEBUG COMMENT
321 # pr in t ( ”” )
322 # pr in t (”VBOF Reaction Informat ion ”)
323 # pr in t ( v i r u s r e a c t i o n )
324 # f o r i i in v i r u s r e a c t i o n . metabo l i t e s :
325 # pr in t (”%9 s : %s ” % ( i i . id , i i . va lue s ) )
326 # pr in t ( v i r u s r e a c t i o n )
327
328 # [ 6 ] Output re turn v a r i a b l e s





334 # Generation o f the human≠v i r u s i n t e r g r a t e d model (HVM) : generated
from a
335 # user≠supp l i ed host s t o i c h i o m e t r i c model and a given VBOF ( generated
: VBOF. py )
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336 # Inputs :
337 # Model User≠supp l i ed model f i l e f o r d e s i r e d host [ . mat , .
xml ]
338 # VBOF Virus biomass o b j e c t i v e func t i on
339
340 # Outputs :
341 # hvm Integ ra t ed host≠v i r u s model
342
343 de f HVM( Model ,VBOF) :
344 ”Generate HVM”
345
346 # [ 1 ] I n t i a l Setup
347 # Fi le ≠type dependent load ing
348 i f ” . mat” . lower ( ) in Model . lower ( ) :
349 hostModel = cobra . i o . load matlab model ( Model )
350 e l i f ” . xml” . lower ( ) in Model . lower ( ) :
351 hostModel = cobra . i o . read sbml model ( Model )
352 e l s e :
353 r a i s e ValueError ( ’ Unsupported f i l e type , unable to load model
: s e e README’ )
354 # [ 2 ] VBOF i n t e g r a t i o n
355 hostModel . add reac t i on (VBOF)
356 # [ 3 ] Al te r the bounds o f VBOF
357 hostModel . r e a c t i o n s [ ≠1 ] . r e v e r s i b i l i t y = False
358 re turn ( hostModel )
359 #######
Listing 2: Viranet Sub-Package: generation.py
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A.3 info.py
1 # VIRANET DEFINITIONS #
2 # Metabol i te ( verbose to model ) d e f i n i t i o n s
3 metDict = {
4 ’ atp ’ : ’ atp [ c ] ’ , # ATP, ChEBI 15422
5 ’ ctp ’ : ’ ctp [ c ] ’ , # CTP, ChEBI 17677
6 ’ gtp ’ : ’ gtp [ c ] ’ , # GTP, ChEBI 15996
7 ’ utp ’ : ’ utp [ c ] ’ , # UTP, ChEBI 15713
8 ’A ’ : ’ a la≠L [ c ] ’ , # Ala l ine , ChEBI 16977
9 ’R ’ : ’ arg≠L [ c ] ’ , # Arginine , ChEBI 16467
10 ’N ’ : ’ asn≠L [ c ] ’ , # Asparagine , ChEBI 17196
11 ’D ’ : ’ asp≠L [ c ] ’ , # Aspartate , ChEBI 17053
12 ’C ’ : ’ cys≠L [ c ] ’ , # Cysteine , ChEBI 17561
13 ’Q ’ : ’ gln≠L [ c ] ’ , # Glutamine , ChEBI 18050
14 ’E ’ : ’ glu≠L [ c ] ’ , # Glutamate , ChEBI 16015
15 ’G ’ : ’ g ly [ c ] ’ , # Glycine , ChEBI 15428
16 ’H ’ : ’ h i s ≠L [ c ] ’ , # Hi s t id ine , ChEBI 15971
17 ’ I ’ : ’ i l e ≠L [ c ] ’ , # I s o l e u c i n e , ChEBI 17191
18 ’L ’ : ’ leu≠L [ c ] ’ , # Leucine , ChEBI 15603
19 ’K ’ : ’ lys ≠L [ c ] ’ , # Lysine , ChEBI 18019
20 ’M’ : ’met≠L [ c ] ’ , # Methionine , ChEBI 16643
21 ’F ’ : ’ phe≠L [ c ] ’ , # Phenyla lanine , ChEBI 17295
22 ’P ’ : ’ pro≠L [ c ] ’ , # Pro l ine , ChEBI 17203
23 ’ S ’ : ’ ser≠L [ c ] ’ , # Ser ine , ChEBI 17115
24 ’T ’ : ’ thr≠L [ c ] ’ , # Threonine , ChEBI 16857
25 ’W’ : ’ trp≠L [ c ] ’ , # Tryptophan , ChEBI 16828
26 ’Y ’ : ’ tyr≠L [ c ] ’ , # Tyrosine , ChEBI 17895
27 ’V ’ : ’ val≠L [ c ] ’ , # Valine , ChEBI 16414
28 ’ h2o ’ : ’ h2o [ c ] ’ , # H2O
29 ’ adp ’ : ’ adp [ c ] ’ , # ADP
30 ’ Pi ’ : ’ p i [ c ] ’ , # Phosphate
31 ’ h ’ : ’ h [ c ] ’ , # Hydrogen [ Proton ]
32 ’ PPi ’ : ’ ppi [ c ] ’ , # Pyrophosphate
33 }
34 # Nucleot ide d i c t i o n a r y with molecu lar weights
35 # Source : ChEBI https : //www. eb i . ac . uk/ cheb i /
36 ntpsDict = {
37 ’ atp ’ : 507 .181 , # ATP, ChEBI 15422
38 ’ gtp ’ : 483 .15644 , # GTP, ChEBI 17677
39 ’ ctp ’ : 523 .18062 , # CTP, ChEBI 15996
40 ’ utp ’ : 484 .14116 , # UTP, ChEBI 15713 (TTP i s
psuedo f o r UTP in v i r a l genome )
41 }
42 # Amino Acids d i c t i o n a r y with molecu lar weights
43 # Source : ChEBI https : //www. eb i . ac . uk/ cheb i /
44 aaDict = {
45 ’A ’ : 89 .09322 , # Alanine , ChEBI 16977
46 ’R ’ : 174 .201 , # Arginine , ChEBI 16467
47 ’N ’ : 132 .118 , # Asparagine , ChEBI 17196
48 ’D ’ : 133 .1027 , # Aspartate , ChEBI 17053
49 ’C ’ : 121 .158 , # Cysteine , ChEBI 17561
50 ’Q ’ : 146 .14458 , # Glutamine , ChEBI 18050
51 ’E ’ : 147 .1293 , # Glutamate , ChEBI 16015
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52 ’G ’ : 75 .06664 , # Glycine , ChEBI 15428
53 ’H ’ : 155 .15468 , # Hi s t id ine , ChEBI 15971
54 ’ I ’ : 131 .17296 , # I s o l e u c i n e , ChEBI 17191
55 ’L ’ : 131 .17296 , # Leucine , ChEBI 15603
56 ’K ’ : 146 .18764 , # Lysine , ChEBI 18019
57 ’M’ : 149 .21238 , # Methionine , ChEBI 16643
58 ’F ’ : 165 .18918 , # Phenyla lanine , ChEBI 17295
59 ’P ’ : 115 .1305 , # Pro l ine , ChEBI 17203
60 ’ S ’ : 105 .09262 , # Ser ine , ChEBI 17115
61 ’T ’ : 119 .1192 , # Threonine , ChEBI 16857
62 ’W’ : 204 .22526 , # Tryptophan , ChEBI 16828
63 ’Y ’ : 181 .18858 , # Tyrosine , ChEBI 17895
64 ’V ’ : 117 .14638 , # Valine , ChEBI 16414
65 }
66 # Misc . d i c t i o n a r y with molecular weights
67 # Source : ChEBI https : //www. eb i . ac . uk/ cheb i /
68 miscDict = {
69 ’ PPi ’ : 173 .94332 , # Pyrophosphate , ChEBI 18361
70 }
71 # Nuc l eo t ide s L i s t
72 ntpsMets = l i s t ( ntpsDict . keys ( ) )
73 # Amino Acids L i s t
74 aaMets = l i s t ( aaDict . keys ( ) )
75 # Avogadro ’ s Number
76 N A = 6.0221409 e+23
77 # Energy requirement c o e f f i c i e n t s
78 # Source : Haynie , D. (2008) . B i o l o g i c a l Thermodynamics (2nd ed . ) .
Cambridge : Cambridge Un ive r s i ty Press .
79 k atp = 4
80 k ppi = 1
Listing 3: Viranet Sub-Package: info.py
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A.4 tools.py
1 # VIRANET TOOLS #
2 #######
3 # objSto
4 # S t r i p s s t o i c h i o m e t r i c c o e f f i c i e n t s from the o b j e c t i v e s r e a c t i o n s
5 # usage
6 # Inputs :
7 # HVM Integ ra t ed host≠v i r u s model
8 # HostRxn Host o b j e c t i v e r eac t i on , e i t h e r :
9 # ≠ Index value o f r e a c t i o n in Model . r e a c t i o n s
[ i n t ]
10 # ≠ Reaction ID o f the host≠o b j e c t i v e r e a c t i o n
[ s t r ]
11 #
12 # Outputs :
13 # hostSto S t o i c h i o m e t r i c c o e f f i c i e n t s with metabo l i t e s f o r
host o b j e c t i v e
14 # vi ru sS to S t o i c h i o m e t r i c c o e f f i c i e n t s with metabo l i t e s f o r
v i r u s o b j e c t i v e
15 #
16
17 de f objSto (HVM, HostRxn ) :
18 ” D i f f e r e n t i a l usage o f amino ac id s and n u c l e o t i d e s ”
19 # [ 1 ] I n i t i a l Setup
20 # Function Dependencies
21 import pandas as pd
22 import numpy as np
23 # I d e n t i f y the host o b j e c t i v e r e a c t i o n
24 t ry :
25 i n tTes t = i n t ( HostRxn )
26 hostIdx = HostRxn
27 except :
28 f o r i i in range ( l en (HVM. r e a c t i o n s ) ) :
29 i f HostRxn in s t r (HVM. r e a c t i o n s [ i i ] ) :
30 hostIdx = i i
31 v i ru s Idx = len (HVM. r e a c t i o n s ) ≠ 1 # ViraNet ( c ) appends
v i r u s r e a c t i o n to end in genHVM. py
32 objIdx = [ hostIdx , v i ru s Idx ]
33 hostID = HVM. r e a c t i o n s [ hostIdx ] . id
34 virusID = HVM. r e a c t i o n s [ v i ru s Idx ] . id
35 # Condit ion : ensure v i r u s r e a c t i o n i s v i r u s o b j e c t i v e
36 i f ’ prodrxn VN ’ not in v irusID :
37 r a i s e ValueError ( ’ Unsupported ob j e c t i v e , unable to ana lyse :
r e f e r to README’ )
38 # Convert model i n to an array
39 m = HVM. to ar ray based mode l ( )
40 # Create data frame
41 mFrame = pd . DataFrame (
42 data = m. S . todense ( ) ,
43 columns = m. r e a c t i o n s . l i s t a t t r ( ” id ” ) ,
44 index = m. metabo l i t e s . l i s t a t t r ( ” id ” )
45 )
46 # [ 2 ] S t o i c h i o m e t r i c Data
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47 # Str ip the host and v i r u s o b j e c t i v e func t i on s t o i c h i o m e t r i c
c o e f f i c i e n t s
48 hostS = mFrame [ hostID ]
49 v i rusS = mFrame [ v i rusID ]
50 # Record only non zero va lue s
51 hostSto = hostS . l o c [ ˜ ( hostS==0) ]
52 v i ru sS to = v i rusS . l o c [ ˜ ( v i rusS==0) ]
53 # [ 3 ] Create output
54 hostSto = pd . DataFrame ( hostSto )
55 v i ru sS to = pd . DataFrame ( v i ru sS to )





61 # Checks a model f o r any a r b i t r a r i l y l a r g e bounds , removes the se
62 # and r e p l a c e s with i n f i n i t e bounds
63 # Work based upon Kelk et a l 2012
64 # Kelk , S . M. , O l i v i e r , B. G. , Stougie , L . , & Bruggeman , F . J . (2012)
. Optimal f l u x spaces o f genome≠s c a l e s t o i c h i o m e t r i c models are
determined by a few subnetworks . S c i e n t i f i c Reports , 2 , 580 . http
:// doi . org /10.1038/ srep00580
65 # Inputs :
66 # Model User≠supp l i ed model f i l e [ . mat , . xml ]
67 #
68 # Outputs :
69 # infModel Model with bound c o r r e c t i o n s app l i ed
70 de f boundCheck ( Model ) :
71 ” Reaction bound checker ”
72 # [ 1 ] I n i t i a l Setup
73 # Function Dependencies
74 import numpy as np
75 # Create po in t e r
76 altModel = Model
77 # [ 2 ] I d e n t i f y and c o r r e c t a r b i t r a r i l y l a r g e r e a c t i o n bounds
78 f o r i i in range ( l en ( altModel . r e a c t i o n s ) ) :
79 # Temporari ly record the lower and upper bounds
80 tmpLb = altModel . r e a c t i o n s [ i i ] . lower bound
81 tmpUb = altModel . r e a c t i o n s [ i i ] . upper bound
82 # Condi t iona l statement
83 i f tmpLb <= ≠1000:
84 altLb = ≠np . i n f
85 altModel . r e a c t i o n s [ i i ] . lower bound = altLb
86 i f tmpUb >= 1000 :
87 altUb = np . i n f
88 altModel . r e a c t i o n s [ i i ] . upper bound = altUb
89 # [ 3 ] Output model
90 re turn altModel
91 #######
92 # rangeCa lcu la to r
93 # Cal cu l a t e s , us ing FVA r e s u l t s f o r host and v i rus , the f l u x range
to use in the
94 # host≠der ived enforcement a n a l y s i s
95 # Inputs :
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96 # hostIdx Index ( model . r e a c t i o n s ) f o r the host≠o b j e c t i v e
r e a c t i o n
97 # vi ru s Idx Index ( model . r e a c t i o n s ) f o r the v i rus ≠o b j e c t i v e
r e a c t i o n
98 # Optional Inputs
99 # s o l v e r Dec lare s o l v e r to use f o r cobrapy : d e f a u l t i s
cg lpk
100 # Outputs
101 # enfVirus Vector o f v i r u s optima va lue s with a d d i t i o n a l
host≠c o n s t r a i n t
102 # maxEnfBound Maximum enf bound
103 # minEnfBound Minimum enf bound
104 de f rangeCa lcu la to r (HVM, hostIdx , v i rus Idx , s o l v e r ) :
105 ” Enforcement bound c r e a t o r ”
106 # [ 1 ] I n i t i a l Setup
107 # Function Dependencies
108 import cobra
109 import numpy as np
110 import pandas as pd
111 # Create the v i r u s optima vec to r
112 en fVi rus = np . z e r o s ( ( l en (HVM. r e a c t i o n s ) ,1 ) )
113 maxEnfBound = np . z e ro s ( ( l en (HVM. r e a c t i o n s ) ,1 ) )
114 minEnfBound = np . z e ro s ( ( l en (HVM. r e a c t i o n s ) ,1 ) )
115 # [ 2 ] Perform FVA f o r each o b j e c t i v e
116 # Object ive r e a c t i o n s
117 hostObj = HVM. r e a c t i o n s [ hostIdx ]
118 virusObj = HVM. r e a c t i o n s [ v i ru s Idx ]
119 # Host Optimisat ion
120 HVM. change ob j e c t i v e ( hostObj )
121 # Ensure no f l u x can go through the v i r u s r e a c t i o n
122 # Store the bounds
123 virusLb = HVM. r e a c t i o n s [ v i ru s Idx ] . lower bound
124 virusUb = HVM. r e a c t i o n s [ v i ru s Idx ] . upper bound
125 HVM. r e a c t i o n s [ v i ru s Idx ] . lower bound = 0
126 HVM. r e a c t i o n s [ v i ru s Idx ] . upper bound = 0
127 # FVA
128 varHost = cobra . f l u x a n a l y s i s . f l u x v a r i a b i l i t y a n a l y s i s (HVM,
s o l v e r=s o l v e r )
129 # Return v i r u s o b j e c t i v e bounds
130 HVM. r e a c t i o n s [ v i ru s Idx ] . lower bound = virusLb
131 HVM. r e a c t i o n s [ v i ru s Idx ] . upper bound = virusUb
132 # Virus Optimisat ion
133 HVM. change ob j e c t i v e ( v irusObj )
134 # Ensure no f l u x can go through the host r e a c t i o n
135 # Store the bounds
136 hostLb = HVM. r e a c t i o n s [ hostIdx ] . lower bound
137 hostUb = HVM. r e a c t i o n s [ hostIdx ] . upper bound
138 HVM. r e a c t i o n s [ hostIdx ] . lower bound = 0
139 HVM. r e a c t i o n s [ hostIdx ] . upper bound = 0
140 # FVA
141 varVirus = cobra . f l u x a n a l y s i s . f l u x v a r i a b i l i t y a n a l y s i s (HVM,
s o l v e r=s o l v e r )
142 # Return host o b j e c t i v e bounds
143 HVM. r e a c t i o n s [ hostIdx ] . lower bound = hostLb
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144 HVM. r e a c t i o n s [ hostIdx ] . upper bound = hostUb
145 # Create data frames
146 hostFVA = pd . DataFrame . f r om d i c t ( varHost )
147 hostFVA = hostFVA . t ranspose ( )
148 virusFVA = pd . DataFrame . f r om d i c t ( varVirus )
149 virusFVA = virusFVA . t ranspose ( )
150 # [ 3 ] Condit ion statements to determine the c a l c u l a t i o n and FVA
step s
151 # I n i t i a t e loop
152 f o r i i in range ( l en (HVM. r e a c t i o n s ) ) :
153 # Create temporary host and v i r u s max | min v a r i a b l e s
154 hostMax = varHost [HVM. r e a c t i o n s [ i i ] . id ] [ ’maximum ’ ]
155 hostMin = varHost [HVM. r e a c t i o n s [ i i ] . id ] [ ’minimum ’ ]
156 virusMax = varVirus [HVM. r e a c t i o n s [ i i ] . id ] [ ’maximum ’ ]
157 virusMin = varVirus [HVM. r e a c t i o n s [ i i ] . id ] [ ’minimum ’ ]
158 # Record the upper and lower bounds
159 tmpLb = HVM. r e a c t i o n s [ i i ] . lower bound
160 tmpUb = HVM. r e a c t i o n s [ i i ] . upper bound
161 # Condi t iona l : H+ > V+ && H≠ < V≠
162 i f ( hostMax > virusMax ) and ( hostMin < virusMin ) :
163 #######
164 # Calcu l a t i on o f bounds f o r cond i t i on [ 1 ]
165 enfMax1 = hostMax
166 enfMin1 = ( hostMax ≠ ( ( hostMax ≠ virusMax ) / 2) )
167 # Apply bounds to r e a c t i o n
168 HVM. r e a c t i o n s [ i i ] . lower bound = enfMin1
169 HVM. r e a c t i o n s [ i i ] . upper bound = enfMax1
170 # Zero≠bound host
171 HVM. r e a c t i o n s [ hostIdx ] . lower bound = 0
172 HVM. r e a c t i o n s [ hostIdx ] . upper bound = 0
173 # Optimize f o r v i r u s
174 HVM. change ob j e c t i v e ( v irusObj )
175 s o l = HVM. opt imize ( o b j e c t i v e s e n s e=’ maximize ’ , s o l v e r=
s o l v e r )
176 # Record the optima
177 zMax = s o l . f
178 # Return host bounds to o r i g i n a l
179 HVM. r e a c t i o n s [ hostIdx ] . lower bound = hostLb
180 HVM. r e a c t i o n s [ hostIdx ] . upper bound = hostUb
181 # Return r e a c t i o n bounds to o r i g i n a l
182 HVM. r e a c t i o n s [ i i ] . lower bound = tmpLb
183 HVM. r e a c t i o n s [ i i ] . upper bound = tmpUb
184 # Calcu l a t i on o f bounds f o r cond i t i on [ 2 ]
185 enfMin2 = hostMin
186 enfMax2 = ( hostMin ≠ ( ( hostMin ≠ virusMin ) / 2) )
187 # Apply bounds to r e a c t i o n
188 HVM. r e a c t i o n s [ i i ] . lower bound = enfMin2
189 HVM. r e a c t i o n s [ i i ] . upper bound = enfMax2
190 # Zero≠bound host
191 HVM. r e a c t i o n s [ hostIdx ] . lower bound = 0
192 HVM. r e a c t i o n s [ hostIdx ] . upper bound = 0
193 # Optimize f o r v i r u s
194 HVM. change ob j e c t i v e ( v irusObj )
195 s o l = HVM. opt imize ( o b j e c t i v e s e n s e=’ maximize ’ , s o l v e r=
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s o l v e r )
196 # Record the optima
197 zMin = s o l . f
198 # Return host bounds to o r i g i n a l
199 HVM. r e a c t i o n s [ hostIdx ] . lower bound = hostLb
200 HVM. r e a c t i o n s [ hostIdx ] . upper bound = hostUb
201 # Return r e a c t i o n bounds to o r i g i n a l
202 HVM. r e a c t i o n s [ i i ] . lower bound = tmpLb
203 HVM. r e a c t i o n s [ i i ] . upper bound = tmpUb
204 # COMPARISON #
205 # Compare zMax and zMin to f i n d which i s s m a l l e s t
206 i f zMax < zMin :
207 en fVi rus [ i i ] = zMax
208 # Record the bound
209 maxEnfBound [ i i ] = enfMax1
210 minEnfBound [ i i ] = enfMin1
211 e l i f zMin < zMax :
212 en fVi rus [ i i ] = zMin
213 # Record the bound
214 maxEnfBound [ i i ] = enfMax2
215 minEnfBound [ i i ] = enfMin2
216 e l s e :
217 en fVi rus [ i i ] = zMax
218 # Record the bound
219 maxEnfBound [ i i ] = enfMax1
220 minEnfBound [ i i ] = enfMin1
221 # Condi t iona l : H+ > V+
222 e l s e :
223 i f hostMax > virusMax :
224 #######
225 # Calcu l a t i on o f bounds
226 enfMax = hostMax
227 enfMin = ( hostMax ≠ ( ( hostMax ≠ virusMax ) / 2) )
228 # Apply bounds to r e a c t i o n
229 HVM. r e a c t i o n s [ i i ] . lower bound = enfMin
230 HVM. r e a c t i o n s [ i i ] . upper bound = enfMax
231 # Zero≠bound host
232 HVM. r e a c t i o n s [ hostIdx ] . lower bound = 0
233 HVM. r e a c t i o n s [ hostIdx ] . upper bound = 0
234 # Optimize f o r v i r u s
235 HVM. change ob j e c t i v e ( v irusObj )
236 s o l = HVM. opt imize ( o b j e c t i v e s e n s e=’ maximize ’ , s o l v e r=
s o l v e r )
237 # Record the optima
238 en fVi rus [ i i ] = s o l . f
239 # Return host bounds to o r i g i n a l
240 HVM. r e a c t i o n s [ hostIdx ] . lower bound = hostLb
241 HVM. r e a c t i o n s [ hostIdx ] . upper bound = hostUb
242 # Return r e a c t i o n bounds to o r i g i n a l
243 HVM. r e a c t i o n s [ i i ] . lower bound = tmpLb
244 HVM. r e a c t i o n s [ i i ] . upper bound = tmpUb
245 # Record the bound
246 maxEnfBound [ i i ] = enfMax
247 minEnfBound [ i i ] = enfMin
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248 #######
249 e l s e :
250 # Condi t iona l : H≠ < V≠
251 i f hostMin < virusMin :
252 #######
253 enfMin = hostMin
254 enfMax = ( hostMin ≠ ( ( hostMin ≠ virusMin ) / 2) )
255 # Apply bounds to r e a c t i o n
256 HVM. r e a c t i o n s [ i i ] . lower bound = enfMin
257 HVM. r e a c t i o n s [ i i ] . upper bound = enfMax
258 # Zero≠bound host
259 HVM. r e a c t i o n s [ hostIdx ] . lower bound = 0
260 HVM. r e a c t i o n s [ hostIdx ] . upper bound = 0
261 # Optimize f o r v i r u s
262 HVM. change ob j e c t i v e ( v irusObj )
263 s o l = HVM. opt imize ( o b j e c t i v e s e n s e=’ maximize ’ ,
s o l v e r=s o l v e r )
264 # Record the optima
265 en fVi rus [ i i ] = s o l . f
266 # Return host bounds to o r i g i n a l
267 HVM. r e a c t i o n s [ hostIdx ] . lower bound = hostLb
268 HVM. r e a c t i o n s [ hostIdx ] . upper bound = hostUb
269 # Return r e a c t i o n bounds to o r i g i n a l
270 HVM. r e a c t i o n s [ i i ] . lower bound = tmpLb
271 HVM. r e a c t i o n s [ i i ] . upper bound = tmpUb
272 # Record the bound
273 maxEnfBound [ i i ] = enfMax
274 minEnfBound [ i i ] = enfMin
275 #######
276 e l s e :
277 #######
278 enfMax = hostMax
279 enfMin = hostMin
280 # Apply bounds to r e a c t i o n
281 HVM. r e a c t i o n s [ i i ] . lower bound = enfMin
282 HVM. r e a c t i o n s [ i i ] . upper bound = enfMax
283 # Zero≠bound host
284 HVM. r e a c t i o n s [ hostIdx ] . lower bound = 0
285 HVM. r e a c t i o n s [ hostIdx ] . upper bound = 0
286 # Optimize f o r v i r u s
287 HVM. change ob j e c t i v e ( v irusObj )
288 s o l = HVM. opt imize ( o b j e c t i v e s e n s e=’ maximize ’ ,
s o l v e r=s o l v e r )
289 # Record the optima
290 en fVi rus [ i i ] = s o l . f
291 # Return host bounds to o r i g i n a l
292 HVM. r e a c t i o n s [ hostIdx ] . lower bound = hostLb
293 HVM. r e a c t i o n s [ hostIdx ] . upper bound = hostUb
294 # Return r e a c t i o n bounds to o r i g i n a l
295 HVM. r e a c t i o n s [ i i ] . lower bound = tmpLb
296 HVM. r e a c t i o n s [ i i ] . upper bound = tmpUb
297 # Record the bound
298 maxEnfBound [ i i ] = enfMax
299 minEnfBound [ i i ] = enfMin
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300 #######
301 # [ 4 ] Output
302 re turn ( enfVirus , maxEnfBound , minEnfBound )
303 #######
Listing 4: Viranet Sub-Package: tools.py
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A.5 main.py
1 #######
2 # main . py performs a n a l y s i s on a user≠de f ined host model , and a user≠
3 # supp l i ed v i r u s genome f i l e ( from NCBI > Genbank )
4 # A host≠v i r u s i n t e g r a t e d model i s c r ea ted and the f o l l o w i n g a n a l y s i s
performed :
5 # ≠ Comparison o f f l u x d i s t r i b u t i o n
6 # ≠ Analys i s o f the e f f e c t o f s i n g l e ≠r e a c t i o n knockouts on v i r u s
optima
7 # ≠ Analys i s o f the e f f e c t o f s i n g l e ≠r e a c t i o n host≠der ived f l u x
enforcement on
8 # v i r u s optima
9 #######
10 # Setup o f workspace
11 # Python Dependencies
12 import cobra
13 import numpy as np





19 # Intra ≠package dependenc ies
20 from v i r ane t import gene ra t i on
21 from v i r ane t import a n a l y s i s
22 from v i r ane t import i n f o
23 from v i r ane t import t o o l s
24
25 #######
26 # s i n g l e A n a l y s i s
27 # Performs a n a l y s i s on a i n t e g r a t e d host≠v i r u s model , f o r a user≠
de f ined
28 # metabol ic model and user≠de f ined v i r u s
29 # Inputs :
30 # Model User≠supp l i ed model f i l e f o r d e s i r e d host [ . mat
, . xml ]
31 # VirusGB User≠supp l i ed GenBank f i l e (NCBI) f o r d e s i r e d
v i r u s [ . gb , . txt ]
32 # HostRxn Host o b j e c t i v e r eac t i on , e i t h e r :
33 # ≠ Index value o f r e a c t i o n in Model . r e a c t i o n s
[ i n t ]
34 # ≠ Reaction ID o f the host≠o b j e c t i v e r e a c t i o n
[ s t r ]
35 # Optional Inputs :
36 # s o l v e r User≠s p e c i f i e d s o l v e r ( d e f a u l t = CGLPK)
37 # p r e a n a l y s i s User≠s p e c i f i e d pre≠a n a l y s i s o f model ( d e f a u l t =
False )
38 # ≠ Checking f o r a r b i t r a r i l y l a r g e (> 1000)
r e a c t i o n f l u x bounds
39 # use fva Use the Host FBA r e s u l t ( Fa l se ) or use the FVA
range as
40 # the a d d i t i o n a l c o n s t r a i n t ( True )
41 #
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42 # Outputs :
43 # ViraNet Analys i s Fu l l a n a l y s i s o f the HVM, wr i t t en to . csv f i l e s
44
45 de f s i n g l e A n a l y s i s ( Model , VirusGB , HostRxn , s o l v e r=” cglpk ” , fbaType=” fba ”
, p r e a n a l y s i s=False , use fva=False , userange=False ) :
46 ” Ana lys i s o f Host≠Virus model”
47 # Generate the necce s sa ry v i r u s o b j e c t i v e func t i on and i n t e g r a t e d
host≠v i r u s model
48 # r e q u i r e f o r the a n a l y s i s
49 # [ 1 ] VBOF Generation
50 v i rusReact i on = genera t i on .VBOF( VirusGB )
51 pr in t ( ” [ 1 ] VBOF Generated ” )
52
53 # [ 2 ] In t e r g r a t e d Host≠Virus Model (HVM)
54 ( virusModel ) = gene ra t i on .HVM( Model , v i ru sReac t i on )
55 pr in t ( ” [ 2 ] HVM Generated ” )
56
57 # OPTIONAL STEPS #
58 i f p r e a n a l y s i s == True :
59 # [ I ] Checking model f o r a r b i t r a r i l y l a r g e bounds
60 virusModel = t o o l s . boundCheck ( virusModel )
61 pr in t ( ” [ 2A] HVM Reaction Bounds Checked” )
62
63 # [ 3 ] Host≠Virus Optimisat ion
64 # Optimise the o r i g i n a l model
65 ( objIdx , hostF , hostX , virusF , virusX ) = a n a l y s i s . opt imi se ( virusModel
, HostRxn , so lve r , fbaType )
66 pr in t ( ” [ 3 ] HVM Optimisat ion Complete” )
67
68 # [ 4 ] Host≠Virus D i f f e r e n t i a l Ana lys i s
69 ( r e l d i f , a b s d i f ) = a n a l y s i s . d i f f e r e n t i a l ( virusModel , HostRxn )
70 pr in t ( ” [ 4 ] HVM D i f f e r e n t i a l Ana lys i s Complete” )
71
72 # [ 5 ] Host≠Virus Comparison
73 (hvmComp, hvmStat , hostXd , virusXd ) = a n a l y s i s . compare ( objIdx , hostX ,
virusX )
74 pr in t ( ” [ 5 ] HVM Comparison Complete” )
75
76 # [ 6 ] Host≠Virus V a r i a b i l i t y Ana lys i s
77 (hostFVA , virusFVA ) = a n a l y s i s . v a r i a b i l i t y ( virusModel , HostRxn ,
s o l v e r )
78 pr in t ( ” [ 6 ] HVM V a r i a b i l i t y Ana lys i s Complete” )
79
80 # [ 7 ] Knockout Ana lys i s
81 ( koVirus ) = a n a l y s i s . knockout ( virusModel , HostRxn , s o l v e r )
82 pr in t ( ” [ 7 ] HVM Knockout Ana lys i s Complete” )
83
84 # [ 8 ] Enforcement Ana lys i s
85 # Condi t iona l on userange
86 i f userange == False :
87 ( enfVirus , , ) = a n a l y s i s . en f o r c e ( virusModel , hostX , HostRxn ,
so lve r , usefva , userange )
88 e l i f userange == True :
89 ( enfVirus , maxEnfBound , minEnfBound ) = a n a l y s i s . en f o r c e (
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virusModel , hostX , HostRxn , so lve r , usefva , userange )
90 pr in t ( ” [ 8 ] HVM Host≠Derived Enforcement Ana lys i s Complete” )
91
92 # [ 9 ] Function output : setup
93 # I d e n t i f y the host o b j e c t i v e r e a c t i o n
94 t ry :
95 i n tTes t = i n t ( HostRxn )
96 hostIdx = HostRxn
97 except :
98 f o r i i in range ( l en ( virusModel . r e a c t i o n s ) ) :
99 i f HostRxn in s t r ( virusModel . r e a c t i o n s [ i i ] ) :
100 hostIdx = i i
101 # Record the other r e a c t i o n s
102 v i ru s Idx = len ( virusModel . r e a c t i o n s ) ≠ 1 # ViraNet ( c )
appends v i r u s r e a c t i o n to end in genHVM. py
103 objIdx = [ hostIdx , v i ru s Idx ]
104 hostID = virusModel . r e a c t i o n s [ hostIdx ] . id
105 virusID = virusModel . r e a c t i o n s [ v i ru s Idx ] . id
106 # Condit ion : ensure v i r u s r e a c t i o n i s v i r u s o b j e c t i v e
107 i f ’ prodrxn VN ’ not in v irusID :
108 r a i s e ValueError ( ’ Unsupported ob j e c t i v e , unable to ana lyse :
r e f e r to README’ )
109 # Create array≠model and obta in necce s sa ry in fo rmat ion
110 m = virusModel . to ar ray based mode l ( )
111 mRxns = m. r e a c t i o n s . l i s t a t t r ( ” id ” )
112 # Remove the o b j e c t i v e r e a c t i o n s
113 i f hostID in mRxns :
114 mRxns . remove ( hostID )
115 i f v i rusID in mRxns :
116 mRxns . remove ( v i rusID )
117 # Obtain subsystem in format ion
118 subSystems = [ ]
119 f o r i i in range ( l en ( virusModel . r e a c t i o n s ) ) :
120 i f not ( i i in objIdx ) :
121 subSystems . append ( virusModel . r e a c t i o n s [ i i ] . subsystem )
122
123 # [ 1 0 ] s i n g l e A n a l y s i s Output Generation
124 # Virus name and date
125 date = ( time . s t r f t i m e ( ”%d %m %Y” ) )
126 idVi rus = virusID . r e p l a c e ( ” prodrxn VN” , ”” )
127 idVi rus = ” ” + idVirus + ” ” + date
128
129 # OUTPUT [ 1 ] : Host≠Virus Optimisat ion Comparisons
130 # Store as l i s t
131 hostFlux = l i s t (hvmComp [ : , 0 ] )
132 v i rusF lux = l i s t (hvmComp [ : , 1 ] )
133 hostSolX = l i s t ( hostXd )
134 virusSolX = l i s t ( virusXd )
135 # Store in dataframe
136 hvmComparison = pd . DataFrame ( [ mRxns , subSystems , hostSolX ,
virusSolX , hostFlux , v i rusFlux ] )
137 hvmComparison = hvmComparison . t ranspose ( )
138 hvmComparison . columns = [ ’ Reaction ’ , ’ Subsystem ’ , ’ Host Flux mmol/
gDW/h≠1 ’ , ’ Virus Flux mmol /gDW/h≠1 ’ , ’ Host Flux %’ , ’ V i rus F lux %’ ]
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139 t i t l e = ” ViraNet Comparison ” + idVirus + ” . csv ”
140 # Write to csv
141 hvmComparison . t o c s v ( t i t l e , index=False )
142
143 # OUTPUT [ 2 ] : Host≠Virus Optimisat ion Comparison Stat s
144 # Store as l i s t
145 compStats = l i s t ( hvmStat )
146 nameStats = [ ’ Upregulated ’ , ’ Downregulated ’ , ’ Act ivated ’ , ’
I na c t i va t ed ’ , ’ Reversed ’ ]
147 # Store in dataframe
148 hvmComparisonStats = pd . DataFrame ( [ nameStats , compStats ] )
149 hvmComparisonStats = hvmComparisonStats . t ranspose ( )
150 hvmComparisonStats . columns = [ ’ R e g u l a t i o n s t a t e ’ , ’Num Rxns ’ ]
151 t i t l e = ” ViraNet ComparisonStats ” + idVirus + ” . csv ”
152 # Write to csv
153 hvmComparisonStats . t o c s v ( t i t l e , index=False )
154
155 # OUTPUT[ 3 ] : Host≠v i r u s v a r i a b i l i t y a n a l y s i s us ing FVA
156 # Create t i t l e host
157 t i t l e = ”ViraNet HostFVA” + idVirus + ” . csv ”
158 # Write to csv
159 hostFVA . t o c s v ( t i t l e , index=True )
160 # Create t i t l e v i r u s
161 t i t l e = ”ViraNet VirusFVA” + idVirus + ” . csv ”
162 # Write to csv
163 virusFVA . t o c s v ( t i t l e , index=True )
164
165 # OUTPUT[ 4 ] : Host≠v i r u s d i f f e r e n t i a l usage o f amino ac id s and
n u c l e o t i d e s
166 # Create l i s t s f o r the r e l a t i v e and abso lu t e measurements
167 r e l a t i v e D i f f = l i s t ( r e l d i f . va lue s ( ) )
168 a b s o l u t e D i f f = l i s t ( a b s d i f . va lue s ( ) )
169 orderedMets = l i s t ( r e l d i f . keys ( ) )
170 # Store in dataframe
171 hvmDi f f e r en t i a l = pd . DataFrame ( [ orderedMets , r e l a t i v e D i f f ,
a b s o l u t e D i f f ] )
172 hvmDi f f e r en t i a l = hvmDi f f e r en t i a l . t ranspose ( )
173 hvmDi f f e r en t i a l . columns = [ ’ Obj Met ’ , ’ Re l a t i v e d ’ , ’ Absolute d
’ ]
174 t i t l e = ” V i r a N e t D i f f e r e n t i a l U s a g e ” + idVirus + ” . csv ”
175 # Write to csv
176 hvmDi f f e r en t i a l . t o c s v ( t i t l e , index=False )
177
178 # OUTPUT [ 5 ] : Virus optima and e f f e c t s o f knockout and host≠
der ived enforcement
179 # Store as l i s t w h i l s t removing o b j e c t i v e r e a c t i o n s
180 resultKO = l i s t (np . d e l e t e ( koVirus , objIdx ) )
181 resultEF = l i s t (np . d e l e t e ( enfVirus , objIdx ) )
182 i f userange == True :
183 resultMaxEnfBound = l i s t (np . d e l e t e (maxEnfBound , objIdx ) )
184 resultMinEnfBound = l i s t (np . d e l e t e ( minEnfBound , objIdx ) )
185 # Convert to percentage o f wild≠type [ unconstra ined ] v i r u s optima
186 f o r i i in range ( l en ( resultKO ) ) :
187 i f np . i snan ( resultKO [ i i ] ) == False :
206
A | ViraNet Python Code
188 resultKO [ i i ] = ( resultKO [ i i ] / v irusF ) ú 100
189 e l i f np . i snan ( resultKO [ i i ] ) == True :
190 resultKO [ i i ] = 0
191 e l i f resultKO [ i i ] i s None :
192 resultKO [ i i ] = 0
193 i f np . i snan ( resultEF [ i i ] ) == False :
194 resultEF [ i i ] = ( resultEF [ i i ] / v i rusF ) ú 100
195 e l i f np . i snan ( resultEF [ i i ] ) == True :
196 resultEF [ i i ] = 0
197 e l i f resultEF [ i i ] i s None :
198 resultEF [ i i ] = 0
199 # Store in dataframe
200 i f userange == False :
201 hvmKoEnf = pd . DataFrame ( [ mRxns , subSystems , resultKO ,
resultEF ] )
202 hvmKoEnf = hvmKoEnf . t ranspose ( )
203 hvmKoEnf . columns = [ ’ Reaction ’ , ’ Subsystem ’ , ’
Knockout Optima(% WT) ’ , ’ Enforcement Optima(% WT) ’ ]
204 t i t l e = ” ViraNet Knockout Enforcement ” + idVirus + ” . csv ”
205 # Write to csv
206 hvmKoEnf . t o c s v ( t i t l e , index=False )
207 #return (hvmComp, hvmStat , koVirus , en fVi rus )
208 e l i f userange == True :
209 hvmKoEnf = pd . DataFrame ( [ mRxns , subSystems , resultKO ,
resultEF , resultMaxEnfBound , resultMinEnfBound ] )
210 hvmKoEnf = hvmKoEnf . t ranspose ( )
211 hvmKoEnf . columns = [ ’ Reaction ’ , ’ Subsystem ’ , ’
Knockout Optima(% WT) ’ , ’ Enforcement Optima(% WT) ’ , ’
MaximumBound Enf ’ , ’ MinimumBound Enf ’ ]
212 t i t l e = ” ViraNet Knockout Enforcement ” + idVirus + ” . csv ”
213 # Write to csv
214 hvmKoEnf . t o c s v ( t i t l e , index=False )
215 #return (hvmComp, hvmStat , koVirus , en fVi rus )
216 pr in t ( ” ViraNet Ana lys i s Complete” )
217 #######
Listing 5: Viranet Sub-Package: main.py
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Table B1. Biomass objective function stoichiometric coe cients and associated metabolites for the [host] human macrophage
(iAB-AMO-1410) biomass maintenance objective function.
Model Metabolite ID Metabolite Name Macromolecule Stoichiometric Coe cients, S [mmol/gDW]
adp[c] ADP Energy Requirement 25.17352552
ala-L[c] L-Alanine Amino Acids -0.396559456
alpa hs[c] lysophosphatidic acid
(homo sapiens)
Other -0.011499127
amp[c] AMP RNA Nucleotide -0.048664064
arg-L[c] L-Arginine Amino Acids -0.325724532
asn-L[c] L-Asparagine Amino Acids -0.215407845
asp-L[c] L-Aspartate Amino Acids -0.282759085
atp[c] ATP Energy Requirement -25.17352552
chsterol[c] Cholesterol Other -0.020930954
cmp[c] CMP RNA Nucleotide -0.042373167
cys-L[c] L-Cysteine Amino Acids -0.127154496
dag hs[c] diacylglycerol (homo
sapiens)
Other -0.0036682
damp[c] dAMP DNA Nucleotide -0.021495345
dcmp[c] dCMP DNA Nucleotide -0.014937443
dgmp[c] dGMP DNA Nucleotide -0.014937443
dtmp[c] dTMP DNA Nucleotide -0.021495345













Table B1 – continued from previous page
Model Metabolite ID Metabolite Name Macromolecule Stoichiometric Coe cients, S [mmol/gDW]
h2o[c] H2O Energy Requirement -25.17352552
gln-L[c] L-Glutamine Amino Acids -0.280436629
glu-L[c] L-Glutamate Amino Acids -0.424428935
gly[c] Glycine Amino Acids -0.366948135




gmp[c] GMP RNA Nucleotide -0.043710887







his-L[c] L-Histidine Amino Acids -0.153862747
ile-L[c] L-Isoleucine Amino Acids -0.25953452
leu-L[c] L-Leucine Amino Acids -0.580614138
lys-L[c] L-Lysine Amino Acids -0.351852168


















Table B1 – continued from previous page
















phe-L[c] L-Phenylalanine Amino Acids -0.214246617
pi[c] Phosphate Energy Requirement 25.17352552




ser-L[c] L-Serine Amino Acids -0.476684207
sphmyln hs[c] sphingomyelin (homo
sapiens)
Other -0.007049706
tag hs[c] triacylglycerol (homo
sapiens)
Other -0.002742439














Table B1 – continued from previous page
Model Metabolite ID Metabolite Name Macromolecule Stoichiometric Coe cients, S [mmol/gDW]
thr-L[c] L-Threonine Amino Acids -0.303661194




tyr-L[c] L-Tyrosine Amino Acids -0.156185203
ump[c] UMP RNA Nucleotide -0.04602478
val-L[c] L-Valine Amino Acids -0.347207255
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Table C1. Biomass objective function stoichiometric coe cients and associated metabolites for the Chikungunya (CHIKV)
virus biomass objective functions. ú ATP includes both the nucleotide and energy requirement fractions as a single value.
Model Metabolite ID Metabolite Name Macromolecule Stoichiometric Coe cients, S [mmol/gDW]
adp[c] ADP Energy Requirement 23.82348236
ala-L[c] L-Alanine Amino Acids -0.491958902
arg-L[c] L-Arginine Amino Acids -0.272990314
asn-L[c] L-Asparagine Amino Acids -0.257614748
asp-L[c] L-Aspartate Amino Acids -0.211191986
atp[c]* ATP* Nucleotide -23.94009192
ctp[c] CTP Nucleotide -0.116806932
cys-L[c] L-Cysteine Amino Acids -0.233377013
gln-L[c] L-Glutamine Amino Acids -0.257476585
glu-L[c] L-Glutamate Amino Acids -0.29201733
gly[c] Glycine Amino Acids -0.362677826
gtp[c] GTP Nucleotide -0.116806932
h[c] H+ Energy Requirement 23.82348236
h2o[c] H2O Energy Requirement -23.82348236
his-L[c] L-Histidine Amino Acids -0.200138947
ile-L[c] L-Isoleucine Amino Acids -0.291069927
leu-L[c] L-Leucine Amino Acids -0.392678931
lys-L[c] L-Lysine Amino Acids -0.376948088




Table C1 – continued from previous page
Model Metabolite ID Metabolite Name Macromolecule Stoichiometric Coe cients, S [mmol/gDW]
met-L[c] L-Methionine Amino Acids -0.148051503
phe-L[c] L-Phenylalanine Amino Acids -0.162637567
pi[c] Phosphate Energy Requirement 23.82348236
ppi[c] Diphosphate Energy Requirement 0.466793502
pro-L[c] L-Proline Amino Acids -0.433752811
ser-L[c] L-Serine Amino Acids -0.349098379
thr-L[c] L-Threonine Amino Acids -0.439239856
trp-L[c] L-Tryptophan Amino Acids -0.071548687
tyr-L[c] L-Tyrosine Amino Acids -0.233771765
utp[c] UTP Nucleotide -0.116609556





Table C2. Biomass objective function stoichiometric coe cients and associated metabolites for the Dengue (DENV) virus
biomass objective functions. ú ATP includes both the nucleotide and energy requirement fractions as a single value.
Model Metabolite ID Metabolite Name Macromolecule Stoichiometric Coe cients, S [mmol/gDW]
adp[c] ADP Energy Requirement 19.49420757
ala-L[c] L-Alanine Amino Acids -0.241248287
arg-L[c] L-Arginine Amino Acids -0.264837466
asn-L[c] L-Asparagine Amino Acids -0.182944901
asp-L[c] L-Aspartate Amino Acids -0.139783913
atp[c]* ATP* Nucleotide -19.69370267
ctp[c] CTP Nucleotide -0.168695251
cys-L[c] L-Cysteine Amino Acids -0.112589401
gln-L[c] L-Glutamine Amino Acids -0.169450654
glu-L[c] L-Glutamate Amino Acids -0.303294352
gly[c] Glycine Amino Acids -0.445790849
gtp[c] GTP Nucleotide -0.168695251
h[c] H+ Energy Requirement 19.49420757
h2o[c] H2O Energy Requirement -19.49420757
his-L[c] L-Histidine Amino Acids -0.119079001
ile-L[c] L-Isoleucine Amino Acids -0.321011989
leu-L[c] L-Leucine Amino Acids -0.434871841
lys-L[c] L-Lysine Amino Acids -0.327055214




Table C2 – continued from previous page
Model Metabolite ID Metabolite Name Macromolecule Stoichiometric Coe cients, S [mmol/gDW]
met-L[c] L-Methionine Amino Acids -0.244235563
phe-L[c] L-Phenylalanine Amino Acids -0.18167445
pi[c] Phosphate Energy Requirement 19.49420757
ppi[c] Diphosphate Energy Requirement 0.736312022
pro-L[c] L-Proline Amino Acids -0.189400164
ser-L[c] L-Serine Amino Acids -0.264734457
thr-L[c] L-Threonine Amino Acids -0.445344475
trp-L[c] L-Tryptophan Amino Acids -0.101430037
tyr-L[c] L-Tyrosine Amino Acids -0.070080808
utp[c] UTP Nucleotide -0.199495096





Table C3. Biomass objective function stoichiometric coe cients and associated metabolites for the Zika (ZIKV) virus biomass
objective functions. ú ATP includes both the nucleotide and energy requirement fractions as a single value.
Model Metabolite ID Metabolite Name Macromolecule Stoichiometric Coe cients, S [mmol/gDW]
adp[c] ADP Energy Requirement 19.76542883
ala-L[c] L-Alanine Amino Acids -0.388789243
arg-L[c] L-Arginine Amino Acids -0.270454656
asn-L[c] L-Asparagine Amino Acids -0.144194657
asp-L[c] L-Aspartate Amino Acids -0.22539596
atp[c]* ATP* Nucleotide -19.94634684
ctp[c] CTP Nucleotide -0.18781858
cys-L[c] L-Cysteine Amino Acids -0.118368748
gln-L[c] L-Glutamine Amino Acids -0.106548954
glu-L[c] L-Glutamate Amino Acids -0.239948655
gly[c] Glycine Amino Acids -0.475251379
gtp[c] GTP Nucleotide -0.18781858
h[c] H+ Energy Requirement 19.76542883
h2o[c] H2O Energy Requirement -19.76542883
his-L[c] L-Histidine Amino Acids -0.14316982
ile-L[c] L-Isoleucine Amino Acids -0.275032264
leu-L[c] L-Leucine Amino Acids -0.463192456
lys-L[c] L-Lysine Amino Acids -0.312165548




Table C3 – continued from previous page
Model Metabolite ID Metabolite Name Macromolecule Stoichiometric Coe cients, S [mmol/gDW]
met-L[c] L-Methionine Amino Acids -0.181772038
phe-L[c] L-Phenylalanine Amino Acids -0.15598029
pi[c] Phosphate Energy Requirement 19.76542883
ppi[c] Diphosphate Energy Requirement 0.73740485
pro-L[c] L-Proline Amino Acids -0.163837379
ser-L[c] L-Serine Amino Acids -0.330885916
thr-L[c] L-Threonine Amino Acids -0.368497457
trp-L[c] L-Tryptophan Amino Acids -0.10098067
tyr-L[c] L-Tyrosine Amino Acids -0.119154457
utp[c] UTP Nucleotide -0.180918006
val-L[c] L-Valine Amino Acids -0.363919849
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D RESULTS OF SINGLE-REACTION ANALYSES
Table D1. Results for the single-reaction knockout analysis. Model reaction iden-
tifiers are listed. The resulting virus optima, for Chikungunya (CHIKV), Dengue
(DENV) and Zika (ZIKV), are shown as a percentage of the original model (with-
out the additional constraints imposed by the analyses), identified as normalised.








ADSL1 0 0 0
ADSL2 0 0 0
ADSS 0 0 0
AHC 0 0 0
AICART 0 0 0
AIRCr 0 0 0
ALATA L 0 0 0
ASNS1 0 0 0
ASPCTr 0 0 0
CBPS 0 0 0
CTPS1 0 0 0
CYOR-u10m 0 0 0
CYSTGL 0 0 0
CYSTS 0 0 0
DHORD9 0 0 0
DHORTS 0 0 0
G5SADrm 0 0 0
GARFT 0 0 0
GHMT2r 0 0 0
GK1 0 0 0
GLUPRT 0 0 0
GMPS2 0 0 0
IMPC 0 0 0
IMPD 0 0 0
METAT 0 0 0
O2t 0 0 0
OMPDC 0 0 0
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ORPT 0 0 0
P5CRxm 0 0 0
PGCD 0 0 0
PHETHPTOX2 0 0 0
PRAGSr 0 0 0
PRAIS 0 0 0
PRASCS 0 0 0
PRFGS 0 0 0
PROtm 0 0 0
PRPPS 0 0 0
PSERT 0 0 0
PSP L 0 0 0
RPI 0 0 0
THBPT4ACAMDASE 0 0 0
221
D | Appendices
Table D2. Results for the single-reaction host-derived enforcement analysis.
Model reaction identifiers are listed. The resulting virus optima, for Chikun-
gunya (CHIKV), Dengue (DENV) and Zika (ZIKV), are shown as a percentage of
the original model (without the additional constraints imposed by the analyses),
identified as normalised.








2HBO 97.69894576 87.50411496 88.88898347
2HBt2 97.69894576 87.50411496 88.88898347
2MCITt 97.69894576 87.50411496 88.88898347
3AIBt 96.86520383 100 97.45470325
3AIBTm 96.86520383 100 97.45470325
3AIBtm 96.86520383 100 97.45470325
3HBCOAHLm 96.86520383 100 97.45470325
5HLTDL 100 91.29144293 84.31838353
5HTRPVESSEC 100 91.29144293 84.31838353
ACOAD9m 96.86520383 100 97.45470325
ADEt 100 100 96.08800042
ADKd 100 100 98.19941198
ADSL1 89.17494143 71.14031648 69.28858385
ADSL2 85.93080959 71.02942248 67.37488509
ADSS 89.17494143 71.14031648 69.28858385
AHC 85.47563846 100 100
AICART 85.93080959 71.02942248 67.37488509
AIRCr 85.93080959 71.02942248 67.37488509
ARGN 100 100 97.00311453
ARGNm 100 100 97.00311453
ARGtm 100 100 97.00311453
ASPCTr 84.8214277 70.38012844 66.83842673
CAMPt 100 100 96.20591187
CBPS 84.8214277 70.38012844 66.83842673
CBPSam 100 100 96.08800042
CGMPt 100 100 97.16065675
CREATt4(2)r 100 100 97.27110861
CTPS1 73.61994513 65.09891901 61.22143988
CYSAMO 93.31242113 92.74364952 92.04750607
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CYSTA 93.31242113 92.74364952 92.04750607
CYSTGL 85.47563846 81.15250586 84.63484423
CYSTS 85.47563846 81.15250586 84.63484423
DATPtn 100 100 98.19941198
DCYTt 100 100 96.27272207
DGSNt 100 100 96.08800042
DGTPtn 100 100 96.17860361
DHFR 100 100 98.52661862
DHORD9 84.8214277 70.38012844 66.83842673
DHORTS 84.8214277 70.38012844 66.83842673
DINt 100 100 97.18804875
DURIPP 100 100 98.50062324
ECOAH12m 96.86520383 100 97.45470325
GACMTRc 100 100 97.27110861
GARFT 85.93080959 71.02942248 67.37488509
GHMT2r 100 86.61097405 79.21647585
GK1 50 50 50
GLUPRT 85.93080959 71.02942248 67.37488509
GLYAMDTRc 100 100 97.27110861
GMPS2 82.69215956 70.8982818 65.53149683
GUAt 100 100 96.08800042
H2CO3D 84.8214277 70.38012844 66.83842673
H2CO3D2 84.8214277 70.38012844 66.83842673
HIBDm 96.86520383 100 97.45470325
HYPTROX 93.31242113 92.74364952 92.04750607
HYXNt 100 100 96.08800042
ILEtec 0 100 100
IMPC 85.93080959 71.02942248 67.37488509
IMPD 82.69215956 70.8982818 65.53149683
MCITS 97.69894576 87.50411496 88.88898347
MCLACCYSR 93.31242113 92.74364952 92.04750607
MCLOR 93.31242113 92.74364952 92.04750607
MERCPLACCYSt 93.31242113 92.74364952 92.04750607
METAT 85.47563846 100 100
MMMm 96.86520383 100 97.45470325
MMTSADm 96.86520383 100 97.45470325
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NDPK5m 100 100 97.1449818
OBDHc 97.69894576 87.50411496 88.88898347
OCBTm 100 100 96.08800042
OIVD2m 96.86520383 100 97.45470325
OMPDC 84.8214277 70.38012844 66.83842673
ORPT 84.8214277 70.38012844 66.83842673
P5CRxm 100 100 94.78932681
PAN4PP 93.31242113 92.74364952 92.04750607
PGCD 100 100 94.89710915
PHETHPTOX2 93.50151761 100 100
PNTEH 93.31242113 92.74364952 92.04750607
PNTK 93.31242113 92.74364952 92.04750607
PPCDC 93.31242113 92.74364952 92.04750607
PPNCL3 93.31242113 92.74364952 92.04750607
PRAGSr 85.93080959 71.02942248 67.37488509
PRAIS 85.93080959 71.02942248 67.37488509
PRASCS 85.93080959 71.02942248 67.37488509
PRFGS 85.93080959 71.02942248 67.37488509
PROtm 100 100 94.78932681
PRPPS 85.37611865 70.70477546 67.10665591
PSERT 100 100 94.89710915
PSP L 100 100 94.89710915
PUNP3 100 100 96.64096977
PUNP4 100 100 95.90899165
PUNP5 100 100 97.42933959
PUNP6 100 100 97.18804875
PYNP2r 100 100 95.64877821
RPI 85.37611865 70.70477546 67.10665591
sink Tyr-ggn 0 0 0
TAURt4(2)r 93.31242113 92.74364952 92.04750607
THBPT4ACAMDASE 93.50151761 100 100
THRD L 95.01363988 90.9874608 90.9874608
THYMt 100 100 98.80704485
TMDPP 100 100 98.80704485
TMDS 100 100 98.52661862
TRPHYDRO2 100 91.29144293 84.31838353
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URAt 100 100 96.10807398
UREAtm 100 100 97.00311453
VALt5m 96.86520383 100 97.45470325
VALTAm 96.86520383 100 97.45470325
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E RESULTS OF SINGLE-REACTION MUTATION SENSITIVITY
ANALYSIS
Table E1 [Dropbox Link]. Summary of results for the host-derived enforce-
ment analysis for di erent conditions: altered media conditions; virus genome
point mutations; virus biomass objective function randomised stoichiometric co-
e cients. Reactions are selected when they are able to reduce virus optima to
below 100% of the original virus optima in the original model (without additional
constraints).
• https://www.dropbox.com/s/5wnt5d46p87oqqt/Appendix%20E1.xlsx?dl=0
Table E2 [Dropbox Link]. Results from the in-silico media variation sensitivity
analyses to evaluate the e ectiveness of the host-derived enforcement antiviral
targets over a range of varied media compositions for Chikungunya (CHIKV),




F RESULTS OF DOUBLE-REACTION ANALYSES
Table F1 [Dropbox Link]. Double-reaction broad-targets.
• https://www.dropbox.com/s/tw0hzdl7wn06do9/Appendix%20F1.csv?dl=0
Table F2 [Dropbox Link]. Double-reaction specific-targets.
• https://www.dropbox.com/s/moqgpagr5uhn7bz/Appendix%20F2.csv?dl=0
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